# 2025年12月4日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 阿替普酶在急性缺血性卒中后4.5至24小时的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41335445](https://pubmed.ncbi.nlm.nih.gov/41335445)
**期刊：** JAMA
**PMID：** 41335445
**DOI：** 10.1001/jama.2025.19376

### 第一部分 原文与翻译

**英文原标题：** Alteplase 4.5 to 24 Hours After Acute Ischemic Stroke.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究探讨了阿替普酶在急性缺血性卒中后4.5至24小时扩展时间窗内的应用，突破了传统溶栓治疗3-4.5小时的时间限制。研究通过评估延长治疗时间窗的疗效和安全性，为错过标准治疗时间窗的患者提供了新的治疗可能性。该研究具有重要的临床创新价值，可能改变急性缺血性卒中的治疗策略，但需要关注延长治疗时间窗可能带来的出血风险增加等安全性问题，其研究结果对优化卒中溶栓治疗具有重要指导意义。

---

## 2. 帕博西尼、曲妥珠单抗和内分泌治疗在经治的HER2阳性且PAM50 Luminal型晚期乳腺癌中的应用：随机II期SOLTI-1303 PATRICIA试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41335375](https://pubmed.ncbi.nlm.nih.gov/41335375)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41335375
**DOI：** 10.1158/1078-0432.CCR-25-2882

### 第一部分 原文与翻译

**英文原标题：** Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial.

**英文摘要原文：**
PURPOSE: Based on the results from SOLTI-PATRICIA trial (NCT02448420) cohorts A/B, a direct comparison with standard-of-care treatments is needed to evaluate the efficacy and safety of palbociclib, trastuzumab and endocrine therapy (ET) in PAM50-luminal A/B pretreated patients.

PATIENTS AND METHODS: SOLTI-PATRICIA cohort C is a randomised, multicentre, prospective, open-label, phase II study. Pretreated patients with HER2-positive, HR-positive, and PAM50-Luminal A/B ABC were randomised 1:1 to receive either i) the triplet regimen or ii) trastuzumab-based treatment of physician's choice (TPC). Patients allocated in the TPC arm were eligible for re-randomization upon disease progression, if the inclusion criteria were still met. The primary endpoint was investigator-assessed progression-free survival (PFS) per RECIST 1.1.

RESULTS: 264 participants were pre-screened between August 2019-2023, and 73 patients were randomised (including seven re-randomisations). In the TPC arm: 48.5% were treated with trastuzumab plus chemotherapy, 39.4% with T-DM1 and 12.1 % with trastuzumab plus ET. The triplet was associated with a significantly better PFS compared to TPC (stratified hazard ratio=0.52 [95% CI 0.29-0.95]; two-sided p=0.03). PFS rates after 24 months were 24.0% with the triplet and 4.3% in the TPC arm. The overall response rate was 18.9% (95% CI 8.6-35.7) and 7.1% (95% CI 1.2-25.0), respectively. In the triplet arm, grade ≥3 adverse events occurred in 61.5% of patients, with neutropenia being the most frequent (53.9%). No permanent discontinuations due to toxicity were observed.

CONCLUSIONS: Combining palbociclib, trastuzumab, and ET was safe and improved significantly PFS, compared to TPC in previously treated HER2-positive, PAM50 luminal A/B ABC patients.

**中文摘要译文：**
目的：基于SOLTI-PATRICIA试验（NCT02448420）队列A/B的结果，需要与标准治疗方案进行直接比较，以评估帕博西尼、曲妥珠单抗和内分泌治疗（ET）在PAM50-Luminal A/B型经治患者中的疗效和安全性。

患者与方法：SOLTI-PATRICIA队列C是一项随机、多中心、前瞻性、开放标签的II期研究。经治的HER2阳性、HR阳性且PAM50-Luminal A/B型晚期乳腺癌患者按1:1比例随机分配接受：i）三联方案，或ii）基于曲妥珠单抗的医生选择治疗（TPC）。分配到TPC组的患者在疾病进展后，如果仍符合入组标准，有资格进行再次随机化。主要终点是研究者根据RECIST 1.1标准评估的无进展生存期（PFS）。

结果：2019年8月至2023年间，共预筛选了264名参与者，73名患者被随机分配（包括7例再次随机化）。在TPC组中：48.5%的患者接受了曲妥珠单抗联合化疗，39.4%接受了T-DM1，12.1%接受了曲妥珠单抗联合内分泌治疗。与TPC相比，三联方案与显著更好的PFS相关（分层风险比=0.52 [95% CI 0.29-0.95]；双侧p=0.03）。24个月时的PFS率在三联方案组为24.0%，在TPC组为4.3%。总体缓解率分别为18.9%（95% CI 8.6-35.7）和7.1%（95% CI 1.2-25.0）。在三联方案组中，≥3级不良事件发生率为61.5%，其中中性粒细胞减少症最为常见（53.9%）。未观察到因毒性导致的永久性停药。

结论：与TPC相比，帕博西尼、曲妥珠单抗和内分泌治疗的联合方案是安全的，并显著改善了先前接受过治疗的HER2阳性、PAM50 Luminal A/B型晚期乳腺癌患者的PFS。

### 第二部分 AI 大师评价

本研究旨在评估帕博西尼、曲妥珠单抗和内分泌治疗三联方案在经治的HER2阳性且PAM50 Luminal型晚期乳腺癌中的疗效与安全性。通过随机II期临床试验设计，直接比较该三联方案与基于曲妥珠单抗的医生选择治疗。关键发现显示三联方案显著改善无进展生存期（风险比0.52），24个月PFS率提高近6倍，且安全性可控。该研究的创新性在于针对HER2阳性且Luminal型这一特定分子亚群探索靶向联合治疗策略，为精准治疗提供了重要证据，具有明确的临床转化价值。然而，作为II期研究，样本量相对有限，且长期生存获益仍需进一步验证。

---

## 3. 一项关于sapacitabine与olaparib联合治疗BRCA1/2突变转移性乳腺癌的Ib期研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41335237](https://pubmed.ncbi.nlm.nih.gov/41335237)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41335237
**DOI：** 10.1158/1078-0432.CCR-25-0571

### 第一部分 原文与翻译

**英文原标题：** A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer.

**英文摘要原文：**
PURPOSE: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC), in patients with germline BRCA1/2 (gBRCA1/2)-mutated HER2-negative metastatic breast cancer.

PATIENTS AND METHODS: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor-naive were enrolled. The primary objective was determination of the recommended phase 2 dose (RP2D) of sapacitabine with olaparib. Archival samples were subjected to immunohistochemistry (IHC) for biomarkers of homologous recombination repair (HRR) deficiency and replication stress. Serial blood samples were collected for circulating tumor DNA (ctDNA) analysis.

RESULTS: Ten patients (3 BRCA1, 7 BRCA2) were enrolled. The RP2D was not determined due to hematological toxicities. The objective response rate (ORR) was 50% (95% CI: 18.7% - 81.3%) with median progression-free survival (mPFS) of 9.7 months (95% CI: 8.02 - NA). Three patients had clinical benefit greater than 15 months, including 2 who remained on trial for more than 40 months. Tumors from responding patients demonstrated HRR deficiency and/or replication stress by IHC. At progression, ctDNA from 2 patients had evidence of BRCA reversion mutation associated with a microhomology-mediated end-joining (MMEJ) signature, and 3 patients had acquired putative non-reversion mechanisms of resistance.

CONCLUSIONS: Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematological toxicity is warranted.

**中文摘要译文：**
目的：我们探讨了PARP抑制剂联合sapacitabine（一种口服生物可利用的脱氧胞苷类似物2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶[CNDAC]的前药）在种系BRCA1/2（gBRCA1/2）突变HER2阴性转移性乳腺癌患者中的疗效。

患者与方法：在这项关于sapacitabine和olaparib的Ib期研究者发起的研究中，纳入了既往未接受过PARP抑制剂治疗的患者。主要目标是确定sapacitabine联合olaparib的推荐II期剂量（RP2D）。对存档样本进行了同源重组修复（HRR）缺陷和复制应激生物标志物的免疫组织化学（IHC）检测。收集了系列血液样本用于循环肿瘤DNA（ctDNA）分析。

结果：共纳入10名患者（3名BRCA1突变，7名BRCA2突变）。由于血液学毒性，未能确定RP2D。客观缓解率（ORR）为50%（95% CI：18.7% - 81.3%），中位无进展生存期（mPFS）为9.7个月（95% CI：8.02 - NA）。三名患者的临床获益超过15个月，其中两名患者在试验中持续超过40个月。通过IHC检测，缓解患者的肿瘤表现出HRR缺陷和/或复制应激。在疾病进展时，两名患者的ctDNA显示出与微同源介导的末端连接（MMEJ）特征相关的BRCA回复突变证据，三名患者获得了假定的非回复耐药机制。

结论：Sapacitabine联合olaparib导致高发生率的血液学毒性。然而，50%的ORR、9.7个月的mPFS以及部分患者反应的持久性表明可能存在组合治疗获益。有必要进一步探索olaparib与不同sapacitabine给药方案或替代使用PARP1选择性抑制剂，以潜在地降低血液学毒性。

### 第二部分 AI 大师评价

本研究是一项探索性Ib期临床试验，旨在评估PARP抑制剂olaparib联合新型核苷类似物前药sapacitabine在BRCA1/2突变转移性乳腺癌中的疗效和安全性。研究采用剂量探索设计，结合肿瘤组织生物标志物分析和ctDNA动态监测，全面评估治疗反应和耐药机制。核心发现显示该联合方案具有50%的客观缓解率和9.7个月的中位无进展生存期，部分患者获得长期临床获益，但伴随显著的血液学毒性。创新性在于首次探索这种特定药物组合，并通过生物标志物分析揭示了HRR缺陷、复制应激以及BRCA回复突变等耐药机制。该研究为BRCA突变乳腺癌的联合治疗策略提供了重要参考，但受限于小样本量和未确定的推荐剂量，需要更大规模的优化研究来验证其临床价值。

---

## 4. XPR1调控胎儿肝脏巨噬细胞发育、身份特征及核红细胞清除

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41335223](https://pubmed.ncbi.nlm.nih.gov/41335223)
**期刊：** The Journal of experimental medicine
**PMID：** 41335223
**DOI：** 10.1084/jem.20241587

### 第一部分 原文与翻译

**英文原标题：** XPR1 regulates fetal liver macrophage development, identity, and pyrenocyte clearance.

**英文摘要原文：**
Inorganic phosphate (Pi) is an essential nutrient for all organisms. It has critical functions in lipid and nucleic acid synthesis, protein signaling and bone growth. Loss-of-function mutations in Pi transporters lead to embryonic and neonatal lethality. Here, we show that the only known Pi exporter, XPR1, is critical for the development of fetal macrophages in the liver and the spleen. Single-cell RNA-seq and flow cytometry analyses in conditional mice lacking Xpr1 in hematopoietic and/or CD206+ cells revealed loss of the Kupffer cell transcriptional program and a shift in the development of fetal liver monocytes towards an interferon-activated monocyte/macrophage state. Functionally, Xpr1 deficiency in embryos led to a failure to clear nuclei expelled from erythroblasts. In adulthood, splenic red pulp and bone marrow macrophages were also reduced upon loss of intrinsic Xpr1. Collectively, these findings reveal that XPR1 is required for the development, identity, and function of macrophages involved in erythropoiesis.

**中文摘要译文：**
无机磷酸盐（Pi）是所有生物体的必需营养素。它在脂质和核酸合成、蛋白质信号传导及骨骼生长中具有关键功能。Pi转运蛋白的功能丧失突变会导致胚胎和新生儿致死。本文中，我们发现目前已知的唯一Pi输出蛋白XPR1对于肝脏和脾脏中胎儿巨噬细胞的发育至关重要。在造血细胞和/或CD206+细胞中缺失Xpr1的条件性小鼠中进行单细胞RNA测序和流式细胞术分析，结果显示库普弗细胞转录程序的丧失，以及胎儿肝脏单核细胞发育向干扰素激活的单核细胞/巨噬细胞状态的转变。功能上，胚胎中Xpr1缺陷导致无法清除从成红细胞排出的细胞核。在成年期，内在Xpr1缺失也会导致脾脏红髓和骨髓巨噬细胞减少。总之，这些发现揭示了XPR1是参与红细胞生成的巨噬细胞的发育、身份特征和功能所必需的。

### 第二部分 AI 大师评价

本研究旨在阐明无机磷酸盐输出蛋白XPR1在胎儿巨噬细胞发育和功能中的关键作用。通过使用条件性基因敲除小鼠模型，结合单细胞RNA测序和流式细胞术分析，研究团队发现XPR1缺失导致库普弗细胞转录程序丧失，并促使胎儿肝脏单核细胞向干扰素激活状态转变。关键发现表明XPR1对于清除红细胞生成过程中排出的细胞核至关重要，揭示了磷酸盐代谢与巨噬细胞介导的红细胞成熟之间的新联系。这项研究的创新性在于首次将XPR1功能与胎儿巨噬细胞发育和红细胞生成联系起来，为理解先天性贫血和巨噬细胞相关疾病提供了新的分子机制，具有重要的基础研究价值和潜在的临床转化意义。

---

## 5. KRAS撤除在胆管癌中导致免疫浸润和肿瘤消退

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41332325](https://pubmed.ncbi.nlm.nih.gov/41332325)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41332325
**DOI：** 10.1002/advs.202511312

### 第一部分 原文与翻译

**英文原标题：** KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression.

**英文摘要原文：**
Cholangiocarcinoma (CCA) is a liver cancer subtype with poor survival rates. KRAS mutations are found in 15-40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown, partly due to the lack of conditional animal models. A conditional TRE.Kras/Trp53 knock-out (TKP) CCA mouse model is engineered using the transposon system and CRISPR-Cas9. Withdrawal of Kras results in >90% tumor regression by day 7, accompanied by infiltration and enrichment of activated CD8 T cells, shown by IHC, co-IF staining, and single-cell RNA-Seq. Bulk RNA-Seq of TKP cell line suggested that Kras withdrawal stimulates the transforming growth factor beta pathway and induces senescence. Cytokine array characterizes the secretion of pro-inflammatory factors, including IL-15 and CCL17. Lentiviral overexpression of murine IL-15 and CCL17 delays CCA tumor progression in a syngeneic transplant model. Consistently, expression of IL-15 resulted in blockade of tumor progression in the TKP CCA model. These findings highlight the importance of oncogenic Kras in CCA tumor maintenance and underscore KRAS inhibition as a potential therapeutic approach for CCA.

**中文摘要译文：**
胆管癌（CCA）是一种生存率较低的肝癌亚型。在15-40%的胆管癌中发现KRAS突变，这代表了一个新的潜在治疗靶点。KRAS抑制是否会导致胆管癌肿瘤消退尚不清楚，部分原因是缺乏条件性动物模型。使用转座子系统和CRISPR-Cas9技术构建了一个条件性TRE.Kras/Trp53敲除（TKP）胆管癌小鼠模型。KRAS撤除在第7天导致>90%的肿瘤消退，伴随着活化的CD8 T细胞的浸润和富集，这通过免疫组化、共免疫荧光染色和单细胞RNA测序得到证实。TKP细胞系的大量RNA测序表明，KRAS撤除刺激转化生长因子β通路并诱导衰老。细胞因子阵列表征了促炎因子的分泌，包括IL-15和CCL17。在小鼠同种移植模型中，鼠源IL-15和CCL17的慢病毒过表达延缓了胆管癌肿瘤进展。一致地，在TKP胆管癌模型中，IL-15的表达导致肿瘤进展被阻断。这些发现强调了致癌性KRAS在胆管癌肿瘤维持中的重要性，并强调了KRAS抑制作为胆管癌潜在治疗方法的潜力。

### 第二部分 AI 大师评价

本研究通过构建条件性KRAS/TP53敲除胆管癌小鼠模型，首次系统性地探究了KRAS抑制在胆管癌治疗中的作用机制。研究创新性地发现KRAS撤除不仅直接导致肿瘤消退，还通过激活TGF-β通路、诱导细胞衰老，并促进CD8 T细胞浸润和促炎因子分泌，揭示了KRAS抑制的免疫调节功能。该研究为KRAS突变型胆管癌提供了重要的临床前证据，将KRAS靶向治疗从理论可能性推向实际应用前景，但研究主要基于小鼠模型，其临床转化效果仍需进一步验证。

---

## 6. 靶向DESI2作为JAK2突变白血病的新型治疗策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41332324](https://pubmed.ncbi.nlm.nih.gov/41332324)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41332324
**DOI：** 10.1002/advs.202515127

### 第一部分 原文与翻译

**英文原标题：** Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.

**英文摘要原文：**
The JAK2-V617F mutation is the most common genetic alteration in myeloproliferative neoplasms (MPN), which can progress to secondary acute myeloid leukemia (sAML), a chemotherapy-resistant disease with limited treatment options and a poor prognosis. Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance. Here, the deSUMOylase DESI2 is identified as a novel component of the JAK2-V617F complex by mass spectrometry-based proteomics. Mechanistically, DESI2 selectively binds to and stabilizes JAK2-V617F by mediating its deSUMOylation and deubiquitination at lysine 962 (K962). Importantly, DESI2 protein is specifically and highly expressed in JAK2-mutant-driven cell lines and MPN primary clinical samples, suggesting its potential role in JAK2-V617F regulation and disease progression. Genetic depletion of DESI2 suppresses both JAK2 mutant cell growth and MPN disease onset in vitro and in vivo. Moreover, through a compound screen, followed by chemical proteomics and compound optimization, WWQ-03-012 is discovered, which selectively degrades mutant JAK2, induces primary leukemia cells death, and inhibits MPN progression through targeting DESI2 enzymatic activity in vitro and in vivo. These studies provide a novel therapeutic strategy against mutated JAK2 signaling in MPN and sAML.

**中文摘要译文：**
JAK2-V617F突变是骨髓增殖性肿瘤（MPN）中最常见的遗传改变，可进展为继发性急性髓系白血病（sAML），这是一种化疗耐药性疾病，治疗选择有限且预后不良。尽管JAK1/2抑制剂鲁索替尼已获临床批准，但其疗效因对正常细胞的毒性和耐药性的发展而受到限制。本研究通过基于质谱的蛋白质组学，鉴定出去SUMO化酶DESI2是JAK2-V617F复合物的一个新组分。从机制上讲，DESI2通过介导JAK2-V617F在赖氨酸962位点（K962）的去SUMO化和去泛素化，选择性结合并稳定JAK2-V617F。重要的是，DESI2蛋白在JAK2突变驱动的细胞系和MPN原代临床样本中特异性高表达，表明其在JAK2-V617F调控和疾病进展中的潜在作用。DESI2的基因敲除在体外和体内均能抑制JAK2突变细胞的生长和MPN疾病的发病。此外，通过化合物筛选，随后进行化学蛋白质组学和化合物优化，发现了WWQ-03-012，该化合物通过靶向DESI2酶活性，选择性降解突变型JAK2，诱导原代白血病细胞死亡，并在体外和体内抑制MPN进展。这些研究为针对MPN和sAML中突变JAK2信号通路提供了一种新型治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索针对JAK2-V617F突变白血病的新型治疗策略，该突变是骨髓增殖性肿瘤的关键驱动因素。研究团队采用质谱蛋白质组学方法，首次鉴定出DESI2作为JAK2-V617F复合物的新组分，并通过机制研究阐明其通过去SUMO化和去泛素化稳定突变蛋白的作用。关键发现包括DESI2在JAK2突变样本中的特异性高表达，以及通过化合物筛选获得的DESI2靶向抑制剂WWQ-03-012能够选择性降解突变JAK2并抑制疾病进展。这项研究的创新性在于发现了JAK2信号通路调控的新机制，并开发了相应的靶向治疗策略，为克服现有JAK抑制剂耐药性问题提供了新思路，具有重要的临床转化价值，尽管其长期安全性和有效性仍需进一步验证。

---

## 7. STARD4通过脂质代谢重编程和AR稳定化在前列腺癌中抑制肿瘤发生并减弱恩杂鲁胺耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331871](https://pubmed.ncbi.nlm.nih.gov/41331871)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41331871
**DOI：** 10.1186/s13046-025-03600-7

### 第一部分 原文与翻译

**英文原标题：** STARD4 suppresses tumorigenesis and attenuates enzalutamide resistance via lipid metabolic reprogramming and AR stabilization in prostate cancer.

**英文摘要原文：**
BACKGROUND: Prostate cancer (PCa) is a globally prevalent malignancy in males and is imposing an increasing epidemiological burden. The androgen receptor (AR) signalling axis is fundamentally implicated in PCa tumorigenesis and disease progression. Although androgen deprivation therapy (ADT) elicits transient therapeutic responses in the majority of cases, progression to castration-resistant prostate cancer (CRPC) remains an almost universal clinical trajectory. Dysregulated lipid homeostasis, manifesting as intracellular lipid deposition, has been mechanistically linked to CRPC pathogenesis and therapeutic failure under enzalutamide regimens. However, effective strategies to mitigate lipid accumulation in PCa remain elusive.

METHODS: STARD4, a key gene involved in lipid metabolism, was identified as functionally significant in PCa through integrated bioinformatics analysis of public databases. RT‒qPCR, western blot analysis, and IHC staining were performed to evaluate STARD4 expression, while Kaplan-Meier survival analysis, Gleason score, and tumor stage were performed to assess its clinical significance in PCa. The biological functions of STARD4 and its contribution to enzalutamide resistance were elucidated through in vitro and in vivo experiments. The effect of STARD4 on abnormal lipid accumulation in PCa cells was evaluated by Oil Red O (ORO) staining, while its impact on endoplasmic reticulum (ER) stress was assessed through ER-tracking imaging and transmission electron microscopy (TEM). Mechanistic exploration involves a combination of techniques, including RNA-seq analysis, Gene ontology analysis, coimmunoprecipitation (Co-IP), and GST pull-down assay, to analyse the interactions and potential mechanisms involving STARD4, AR, and E3 ubiquitin ligase UBE4B.

RESULTS: In this study, we observed that STARD4 expression was markedly reduced in PCa tissues and was correlated with an adverse prognosis. STARD4 overexpression inhibited PCa cell proliferation, migration, and lipid accumulation while promoting apoptosis through ER stress. Mechanistically, STARD4 enhanced the interaction between UBE4B and AR, facilitating AR ubiquitination and degradation and thus suppressing AR signalling. Additionally, the upregulation of STARD4 expression enhanced sensitivity to enzalutamide in resistant cells by diminishing lipid accumulation and inhibiting the AR signalling pathway. In summary, STARD4 functions as a tumour suppressor in PCa by regulating cholesterol metabolism and modulating AR signalling.

CONCLUSIONS: Our findings identify STARD4 as a promising therapeutic target for reversing enzalutamide resistance in PCa while also providing novel insights for future research on lipid metabolism within the tumour microenvironment.

**中文摘要译文：**
背景：前列腺癌（PCa）是全球男性中普遍存在的恶性肿瘤，并正在施加日益增加的流行病学负担。雄激素受体（AR）信号轴在PCa肿瘤发生和疾病进展中具有根本性意义。尽管雄激素剥夺疗法（ADT）在大多数病例中引发短暂的治疗反应，但进展为去势抵抗性前列腺癌（CRPC）仍然是一个几乎普遍的临床轨迹。失调的脂质稳态，表现为细胞内脂质沉积，已在机制上与CRPC的发病机制以及在恩杂鲁胺方案下的治疗失败相关联。然而，减轻PCa中脂质积累的有效策略仍然难以捉摸。

方法：通过公共数据库的综合生物信息学分析，STARD4（一个参与脂质代谢的关键基因）被确定为在PCa中具有功能重要性。通过RT-qPCR、Western印迹分析和IHC染色评估STARD4的表达，同时通过Kaplan-Meier生存分析、Gleason评分和肿瘤分期评估其在PCa中的临床意义。通过体外和体内实验阐明了STARD4的生物学功能及其对恩杂鲁胺耐药的贡献。通过油红O（ORO）染色评估STARD4对PCa细胞异常脂质积累的影响，同时通过内质网（ER）追踪成像和透射电子显微镜（TEM）评估其对ER应激的影响。机制探索涉及多种技术的结合，包括RNA-seq分析、基因本体分析、免疫共沉淀（Co-IP）和GST pull-down实验，以分析涉及STARD4、AR和E3泛素连接酶UBE4B的相互作用和潜在机制。

结果：在本研究中，我们观察到STARD4表达在PCa组织中显著降低，并与不良预后相关。STARD4过表达通过ER应激抑制PCa细胞增殖、迁移和脂质积累，同时促进细胞凋亡。机制上，STARD4增强了UBE4B与AR之间的相互作用，促进AR泛素化和降解，从而抑制AR信号传导。此外，STARD4表达的上调通过减少脂质积累和抑制AR信号通路，增强了耐药细胞对恩杂鲁胺的敏感性。总之，STARD4通过调节胆固醇代谢和调控AR信号传导，在PCa中发挥肿瘤抑制因子的作用。

结论：我们的研究结果将STARD4确定为逆转PCa中恩杂鲁胺耐药性的有前景的治疗靶点，同时也为未来肿瘤微环境中脂质代谢的研究提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在探究STARD4在前列腺癌肿瘤发生和恩杂鲁胺耐药中的作用机制。研究团队采用多组学分析结合体内外实验，系统评估了STARD4的临床意义和生物学功能。关键发现表明STARD4通过促进AR泛素化降解和调节脂质代谢，发挥肿瘤抑制作用并逆转耐药性。该研究的创新性在于首次揭示了STARD4-UBE4B-AR轴在脂质代谢重编程中的调控机制，为克服前列腺癌耐药提供了新的治疗靶点，具有重要的临床转化价值。然而，研究主要聚焦于细胞和动物模型，未来需要更多临床样本验证其治疗潜力。

---

## 8. 基因组范围的循环游离DNA甲基化分析识别出肺癌的表观遗传特征：验证EMP2作为潜在生物标志物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331845](https://pubmed.ncbi.nlm.nih.gov/41331845)
**期刊：** Clinical epigenetics
**PMID：** 41331845
**DOI：** 10.1186/s13148-025-02026-4

### 第一部分 原文与翻译

**英文原标题：** Genome-wide methylation analysis of circulating cell-free DNA identifies an episignature in lung cancer: validation of EMP2 as a potential biomarker.

**英文摘要原文：**
BACKGROUND: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Its poor prognosis is largely attributed to late-stage diagnosis, highlighting the need for sensitive, minimally invasive biomarkers for early detection. In this study, we aimed to identify circulating cell-free DNA (cfDNA) methylation-based biomarkers for LC through genome-wide profiling of plasma-derived cfDNA from patients with LC (stages I-IV) using the Infinium DNA MethylationEPIC array (> 850,000 CpGs). A relaxed elastic net penalized logistic regression model was applied to identify differentially methylated CpGs between LC patients and non-neoplastic controls, and selected candidates were validated in an independent cohort.

RESULTS: A 21-CpG episignature was identified, predominantly hypomethylated in LC, which distinguished cases (n = 25) from controls (n = 8) with a cross-validated area under the curve (AUC) of 0.70. Two CpGs with the largest effect sizes (associated with EMP2 and IKZF2) were selected for validation. Digital droplet PCR (ddPCR) analysis in an independent cohort of 47 individuals (23 LC patients and 24 controls) confirmed significant hypomethylation at the EMP2 locus (median % methylation: 73.60% in tumors vs. 86.83% in controls; p = 0.0034), achieving an AUC of 0.75.

CONCLUSIONS: Our findings support the utility of methylome-wide cfDNA profiling for LC biomarker discovery. EMP2 promoter methylation represents a promising candidate for the minimally invasive detection of LC across heterogeneous clinical presentations.

**中文摘要译文：**
背景：肺癌仍然是全球癌症相关死亡的主要原因。其不良预后很大程度上归因于晚期诊断，这凸显了对早期检测的敏感、微创生物标志物的需求。在本研究中，我们旨在通过使用Infinium DNA甲基化EPIC芯片（>850,000个CpG位点）对肺癌患者（I-IV期）血浆来源的循环游离DNA进行全基因组分析，识别基于cfDNA甲基化的肺癌生物标志物。应用松弛弹性网络惩罚逻辑回归模型来识别肺癌患者与非肿瘤对照之间的差异甲基化CpG位点，并在独立队列中验证选定的候选位点。

结果：识别出一个包含21个CpG位点的表观遗传特征，主要在肺癌中呈现低甲基化，该特征能够区分病例（n=25）与对照（n=8），交叉验证的曲线下面积（AUC）为0.70。选择效应量最大的两个CpG位点（与EMP2和IKZF2相关）进行验证。在包含47名个体（23名肺癌患者和24名对照）的独立队列中进行数字液滴PCR分析，证实了EMP2位点的显著低甲基化（中位甲基化百分比：肿瘤中73.60% vs. 对照中86.83%；p=0.0034），达到的AUC为0.75。

结论：我们的研究结果支持全甲基组cfDNA分析在肺癌生物标志物发现中的应用价值。EMP2启动子甲基化代表了在不同临床表型的肺癌微创检测中一个有前景的候选标志物。

### 第二部分 AI 大师评价

本研究旨在通过全基因组循环游离DNA甲基化分析，开发肺癌的微创早期诊断生物标志物。研究团队采用Infinium EPIC芯片对850,000多个CpG位点进行甲基化谱分析，结合松弛弹性网络模型筛选出21-CpG表观遗传特征，并在独立队列中通过ddPCR验证了EMP2位点的诊断价值。该研究的创新性在于首次系统性地鉴定了肺癌特异的cfDNA甲基化特征，特别是EMP2启动子低甲基化作为跨临床分型的稳定标志物，为肺癌液体活检提供了新的分子靶点。虽然样本量相对有限，且需要更大规模的前瞻性验证，但这项研究为肺癌早期筛查开辟了基于表观遗传学的无创检测新途径，具有重要的临床转化潜力。

---

## 9. LL22NC03-N14H11.1通过抑制IGF2BP3泛素化降解调控MYC的m6A修饰并促进肝细胞癌细胞的糖酵解活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331843](https://pubmed.ncbi.nlm.nih.gov/41331843)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41331843
**DOI：** 10.1186/s13046-025-03606-1

### 第一部分 原文与翻译

**英文原标题：** LL22NC03-N14H11.1 regulates the m6A modification of MYC and promotes glycolytic activity in hepatocellular carcinoma cells by inhibiting IGF2BP3 ubiquitination degradation.

**英文摘要原文：**
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer-related mortality globally. Long non-coding RNAs (lncRNAs) are increasingly recognized for their pivotal roles in hepatocarcinogenesis. Specifically, the lncRNA LL22NC03-N14H11.1 (hereafter referred to as LL22NC03) has been characterized as a potent oncogenic factor in certain cancers. Therefore, our research aimed to investigate the involvement of LL22NC03 in HCC progression. METHODS: We analyzed the expression of IGF2BP3 in HCC specimens obtained from The Cancer Genome Atlas (TCGA) dataset. Further investigation via RNA pull-down and mass spectrometry analysis identified LL22NC03 as a binding partner of IGF2BP3, with LL22NC03 enhancing the stability of IGF2BP3 by inhibiting TRIM25-mediated ubiquitination. Subsequent in vitro and in vivo experiments were conducted to explore the modulation of LL22NC03 expression, in combination with manipulation of IGF2BP3 levels, which significantly impacted glycolysis, proliferation, migration, and invasiveness of HCC cells. RESULTS: The study identified LL22NC03 as a promoter of HCC proliferation and migration of HCC cells. LL22NC03 was observed to bind to the ubiquitination site of IGF2BP3, thereby preventing its degradation and enhancing its stability. This interaction ultimately inhibited the degradation of IGF2BP3. Additionally, the interaction between LL22NC03 and IGF2BP3 facilitated the transcription of MYC, leading to the upregulation of glycolytic genes, including HK2, LDHA, GLUT1, PKM2, and PDK1. Finally, IGF2BP3 played a role in stabilizing MYC by recognizing N6-methyladenosine (m6A) modifications. CONCLUSION: The LL22NC03-IGF2BP3-MYC regulatory axis is critically involved in the progression of HCC, suggesting its potential as a novel therapeutic target for this malignancy.

**中文摘要译文：**
背景：肝细胞癌（HCC）是全球癌症相关死亡率的第五大原因。长链非编码RNA（lncRNA）在肝癌发生中的关键作用日益受到认可。具体而言，lncRNA LL22NC03-N14H11.1（以下简称LL22NC03）已被表征为某些癌症中的强效致癌因子。因此，我们的研究旨在探讨LL22NC03在HCC进展中的参与。方法：我们分析了来自癌症基因组图谱（TCGA）数据集的HCC标本中IGF2BP3的表达。通过RNA pull-down和质谱分析的进一步研究确定了LL22NC03是IGF2BP3的结合伴侣，LL22NC03通过抑制TRIM25介导的泛素化来增强IGF2BP3的稳定性。随后进行了体外和体内实验，以探索LL22NC03表达的调控，结合IGF2BP3水平的操作，显著影响了HCC细胞的糖酵解、增殖、迁移和侵袭能力。结果：该研究确定LL22NC03是HCC细胞增殖和迁移的促进因子。观察到LL22NC03与IGF2BP3的泛素化位点结合，从而防止其降解并增强其稳定性。这种相互作用最终抑制了IGF2BP3的降解。此外，LL22NC03与IGF2BP3之间的相互作用促进了MYC的转录，导致糖酵解基因的上调，包括HK2、LDHA、GLUT1、PKM2和PDK1。最后，IGF2BP3通过识别N6-甲基腺苷（m6A）修饰在稳定MYC中发挥了作用。结论：LL22NC03-IGF2BP3-MYC调控轴在HCC的进展中起着关键作用，表明其作为该恶性肿瘤的新型治疗靶点的潜力。

### 第二部分 AI 大师评价

本研究旨在探究lncRNA LL22NC03在肝细胞癌进展中的作用机制。研究团队采用TCGA数据分析、RNA pull-down与质谱分析、以及体外体内功能实验相结合的方法，系统揭示了LL22NC03通过结合IGF2BP3抑制其TRIM25介导的泛素化降解，从而稳定IGF2BP3蛋白，进而促进MYC转录并上调糖酵解相关基因表达的分子通路。该研究的创新性在于首次阐明了LL22NC03-IGF2BP3-MYC这一新型调控轴在HCC糖代谢重编程中的关键作用，为理解HCC的代谢异常提供了新的分子机制。这一发现不仅具有重要的科研价值，揭示了lncRNA调控蛋白稳定性的新范式，而且为开发针对该通路的靶向治疗策略提供了潜在靶点，对HCC的精准治疗具有临床转化前景。

---

## 10. 用于肺腺癌早期诊断和晚期预后评估的小细胞外囊泡来源RNA标志物的开发与验证

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331809](https://pubmed.ncbi.nlm.nih.gov/41331809)
**期刊：** Molecular cancer
**PMID：** 41331809
**DOI：** 10.1186/s12943-025-02524-2

### 第一部分 原文与翻译

**英文原标题：** Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages.

**英文摘要原文：**
This study developed and validated a diagnostic signature comprising five small extracellular vesicle (sEV)-derived long RNAs (ATF4, GRAP2, MCL1, PAK2, PIK3CB) for distinguishing early-stage lung adenocarcinoma (LUAD) from benign pulmonary nodules and assessing prognosis in advanced LUAD. Utilizing a multi-center cohort of 698 participants, researchers employed RNA sequencing and quantitative PCR to analyze plasma sEV RNA profiles. Differentially expressed mRNAs and long intergenic non-coding RNAs (lincRNAs) were identified using LASSO regression to construct a diagnostic model. The signature demonstrated high diagnostic accuracy with an area under the curve (AUC) of 0.971 in the validation cohort and 0.950 in the prospective cohort. It also surpassed low-dose CT sensitivity (95.24% vs. 71.43%), specificity (100% vs. 93.96%), positive predictive value (100% vs. 45.45%) and negative predictive value (99.67% vs. 97.90%) in the prospective cohort. In advanced LUAD patients undergoing chemoradiotherapy or PD-L1 inhibitor therapy, lower expression of these RNAs correlated with improved progression-free survival (PFS; HR = 0.38-0.39). The signature integrates non-invasively detected sEV RNAs to complement LDCT, addressing its high false-positive rate, and offers prognostic insights for personalized treatment strategies. These findings highlight the clinical potential of sEV-derived long RNAs in early LUAD detection and precision oncology.

**中文摘要译文：**
本研究开发并验证了一个包含五种小细胞外囊泡（sEV）来源长RNA（ATF4、GRAP2、MCL1、PAK2、PIK3CB）的诊断标志物，用于区分早期肺腺癌（LUAD）与良性肺结节，并评估晚期LUAD的预后。研究人员利用包含698名参与者的多中心队列，采用RNA测序和定量PCR分析血浆sEV RNA谱。通过LASSO回归识别差异表达的mRNA和长基因间非编码RNA（lincRNA），构建了诊断模型。该标志物在验证队列中显示出高诊断准确性，曲线下面积（AUC）为0.971，在前瞻性队列中为0.950。在前瞻性队列中，其敏感性（95.24% vs. 71.43%）、特异性（100% vs. 93.96%）、阳性预测值（100% vs. 45.45%）和阴性预测值（99.67% vs. 97.90%）均超过低剂量CT。在接受放化疗或PD-L1抑制剂治疗的晚期LUAD患者中，这些RNA的较低表达与改善的无进展生存期（PFS；HR = 0.38-0.39）相关。该标志物整合了非侵入性检测的sEV RNA，以补充LDCT，解决其高假阳性率问题，并为个性化治疗策略提供预后见解。这些发现突显了sEV来源长RNA在早期LUAD检测和精准肿瘤学中的临床潜力。

### 第二部分 AI 大师评价

本研究旨在开发基于小细胞外囊泡来源RNA的液体活检标志物，用于肺腺癌的早期诊断和晚期预后评估。研究团队采用多中心队列设计，结合RNA测序和LASSO回归分析，成功构建了包含五种长RNA的诊断模型。关键发现显示该标志物具有极高的诊断准确性（AUC达0.971），在敏感性和特异性方面显著优于传统低剂量CT，同时还能预测晚期患者的治疗反应和生存预后。该研究的创新性在于首次系统性地将sEV来源长RNA应用于肺腺癌的全程管理，为临床提供了非侵入性、高精度的诊断工具，有望解决目前肺癌筛查中低剂量CT假阳性率高的难题，推动精准肿瘤学的发展。然而，研究仍需更大规模的前瞻性验证，并探索其在其他肺癌亚型中的适用性。

---

## 11. 一种表达E4BP4的、依赖于微生物群和IL-15的先天样B细胞祖细胞

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331732](https://pubmed.ncbi.nlm.nih.gov/41331732)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41331732
**DOI：** 10.1002/advs.202512444

### 第一部分 原文与翻译

**英文原标题：** A Microbiota- and IL-15-Dependent Innate-Like B Cell Progenitor Expressing E4BP4.

**英文摘要原文：**
While natural killer (NK) cells and B cells arise from common lymphoid progenitors, the existence and nature of cells co-expressing markers of both lineages (NK-B cells) remain controversial. Here, this work identifies a significant population of CD3⁻NKp46⁺CD19⁺NK1.1⁺ cells, termed NK-B cells, enriched in phosphoinositide-dependent protein kinase-1(PDK1)-deficient mice but also present in wild-type bone marrow. Single-cell RNA sequencing and high-dimensional flow cytometry reveal these NK-B cells reside within early B cell developmental stages (pro-B/pre-B). Functionally, upon adoptive transfer into lymphocyte-deficient hosts, NK-B cells preferentially differentiated into B cells. Unlike conventional B cell precursors, NK-B cells exhibit innate characteristics, including the capacity to secrete interferon-gamma (IFN-γ) and transforming growth factor-beta (TGF-β), and expressed CD122 (IL-2/15Rβ) and Toll-like receptor 9 (TLR9). Using a novel E4 promoter-binding protein 4 (E4BP4) reporter model, this work demonstrates that both interleukin-15 (IL-15) signaling (via CD122) and TLR9-mediated sensing of the gut microbiota cooperatively sustain E4BP4 expression within these progenitors. Consequently, germ-free mice and mice deficient in IL-15 or E4BP4 exhibit a profound loss of NK-B cells. These findings unveil a distinct E4BP4-expressing, innate-like B cell progenitor pathway regulated by microbiota and IL-15.

**中文摘要译文：**
虽然自然杀伤（NK）细胞和B细胞都来源于共同的淋巴祖细胞，但共表达两个谱系标记（NK-B细胞）的细胞的存在和性质仍然存在争议。本研究在磷酸肌醇依赖性蛋白激酶-1（PDK1）缺陷小鼠中鉴定出一个显著的CD3⁻NKp46⁺CD19⁺NK1.1⁺细胞群体，称为NK-B细胞，该群体在野生型骨髓中也存在。单细胞RNA测序和高维流式细胞术显示，这些NK-B细胞位于早期B细胞发育阶段（pro-B/pre-B）。在功能上，当通过过继转移进入淋巴细胞缺陷宿主时，NK-B细胞优先分化为B细胞。与传统的B细胞前体不同，NK-B细胞表现出先天特性，包括分泌干扰素-γ（IFN-γ）和转化生长因子-β（TGF-β）的能力，并表达CD122（IL-2/15Rβ）和Toll样受体9（TLR9）。使用一种新型的E4启动子结合蛋白4（E4BP4）报告模型，本研究证明白细胞介素-15（IL-15）信号传导（通过CD122）和TLR9介导的肠道微生物群感知协同维持这些祖细胞中E4BP4的表达。因此，无菌小鼠以及IL-15或E4BP4缺陷小鼠表现出NK-B细胞的显著减少。这些发现揭示了一条独特的、表达E4BP4的、受微生物群和IL-15调节的先天样B细胞祖细胞途径。

### 第二部分 AI 大师评价

本研究旨在探索免疫系统中争议性的NK-B细胞的存在、特性和调控机制。研究团队综合运用了单细胞RNA测序、高维流式细胞术、基因缺陷小鼠模型和过继转移实验等多种先进技术方法。关键发现是鉴定出一种独特的先天样B细胞祖细胞（NK-B细胞），其发育依赖于肠道微生物群通过TLR9的信号传导和IL-15介导的E4BP4表达调控。这项研究的创新性在于首次揭示了微生物群-免疫轴在B细胞早期发育中的具体作用机制，挑战了传统B细胞发育的认知框架。该发现具有重要的科研价值，为理解先天免疫与适应性免疫的交叉调控提供了新视角，并为未来开发针对微生物群相关免疫疾病的治疗策略奠定了理论基础。研究的局限性在于主要基于小鼠模型，其临床转化价值仍需在人类系统中进一步验证。

---

## 12. 分泌型甲硫氨酸腺苷转移酶α2在结直肠癌肝转移中的新作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331630](https://pubmed.ncbi.nlm.nih.gov/41331630)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41331630
**DOI：** 10.1186/s13046-025-03599-x

### 第一部分 原文与翻译

**英文原标题：** A novel role of secreted methionine adenosyltransferase α2 in colorectal liver metastases.

**英文摘要原文：**
BACKGROUND: Colorectal liver metastasis (CRLM) occurs frequently in patients with colorectal cancer (CRC). Methionine adenosyltransferase (MAT) catalyzes the formation of S-adenosylmethionine, the principal methyl donor. MAT1A (encodes MATα1) is expressed mainly in normal adult liver, whereas MAT2A (encodes MATα2) is expressed in all extrahepatic tissues. MAT1A is a major defense against CRLM as loss of Mat1a sensitizes the liver to CRLM. In contrast, MAT2A is overexpressed in CRC and promotes oncogenicity. Here, we sought to determine if CRCs secrete MATα2 and if this influences CRLM.

METHODS: Our study included human hepatocytes, human CRC cells, extracellular vesicle (EV) isolation, chromatin immunoprecipitation (ChIP), ChIP-seq, promoter activity assays, proliferation, migration, and invasion assays, western blotting, immunohistochemistry and immunofluorescence. We confirmed some of the findings using human hepatocyte spheroids, CRLM and normal liver tissue array, and plasma samples.

RESULTS: CRCs secrete MATα2 in free but truncated form (MATα2-t) and intact within EVs (EV-MATα2). EV-MATα2 can be internalized by human hepatocytes and CRCs, found within the nucleus, which then binds to MAT1A and MAT2A promoters on ChIP to lower and increase MAT1A and MAT2A promoter activities, respectively. In human CRLM samples, hepatocytes in nontumor regions express lower MATα1 but higher MATα2 as compared to normal liver. Treating RKO cells with EVs released from RKO cells overexpressing MAT2A promoted cell proliferation, migration, and invasion. MATα2-t was detected at a higher level in media from colon, pancreatic, and prostate cancer cell lines than corresponding normal epithelial cells as well as in the plasma of CRC patients as compared to healthy controls. RKO cells treated with MATα2-t activated focal adhesion kinase (FAK), an important kinase for cancer cell evasion of apoptosis. Conversely, treatment with MATα2 neutralizing antibody inhibited FAK and induced apoptosis.

CONCLUSIONS: CRC cells secrete both MATα2 within EVs and free MATα2-t. EV-MATα2 can be internalized and act as a transcription factor to lower hepatocytes' MAT1A, the major defense against CRLM, while promoting CRC oncogenicity. Freely released MATα2-t acts as a ligand in an autocrine fashion to activate FAK, which is essential for CRC survival. Taken together, secreted MATα2 plays an essential role in promoting CRLM.

**中文摘要译文：**
背景：结直肠癌肝转移（CRLM）在结直肠癌（CRC）患者中频繁发生。甲硫氨酸腺苷转移酶（MAT）催化S-腺苷甲硫氨酸的形成，这是主要的甲基供体。MAT1A（编码MATα1）主要在正常成人肝脏中表达，而MAT2A（编码MATα2）在所有肝外组织中表达。MAT1A是对抗CRLM的主要防御机制，因为Mat1a的缺失会使肝脏对CRLM敏感。相反，MAT2A在CRC中过表达并促进致癌性。本研究旨在确定CRC是否分泌MATα2以及这是否影响CRLM。

方法：我们的研究包括人肝细胞、人CRC细胞、细胞外囊泡（EV）分离、染色质免疫沉淀（ChIP）、ChIP-seq、启动子活性测定、增殖、迁移和侵袭实验、蛋白质印迹、免疫组织化学和免疫荧光。我们使用人肝细胞球体、CRLM和正常肝组织芯片以及血浆样本验证了部分发现。

结果：CRC以游离但截短的形式（MATα2-t）和完整存在于EVs内（EV-MATα2）分泌MATα2。EV-MATα2可被人肝细胞和CRC细胞内化，在细胞核内发现，然后通过ChIP结合到MAT1A和MAT2A启动子上，分别降低和增加MAT1A和MAT2A启动子活性。在人CRLM样本中，非肿瘤区域的肝细胞与正常肝脏相比表达较低的MATα1但较高的MATα2。用过表达MAT2A的RKO细胞释放的EVs处理RKO细胞可促进细胞增殖、迁移和侵袭。与相应的正常上皮细胞相比，在结肠、胰腺和前列腺癌细胞系培养基中检测到更高水平的MATα2-t；与健康对照相比，在CRC患者血浆中也检测到更高水平的MATα2-t。用MATα2-t处理的RKO细胞激活了黏着斑激酶（FAK），这是癌细胞逃避凋亡的重要激酶。相反，用MATα2中和抗体处理可抑制FAK并诱导凋亡。

结论：CRC细胞既在EVs内分泌MATα2，也分泌游离的MATα2-t。EV-MATα2可被内化并作为转录因子降低肝细胞的MAT1A（对抗CRLM的主要防御机制），同时促进CRC的致癌性。自由释放的MATα2-t以自分泌方式作为配体激活FAK，这对CRC生存至关重要。综上所述，分泌的MATα2在促进CRLM中起着至关重要的作用。

### 第二部分 AI 大师评价

本研究旨在揭示结直肠癌细胞分泌的甲硫氨酸腺苷转移酶α2（MATα2）在促进肝转移中的新机制。研究采用多种细胞和分子生物学技术，包括细胞外囊泡分离、染色质免疫沉淀、启动子活性分析等，系统性地探索了MATα2的分泌形式及其功能。关键发现表明，CRC细胞通过两种形式分泌MATα2：细胞外囊泡包裹的完整形式（EV-MATα2）和游离截短形式（MATα2-t），前者作为转录因子调控肝细胞防御基因表达，后者通过激活FAK通路促进癌细胞生存。该研究的创新性在于首次揭示了MATα2的分泌特性及其在转移微环境中的双重作用机制，为理解CRLM的分子基础提供了新视角。其临床价值在于为开发针对分泌型MATα2的治疗策略（如中和抗体）提供了理论依据，可能成为抑制结直肠癌肝转移的新靶点。然而，研究主要基于体外和部分临床样本验证，未来需要在更多体内模型和临床队列中进一步验证这些发现。

---

## 13. 多组学分析揭示小细胞肺癌的异质性、微环境特征及生物标志物图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331472](https://pubmed.ncbi.nlm.nih.gov/41331472)
**期刊：** Molecular cancer
**PMID：** 41331472
**DOI：** 10.1186/s12943-025-02514-4

### 第一部分 原文与翻译

**英文原标题：** Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer.

**英文摘要原文：**
BACKGROUND: Greater understanding of differential therapeutic sensitivity, specifically to immunotherapy, in small-cell lung cancer (SCLC) is required.

METHODS: We explored SCLC heterogeneity through integrated molecular characterization of tumor tissue samples from 159 treatment-naive patients, utilizing genetic, epigenetic, transcriptional, and proteomic profiling, immunohistochemistry staining for multiple biologically relevant markers including transcriptional subtype-defining proteins, and spatial immune profiling using multiplex immunofluorescence.

RESULTS: Multi-omics analysis confirmed high heterogeneity across/within neuroendocrine and non-neuroendocrine subtypes. Methylomics analysis identified four methylome clusters that may enhance subtype prediction, prognosis, and longitudinal monitoring of subtype evolution. Immunohistochemistry analysis showed high MHC-I expression in non-neuroendocrine subtypes, which have greatest potential benefit from adding immunotherapy to chemotherapy; high DLL3 expression associated with neuroendocrine subtypes and an immune-cold tumor microenvironment. Multiplex immunofluorescence demonstrated associations of MHC-I with spatial arrangement and phenotypic features of immune cells in the tumor microenvironment of high-MHC-I-expressing SCLC, providing mechanistic rationale for MHC-I as a potential biomarker of immunotherapy response.

CONCLUSIONS: This multimodal profiling analysis provides further insights into the biologic complexity of SCLC and highlights potential therapeutic vulnerabilities of distinct disease subtypes.

**中文摘要译文：**
背景：需要更深入地理解小细胞肺癌（SCLC）对治疗（特别是免疫治疗）的差异性敏感性。

方法：我们通过对159例初治患者的肿瘤组织样本进行整合分子表征，探索SCLC的异质性，包括遗传学、表观遗传学、转录组学和蛋白质组学分析，针对多个生物学相关标志物（包括定义转录亚型的蛋白）进行免疫组织化学染色，以及使用多重免疫荧光进行空间免疫分析。

结果：多组学分析证实了神经内分泌和非神经内分泌亚型之间/内部的高度异质性。甲基化组学分析确定了四个甲基化组簇，可能增强亚型预测、预后评估和亚型演变的纵向监测。免疫组织化学分析显示非神经内分泌亚型中MHC-I高表达，这些亚型在化疗基础上加用免疫治疗的潜在获益最大；DLL3高表达与神经内分泌亚型和免疫"冷"肿瘤微环境相关。多重免疫荧光显示，在高表达MHC-I的SCLC肿瘤微环境中，MHC-I与免疫细胞的空间排列和表型特征存在关联，为MHC-I作为免疫治疗反应的潜在生物标志物提供了机制依据。

结论：这种多模态分析为SCLC的生物学复杂性提供了进一步见解，并突出了不同疾病亚型的潜在治疗脆弱性。

### 第二部分 AI 大师评价

本研究通过整合多组学技术深入解析了小细胞肺癌的分子异质性，核心目的是探索不同亚型对免疫治疗的敏感性差异。研究采用遗传学、表观遗传学、转录组学、蛋白质组学及空间免疫分析等多模态方法，对159例初治患者进行全面表征。关键发现包括：甲基化组簇可增强亚型预测和监测，MHC-I高表达与非神经内分泌亚型及免疫治疗潜在获益相关，DLL3高表达与神经内分泌亚型及免疫"冷"微环境相关。该研究的创新性在于首次系统整合多组学数据揭示SCLC亚型特异性特征，临床价值在于为精准免疫治疗提供潜在生物标志物（如MHC-I），但样本量相对有限且为回顾性分析，未来需要前瞻性验证。

---

## 14. 用于体内精确检测易损斑块的单核细胞分化激活荧光"侦察"探针

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331403](https://pubmed.ncbi.nlm.nih.gov/41331403)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41331403
**DOI：** 10.1002/advs.202515289

### 第一部分 原文与翻译

**英文原标题：** Monocyte-Differentiation-Activated Fluorescent "Scout" Probe for Precise in Vivo Detection of Vulnerable Plaque.

**英文摘要原文：**
Precise identification of vulnerable plaque (VAP) is essential for the prevention of acute cardiovascular diseases, yet current molecular probes are hampered by poor VAP lesion penetration and high background. Here, the innate tropism of circulating inflammatory monocytes for VAP, and their differentiation-driven expression of legumain (Lgmn) in response to the VAP microenvironment is exploited. A monocyte differentiation-activated fluorescent (MDAF) probe is conceived that hitchhikes monocytes to precisely migrate to VAP and is activated by Lgmn during monocyte differentiation. This activation triggers in situ self-assembly, resulting in spatiotemporally controlled aggregation-induced emission (AIE) fluorescence signals, and turning the monocyte itself into an on-site "scout" that reports plaque instability. In Apoe mice bearing both vulnerable and stable plaques, the MDAF produces a striking OFF/ON fluorescence switch confined to vulnerable lesions, yielding a markedly improved signal-to-noise ratio (SNR). By integrating fluorescence emission computed tomography (FLECT), MDAF probe surpasses the depth limitations of conventional fluorescence imaging. Therefore, the AIE signal of the MDAF probe is more than just a "fluorescent read-out," and it also acts as a crucial safety switch that transforms the monocyte into a ratiometric immune scout for plaque instability. This innovative strategy offers a translatable approach for the precision diagnosis of VAP.

**中文摘要译文：**
精确识别易损斑块（VAP）对于预防急性心血管疾病至关重要，然而目前的分子探针受到VAP病变穿透性差和背景信号高的限制。本研究利用了循环炎症单核细胞对VAP的天然趋向性，以及它们在VAP微环境刺激下分化驱动的legumain（Lgmn）表达。我们设计了一种单核细胞分化激活荧光（MDAF）探针，该探针"搭便车"于单核细胞，精确迁移至VAP，并在单核细胞分化过程中被Lgmn激活。这种激活触发了原位自组装，产生时空可控的聚集诱导发射（AIE）荧光信号，并将单核细胞本身转变为报告斑块不稳定性的现场"侦察兵"。在同时携带易损和稳定斑块的Apoe小鼠中，MDAF探针产生了局限于易损病变的显著OFF/ON荧光开关，显著提高了信噪比（SNR）。通过整合荧光发射计算机断层扫描（FLECT），MDAF探针超越了传统荧光成像的深度限制。因此，MDAF探针的AIE信号不仅仅是一个"荧光读数"，它还充当了一个关键的安全开关，将单核细胞转变为用于斑块不稳定性的比率免疫侦察兵。这一创新策略为VAP的精准诊断提供了一种可转化的方法。

### 第二部分 AI 大师评价

本研究旨在解决易损斑块精准检测的临床难题，创新性地利用单核细胞的天然趋向性和分化特异性表达legumain的特性，开发了一种"搭便车"式荧光探针。该探针通过单核细胞分化激活机制，在斑块部位实现原位自组装和聚集诱导发射，显著提高了检测特异性和信噪比。结合荧光发射计算机断层扫描技术，该策略突破了传统成像的深度限制，将单核细胞转变为报告斑块不稳定性的"免疫侦察兵"，为心血管疾病的早期预警和精准干预提供了极具转化潜力的新工具。然而，该技术仍需在大型动物模型和临床前研究中进一步验证其安全性和有效性。

---

## 15. 更正：维奈托克联合布鲁顿酪氨酸激酶抑制剂固定疗程治疗慢性淋巴细胞白血病：对伊布替尼与阿卡替尼差异的深入分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331358](https://pubmed.ncbi.nlm.nih.gov/41331358)
**期刊：** Leukemia
**PMID：** 41331358
**DOI：** 10.1038/s41375-025-02824-y

### 第一部分 原文与翻译

**英文原标题：** Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究为一篇更正文章，聚焦于慢性淋巴细胞白血病（CLL）的固定疗程治疗策略，具体探讨维奈托克联合布鲁顿酪氨酸激酶抑制剂（BTKi）的治疗方案。研究核心在于比较两种BTKi药物——伊布替尼与阿卡替尼——在联合维奈托克治疗CLL时的潜在差异，为临床选择提供循证依据。虽然作为更正文章，其创新性可能主要体现在对原始研究的修正或补充上，但该主题本身具有重要的临床价值，有助于优化CLL的精准治疗策略，推动个体化医疗发展。由于摘要不可用，无法评估具体的研究方法、关键发现及局限性，建议读者查阅全文获取详细信息。

---

## 16. 小鼠卵子发生和胚胎植入前发育过程中H2A.Z组蛋白变体大规模掺入的主要波动

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331258](https://pubmed.ncbi.nlm.nih.gov/41331258)
**期刊：** Nature communications
**PMID：** 41331258
**DOI：** 10.1038/s41467-025-66919-x

### 第一部分 原文与翻译

**英文原标题：** Major waves of H2A.Z incorporation during mouse oogenesis and preimplantation embryo development.

**英文摘要原文：**
Epigenomes of mammalian oocytes and embryos undergo major transitions essential for successful development. Here, we provide genome-wide maps of histone variant H2A.Z during twelve stages of mouse oogenesis and preimplantation embryo development and relate it to histone marks and genomic features. This revealed that major waves of H2A.Z incorporation occur early in growing oocytes, forming distinct patterns of maternal, embryonic, and persistent H2A.Z enrichment. Late maternal enrichment is inherited by the zygote and precedes reduced formation of lamina associated domains and early replication in the maternal genome of 2-cell embryos. Persistent H2A.Z enrichment is strongly associated with CpG islands and H3K4me3 near transcription start sites of active genes, but thousands of maternal and embryonic H2A.Z incorporation sites exist elsewhere, frequently at transposable elements. The persisting H2A.Z enrichments across related developmental stages enable preservation of epigenetic information despite major concurrent changes in H3K4me3, H3K27me3, and DNA methylation. Altogether, this advances our understanding of how histone variants contribute to epigenetic reprogramming during mammalian oogenesis and early development.

**中文摘要译文：**
哺乳动物卵母细胞和胚胎的表观基因组经历对成功发育至关重要的重大转变。在此，我们提供了小鼠卵子发生和胚胎植入前发育十二个阶段中组蛋白变体H2A.Z的全基因组图谱，并将其与组蛋白修饰和基因组特征相关联。这揭示了H2A.Z掺入的主要波动发生在生长中卵母细胞的早期，形成了母源、胚胎和持久性H2A.Z富集的独特模式。晚期母源富集被受精卵继承，并先于2细胞胚胎母源基因组中核纤层相关结构域形成减少和早期复制。持久性H2A.Z富集与活跃基因转录起始位点附近的CpG岛和H3K4me3密切相关，但数千个母源和胚胎H2A.Z掺入位点存在于其他位置，通常位于转座元件处。跨相关发育阶段的持久性H2A.Z富集使得表观遗传信息得以保存，尽管H3K4me3、H3K27me3和DNA甲基化同时发生重大变化。总之，这增进了我们对组蛋白变体如何促进哺乳动物卵子发生和早期发育过程中表观遗传重编程的理解。

### 第二部分 AI 大师评价

本研究旨在系统解析组蛋白变体H2A.Z在小鼠卵子发生和胚胎植入前发育过程中的动态变化规律。研究团队采用全基因组测序技术，绘制了十二个关键发育阶段H2A.Z的分布图谱，并将其与多种表观遗传标记进行关联分析。核心发现揭示了H2A.Z掺入存在三个主要波动期，分别形成母源、胚胎和持久性富集模式，其中持久性富集与基因活性调控元件密切相关，且在表观遗传重编程过程中表现出信息保存功能。该研究的创新性在于首次系统描绘了H2A.Z在整个早期发育过程中的动态全景图，为理解表观遗传记忆的跨代传递机制提供了新视角，对生殖医学和发育生物学领域具有重要理论价值。然而，研究主要基于小鼠模型，其结论在人类系统中的普适性仍需进一步验证。

---

## 17. 食物源性配体对芳烃受体的生理性激活是抗PD1疗法疗效所必需的

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331250](https://pubmed.ncbi.nlm.nih.gov/41331250)
**期刊：** Nature communications
**PMID：** 41331250
**DOI：** 10.1038/s41467-025-66854-x

### 第一部分 原文与翻译

**英文原标题：** Physiological activation of Aryl hydrocarbon receptor by food-derived ligands is essential for the efficacy of anti-PD1 therapy.

**英文摘要原文：**
Cancer immuno-surveillance and response to therapy are affected by environmental factors, including nutrition. However, the direct effects of individual nutrients remain poorly understood. Here we investigate the impact of dietary ligands of Aryl hydrocarbon receptor (AhR), a transcription factor activated by tryptophan catabolites generated through food digestion and microbiota metabolism. By analyzing pre-clinical tumor models in mice fed on a diet naturally poor in AhR ligands or the same diet supplemented with Indole-3-carbinol, we show that diet-derived AhR ligands are required for the optimal efficacy of anti-PD1 therapy. Using conditional knockout mice, we evidence an essential role for AhR in CD8 T cells, but not NK cells or myeloid cells. Mechanistically, AhR promotes anti-PD1-mediated reinvigoration of progenitor exhausted CD8 T cells and licences the functional response of effector CD8 T cells. Our work allows a better understanding of the role of nutrients in anti-tumor immune responses and has implications for the rational design of dietary interventions for improving the efficacy of checkpoint blockade therapy.

**中文摘要译文：**
癌症免疫监视和对治疗的反应受到环境因素（包括营养）的影响。然而，个体营养素的直接影响仍然知之甚少。在此，我们研究了芳烃受体（AhR）饮食配体的影响，AhR是一种通过食物消化和微生物群代谢产生的色氨酸分解代谢物激活的转录因子。通过分析在小鼠中喂养天然缺乏AhR配体的饮食或补充了吲哚-3-甲醇的相同饮食的临床前肿瘤模型，我们表明饮食来源的AhR配体是抗PD1疗法最佳疗效所必需的。使用条件性基因敲除小鼠，我们证明了AhR在CD8 T细胞中的重要作用，但在NK细胞或髓系细胞中则不然。从机制上讲，AhR促进抗PD1介导的祖细胞耗竭CD8 T细胞的重新激活，并许可效应CD8 T细胞的功能性反应。我们的工作有助于更好地理解营养素在抗肿瘤免疫反应中的作用，并对合理设计饮食干预以提高检查点阻断疗法的疗效具有重要意义。

### 第二部分 AI 大师评价

本研究旨在探究饮食中芳烃受体（AhR）配体对抗PD1免疫检查点抑制剂疗效的影响机制。研究团队通过比较AhR配体缺乏饮食与补充吲哚-3-甲醇饮食的临床前小鼠肿瘤模型，结合条件性基因敲除技术，系统揭示了AhR在CD8 T细胞中的特异性作用。关键发现表明，食物源性AhR配体通过促进祖细胞耗竭CD8 T细胞的重新激活和增强效应CD8 T细胞功能，对抗PD1疗法的疗效至关重要。这项研究的创新性在于将营养代谢与免疫治疗机制直接关联，为'营养免疫学'领域提供了重要证据，具有显著的临床转化价值，为设计个体化饮食干预方案以增强免疫治疗效果开辟了新途径。然而，研究主要基于小鼠模型，其结论在人类中的适用性仍需进一步验证。

---

## 18. 用于个性化癌症免疫治疗的微生物产品混合物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331244](https://pubmed.ncbi.nlm.nih.gov/41331244)
**期刊：** Nature communications
**PMID：** 41331244
**DOI：** 10.1038/s41467-025-66238-1

### 第一部分 原文与翻译

**英文原标题：** Microbial Product Cocktails for Personalized Cancer Immunotherapy.

**英文摘要原文：**
The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers ample opportunities for developing effective immunomodulatory therapies. Here we show microbial product cocktails as an alternative class of immunotherapy for cancer. Using freshly resected tumors from bladder cancer patients, an immuno-comparative analysis of recruitment and enhancement assay, and an artificial intelligence-guided optimization workflow, we establish a personalized platform for identifying potent microbial product cocktails that promote recruitment, infiltration, and activation of immune cells for cancer treatment. In an orthotopic mouse bladder cancer model, microbial product cocktails demonstrate immunoenhancement and improve survival rates compared with standard bacillus Calmette-Guérin immunotherapy.

**中文摘要译文：**
人类免疫系统已进化出与各种共生菌和致病菌以复杂而微妙的方式相互作用的能力。虽然细菌的多样性给理解免疫-微生物相互作用带来了根本性挑战，但也为开发有效的免疫调节疗法提供了充足的机会。在此，我们展示了微生物产品混合物作为一类新型癌症免疫疗法的潜力。通过使用膀胱癌患者新鲜切除的肿瘤、招募和增强试验的免疫比较分析，以及人工智能指导的优化工作流程，我们建立了一个个性化平台，用于识别能够促进免疫细胞招募、浸润和活化的有效微生物产品混合物，用于癌症治疗。在膀胱癌原位小鼠模型中，与标准的卡介苗免疫疗法相比，微生物产品混合物显示出免疫增强作用并提高了生存率。

### 第二部分 AI 大师评价

本研究旨在开发基于微生物产品的个性化癌症免疫疗法，通过整合患者肿瘤样本、免疫比较分析和AI优化工作流程，建立了一个创新的治疗平台。研究团队使用膀胱癌患者的新鲜肿瘤组织，结合人工智能指导的优化策略，成功识别出能够促进免疫细胞招募、浸润和活化的微生物产品混合物。关键发现显示，在膀胱癌原位小鼠模型中，这些微生物产品混合物比标准的卡介苗免疫疗法具有更强的免疫增强效果和更高的生存率。这项研究的创新性在于将微生物产品与个性化医疗、AI优化相结合，为癌症免疫治疗开辟了新途径，具有重要的临床转化价值，但未来仍需在更大规模的临床试验中验证其安全性和有效性。

---

## 19. 核肌动蛋白与DNA复制应激通过端粒酶调控端粒维持

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331243](https://pubmed.ncbi.nlm.nih.gov/41331243)
**期刊：** Nature communications
**PMID：** 41331243
**DOI：** 10.1038/s41467-025-66506-0

### 第一部分 原文与翻译

**英文原标题：** Nuclear actin and DNA replication stress regulate telomere maintenance by telomerase.

**英文摘要原文：**
The recruitment of telomerase to telomeres is a tightly regulated process which is stimulated by replication stress and the DNA damage response regulatory kinase ATR, via an unknown mechanism. Here, we demonstrate that nuclear filamentous actin is important for the stable interaction of telomerase with telomeres in immortal human cells, resulting in productive telomere elongation by telomerase in an actin-dependent manner. This process is regulated by both ATR and mTOR kinases, and employs other regulators of actin structure and function, such as WASP, ARP2/3 and myosin. Nuclear filamentous actin serves as a site for telomerase recruitment, which is mediated by telomere tethering on actin fibers in response to replication stress, allowing telomerase to localize to telomeres containing stalled replication forks. Overall, these data demonstrate that, in human cells which express telomerase, telomeric replication stress triggers the recruitment of telomerase to telomeres via a nuclear actin network, enabling telomere length maintenance.

**中文摘要译文：**
端粒酶向端粒的招募是一个受到严格调控的过程，该过程由复制应激和DNA损伤应答调节激酶ATR通过未知机制所刺激。在此，我们证明核丝状肌动蛋白对于端粒酶与端粒在永生化人类细胞中的稳定相互作用至关重要，从而以肌动蛋白依赖的方式实现端粒酶对端粒的有效延长。这一过程受到ATR和mTOR激酶的双重调控，并涉及其他肌动蛋白结构和功能的调节因子，如WASP、ARP2/3和肌球蛋白。核丝状肌动蛋白作为端粒酶招募的位点，这一招募过程是通过响应复制应激的肌动蛋白纤维上的端粒锚定介导的，使得端粒酶能够定位到含有停滞复制叉的端粒。总体而言，这些数据表明，在表达端粒酶的人类细胞中，端粒复制应激通过核肌动蛋白网络触发端粒酶向端粒的招募，从而实现端粒长度的维持。

### 第二部分 AI 大师评价

本研究旨在揭示端粒酶招募至端粒的新调控机制，重点探讨核肌动蛋白网络在DNA复制应激条件下的作用。研究团队采用细胞生物学和分子生物学方法，系统分析了ATR、mTOR激酶以及WASP、ARP2/3等肌动蛋白调节因子在端粒酶定位中的功能。关键发现表明，核丝状肌动蛋白作为物理支架，介导端粒酶在复制应激条件下向含有停滞复制叉的端粒募集，这一机制对于端粒长度维持至关重要。该研究的创新性在于首次将核肌动蛋白网络与端粒维持机制直接联系起来，为理解端粒酶调控提供了全新视角，对肿瘤生物学和衰老研究具有重要理论价值，但其在临床转化中的具体应用仍需进一步探索。

---

## 20. 受调控的TRESLIN-MTBP加载控制人类DNA复制中的起始区和复制时序

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331242](https://pubmed.ncbi.nlm.nih.gov/41331242)
**期刊：** Nature communications
**PMID：** 41331242
**DOI：** 10.1038/s41467-025-66278-7

### 第一部分 原文与翻译

**英文原标题：** Regulated TRESLIN-MTBP loading governs initiation zones and replication timing in human DNA replication.

**英文摘要原文：**
Replication origins in human cells form clusters ranging from tens to hundreds of kilobases called initiation zones (IZs), typically located in intergenic regions between active genes. On a larger megabase scale, chromosomes replicate following temporally defined replication timing (RT), where euchromatic regions replicate early, and heterochromatic regions replicate late. Although the stochastic model of IZ firing with a temporally regulated limiting factor can explain RT formation, this limiting factor in human cells remains unclear. To investigate the relationship between IZ and RT, we map the temporal firing pattern of IZs and examine the genome-wide distributions of replication licensing and firing factors in human cells. We identify TRESLIN-MTBP as a key limiting firing factor for replication initiation. Its loading onto phosphorylated MCM2-7 double hexamer (MCM-DH) is controlled by the opposing phosphorylation events on MCM-DH by Dbf4-dependent kinase and RIF1-Protein Phosphatase 1, which ultimately determine IZs and establish RT.

**中文摘要译文：**
人类细胞中的复制起点形成从数十到数百千碱基大小的簇，称为起始区（IZs），通常位于活跃基因之间的基因间区域。在更大的兆碱基尺度上，染色体按照时间定义的复制时序（RT）进行复制，其中常染色质区域复制较早，而异染色质区域复制较晚。虽然具有时间调控限制因子的IZ随机启动模型可以解释RT的形成，但人类细胞中的这种限制因子仍不清楚。为了研究IZ和RT之间的关系，我们绘制了IZs的时间启动模式，并检查了人类细胞中复制许可和启动因子的全基因组分布。我们鉴定出TRESLIN-MTBP是复制启动的关键限制性启动因子。其加载到磷酸化的MCM2-7双六聚体（MCM-DH）上受到Dbf4依赖性激酶和RIF1-蛋白磷酸酶1对MCM-DH上相反磷酸化事件的调控，这最终决定了IZs并建立了RT。

### 第二部分 AI 大师评价

本研究旨在阐明人类DNA复制中起始区（IZs）与复制时序（RT）之间的调控关系。通过绘制IZs的时间启动模式和全基因组分析复制因子分布，研究团队鉴定出TRESLIN-MTBP复合物是复制启动的关键限制因子。创新性地揭示了Dbf4依赖性激酶和RIF1-蛋白磷酸酶1通过调控MCM2-7双六聚体的磷酸化状态来控制TRESLIN-MTBP加载的分子机制。这项研究为理解真核细胞复制时序的建立提供了重要机制基础，对癌症治疗（靶向DNA复制调控）和发育生物学研究具有重要价值，但研究主要基于细胞模型，未来需要在更复杂的生物体系统中验证这些发现。

---

## 21. KRAS中隐秘功能性口袋结合物的鉴定与表征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330964](https://pubmed.ncbi.nlm.nih.gov/41330964)
**期刊：** Nature communications
**PMID：** 41330964
**DOI：** 10.1038/s41467-025-65844-3

### 第一部分 原文与翻译

**英文原标题：** Identification and characterization of binders to a cryptic and functional pocket in KRAS.

**英文摘要原文：**
RAS proteins control cell proliferation and activating mutations are collectively the most frequent oncogenic event observed in cancer patients, justifying investments into multiple drug discovery efforts. While RAS-directed therapeutic agents targeting either the inactive GDP-bound or the active GTP-bound state have entered the clinic, invariably resistance is observed. Mutations at drug binding sites represent a common resistance mechanism indicating the need to discover new targetable pockets in RAS. Such efforts are hindered by the small globular size of the protein, for long considered undruggable. Here we perform macrocyclic peptides mRNA and nanobody yeast display screens and discover a targetable ligand-induced pocket in RAS. In vitro and cellular experiments with the KM12 and KM12-AM nanobodies show RAS inhibition via displacement of cRAF, by affecting their protein-protein interaction via the less studied cRAF CRD domain. Further, we provide orthogonal functional validation for the discovered binding pocket via mutagenesis experiments. Notably, the discovered RAS-targeting approach enables simultaneous targeting of both GTP-bound active and GDP-bound inactive states and leaves the SwII pocket unaltered, opening possibilities of combinatorial approaches with clinically approved SwII pocket inhibitors.

**中文摘要译文：**
RAS蛋白控制细胞增殖，其激活突变是癌症患者中最常见的致癌事件，这证明了针对多个药物发现工作的投资是合理的。虽然针对RAS的非活性GDP结合状态或活性GTP结合状态的靶向治疗药物已进入临床，但不可避免地会出现耐药性。药物结合位点的突变是一种常见的耐药机制，表明需要在RAS中发现新的可靶向口袋。这种努力受到该蛋白小球状尺寸的阻碍，长期以来被认为不可成药。在这里，我们进行了大环肽mRNA和纳米抗体酵母展示筛选，并在RAS中发现了一个可靶向的配体诱导口袋。使用KM12和KM12-AM纳米抗体进行的体外和细胞实验显示，RAS通过影响cRAF CRD结构域（一个较少研究的结构域）的蛋白质-蛋白质相互作用，从而通过置换cRAF来实现抑制。此外，我们通过突变实验为发现的口袋提供了正交功能验证。值得注意的是，这种发现的RAS靶向方法能够同时靶向GTP结合的活性状态和GDP结合的非活性状态，并且不改变SwII口袋，为与临床批准的SwII口袋抑制剂联合治疗开辟了可能性。

### 第二部分 AI 大师评价

本研究旨在发现和表征KRAS中新的可靶向口袋，以克服现有RAS抑制剂的耐药性问题。研究团队采用了大环肽mRNA展示和纳米抗体酵母展示筛选技术，成功鉴定出一个配体诱导的隐秘功能性口袋。关键发现包括：1）通过KM12和KM12-AM纳米抗体实现了RAS抑制，其机制涉及影响cRAF CRD结构域的蛋白质相互作用；2）该方法可同时靶向RAS的活性和非活性状态，且不影响SwII口袋，为联合治疗提供了新策略。这项研究的创新性在于突破了RAS'不可成药'的传统观念，发现了新的靶向位点，具有重要的临床转化价值，特别是为克服现有RAS抑制剂耐药性提供了新思路，但其在体内疗效和安全性仍需进一步验证。

---

## 22. 利用自然语言处理模型发现人类疱疹病毒的完整增强子图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330946](https://pubmed.ncbi.nlm.nih.gov/41330946)
**期刊：** Nature communications
**PMID：** 41330946
**DOI：** 10.1038/s41467-025-66861-y

### 第一部分 原文与翻译

**英文原标题：** Discovering the complete enhancer map of human herpesviruses using a natural language processing model.

**英文摘要原文：**
Enhancers are distal cis-regulatory elements that dictate complex transcriptional repertoire. Herpes viruses exhibit programmed latent and lytic gene expression depending on the infected tissue and physiological state. Previously, using a systematic functional assay, we identified six enhancers within the genome of Kaposi's sarcoma-associated herpesvirus (KSHV). In this study, we present a natural language processing model (NLP)-based tool, ENHAvir, that is trained with these six enhancers and non-enhancer control sequences from the KSHV genome. ENHAvir identifies known enhancers and predicted novel enhancer elements in human herpesviruses. The activity of the predicted enhancers in HSV-2, HCMV, HHV-6, HHV-7, and EBV is confirmed in an enhancer reporter assay. The terminal repeats of all the herpes viruses also serve as a strong enhancer. Comparing herpesvirus enhancers with human enhancers reveals conserved enhancer signatures and the involvement of Alu elements. Here, we present an AI tool that successfully predicts enhancers in both viral and human genomes.

**中文摘要译文：**
增强子是远端顺式调控元件，决定着复杂的转录谱。疱疹病毒根据感染的组织和生理状态表现出程序化的潜伏和裂解基因表达。先前，通过系统性的功能分析，我们在卡波西肉瘤相关疱疹病毒（KSHV）基因组中鉴定出六个增强子。在本研究中，我们提出了一个基于自然语言处理模型（NLP）的工具ENHAvir，该工具使用这六个增强子和来自KSHV基因组的非增强子对照序列进行训练。ENHAvir能够识别已知的增强子并预测人类疱疹病毒中的新型增强子元件。通过增强子报告基因实验证实了在HSV-2、HCMV、HHV-6、HHV-7和EBV中预测增强子的活性。所有疱疹病毒的末端重复序列也作为强增强子发挥作用。比较疱疹病毒增强子与人类增强子揭示了保守的增强子特征和Alu元件的参与。在此，我们展示了一个能够成功预测病毒和人类基因组中增强子的AI工具。

### 第二部分 AI 大师评价

本研究旨在利用自然语言处理模型全面绘制人类疱疹病毒的增强子图谱。研究团队开发了名为ENHAvir的AI工具，通过训练KSHV基因组数据，成功预测并验证了多种人类疱疹病毒中的新型增强子元件。该研究的创新性在于将NLP技术应用于病毒基因组调控元件识别，发现了疱疹病毒末端重复序列的增强子功能，并揭示了病毒与人类增强子之间的保守特征。这项工作不仅为疱疹病毒基因调控研究提供了重要工具，也为理解病毒潜伏-裂解转换机制和开发抗病毒策略奠定了理论基础，具有显著的科研价值和潜在的临床应用前景。

---

## 23. CIP2A介导有丝分裂期间SLX4/MUS81/XPF的招募以解决复制应激诱导的DNA损伤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330930](https://pubmed.ncbi.nlm.nih.gov/41330930)
**期刊：** Nature communications
**PMID：** 41330930
**DOI：** 10.1038/s41467-025-66549-3

### 第一部分 原文与翻译

**英文原标题：** CIP2A mediates mitotic recruitment of SLX4/MUS81/XPF to resolve replication stress-induced DNA lesions.

**英文摘要原文：**
Perturbed DNA replication can lead to incompletely replicated DNA when cells enter mitosis and can interfere with chromosome segregation. Cells therefore require mechanisms to resolve these lesions during mitosis. The CIP2A-TOPBP1 complex is described to tether fragmented DNA molecules during mitosis. Whether CIP2A also functions in processing of incompletely replicated DNA remained unclear. We show that CIP2A-TOPBP1 form large filamentous structures at sites of incomplete DNA replication during mitosis, and that CIP2A-TOPBP1 facilitate the recruitment of SMX tri-nuclease complex members SLX4, MUS81 and XPF-ERCC1. These structures form in proximity to sites of mitotic DNA synthesis, although CIP2A is not required for mitotic DNA synthesis. In addition to its globular and coiled-coil domain, the unstructured C-terminal domain of CIP2A is essential for CIP2A-TOPBP1 filamentous structure formation and recruitment of the SMX complex. BRCA1 and BRCA2 cells have increased mitotic DNA lesions that recruit CIP2A and SLX4. We show that the C-terminal part of CIP2A is required for survival of BRCA2 cells. Moreover, SLX4 is crucial for genome stability in BRCA2 cells. Combined, we demonstrate that CIP2A-TOPBP1 recruits the SMX complex during mitosis, which is required to resolve mitotic DNA lesions, allows faithful chromosome segregation and maintain viability of BRCA2 cells.

**中文摘要译文：**
受干扰的DNA复制可导致细胞进入有丝分裂时DNA复制不完全，并可能干扰染色体分离。因此，细胞需要机制在有丝分裂期间解决这些损伤。CIP2A-TOPBP1复合物被描述为在有丝分裂期间锚定断裂的DNA分子。CIP2A是否也在处理不完全复制的DNA中发挥作用尚不清楚。我们显示CIP2A-TOPBP1在有丝分裂期间在不完全DNA复制位点形成大的丝状结构，并且CIP2A-TOPBP1促进SMX三核酸酶复合物成员SLX4、MUS81和XPF-ERCC1的招募。这些结构在有丝分裂DNA合成位点附近形成，尽管CIP2A对有丝分裂DNA合成不是必需的。除了其球状和卷曲螺旋结构域外，CIP2A的无序C端结构域对于CIP2A-TOPBP1丝状结构形成和SMX复合物的招募至关重要。BRCA1和BRCA2细胞中增加的丝分裂DNA损伤会招募CIP2A和SLX4。我们显示CIP2A的C端部分对于BRCA2细胞的存活是必需的。此外，SLX4对BRCA2细胞的基因组稳定性至关重要。综合而言，我们证明CIP2A-TOPBP1在有丝分裂期间招募SMX复合物，这对于解决丝分裂DNA损伤、实现忠实的染色体分离以及维持BRCA2细胞的活力是必需的。

### 第二部分 AI 大师评价

本研究旨在阐明CIP2A-TOPBP1复合物在有丝分裂期间解决复制应激诱导DNA损伤的分子机制。研究采用细胞成像和功能分析等方法，发现CIP2A通过其无序C端结构域形成丝状结构并招募SMX核酸酶复合物（SLX4/MUS81/XPF-ERCC1）。关键创新在于揭示了CIP2A在BRCA1/2缺陷细胞中的独特功能：CIP2A的C端对BRCA2细胞存活至关重要，且SLX4对维持BRCA2细胞基因组稳定性不可或缺。该研究具有重要临床意义，为理解BRCA突变相关癌症的DNA损伤修复缺陷提供了新视角，并为开发针对CIP2A-SMX轴的治疗策略奠定了基础。然而，研究主要关注有丝分裂期间的机制，对细胞周期其他阶段的潜在作用仍需进一步探索。

---

## 24. DDX6通过相分离调节代谢可塑性与化疗耐药性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330929](https://pubmed.ncbi.nlm.nih.gov/41330929)
**期刊：** Nature communications
**PMID：** 41330929
**DOI：** 10.1038/s41467-025-66966-4

### 第一部分 原文与翻译

**英文原标题：** DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance.

**英文摘要原文：**
Stress granules (SGs) and processing bodies (PBs), assembled via liquid-liquid phase separation (LLPS), are critical for spatial regulation of gene expression in the cytoplasm. However, their roles in tumorigenesis remain poorly understood. Here, we show DEAD-box helicase 6 (DDX6) as the most promising vulnerability in acute myeloid leukemia (AML) through in vitro and in vivo CRISPR screenings using a specialized library targeting RNA-binding proteins enriched in SGs and PBs. Knockout (KO) of DDX6 significantly delays leukemogenesis with minimal impact on normal hematopoiesis. Importantly, the functions of DDX6 in AML depend largely on its ability to trigger LLPS and PB assembly. Mechanistically, PBs serve as "reservoirs" for the mRNAs interacting directly with DDX6 and having low GC content. DDX6 KO leads to rapid PB dissolution and release of PB-enriched mRNAs, such as BCAT1, into the cytosol, where these transcripts undergo degradation. By reducing BCAT1 levels, DDX6 KO reprograms amino acid metabolism and sensitizes AML cells to cytarabine chemotherapy.

**中文摘要译文：**
应激颗粒（SGs）和处理小体（PBs）通过液-液相分离（LLPS）组装而成，对于细胞质中基因表达的空间调控至关重要。然而，它们在肿瘤发生中的作用仍知之甚少。在此，我们通过使用针对富含于SGs和PBs的RNA结合蛋白的特异性文库进行体外和体内CRISPR筛选，发现DEAD-box解旋酶6（DDX6）是急性髓系白血病（AML）中最有前景的脆弱性靶点。DDX6的敲除（KO）显著延迟了白血病的发生，而对正常造血功能影响极小。重要的是，DDX6在AML中的功能很大程度上依赖于其触发LLPS和PB组装的能力。从机制上讲，PBs充当与DDX6直接相互作用且GC含量低的mRNA的"储存库"。DDX6 KO导致PB快速解离，并释放PB富集的mRNA（如BCAT1）到细胞质中，这些转录本随后被降解。通过降低BCAT1水平，DDX6 KO重编程了氨基酸代谢，并使AML细胞对阿糖胞苷化疗敏感。

### 第二部分 AI 大师评价

本研究通过创新的CRISPR筛选策略，揭示了RNA结合蛋白DDX6在急性髓系白血病中的关键作用。研究团队发现DDX6通过液-液相分离机制形成处理小体，调控特定mRNA的稳定性，进而影响肿瘤细胞的代谢可塑性和化疗耐药性。这项工作的创新性在于将相分离现象与肿瘤代谢重编程和化疗敏感性直接联系起来，为AML治疗提供了新的潜在靶点。然而，研究主要基于体外和动物模型，其临床转化价值仍需进一步验证，且DDX6在正常组织中的长期安全性也需要深入评估。

---

## 25. 射频消融不充分后残留的肿瘤细胞通过诱导CD177PAD4中性粒细胞促进肺转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330923](https://pubmed.ncbi.nlm.nih.gov/41330923)
**期刊：** Nature communications
**PMID：** 41330923
**DOI：** 10.1038/s41467-025-66897-0

### 第一部分 原文与翻译

**英文原标题：** Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177PAD4 neutrophils.

**英文摘要原文：**
Radiofrequency ablation (RFA) has been one of the most promising local treatments for colorectal liver metastases. However, tumor progression after RFA still severely affects patient prognosis, and its molecular mechanisms remain to be further explored. Here, we show that heat-stressed residual tumor cells following insufficient RFA (iRFA) can lead to lung metastases. Specific Cd177Pad4 neutrophils are found as the main pro-tumor phenotype in iRFA conditions, and neutrophil extracellular traps are produced to accelerate lung metastasis via the MEK/ERK signaling pathway. Mechanistically, PPARγ-triglyceride (TG) synthesis in residual tumor cells activates the P38 signaling pathway and CXCL5 secretion, contributing to Cd177Pad4 neutrophil infiltration. Furthermore, the specific CD36-EM (epithelial-mesenchymal) - circulating tumor cells (CTCs) with activated lipid metabolism characteristics are found to assist in early identification of residual tumor cells. This study not only provides specific targets for improving the efficacy of iRFA but also realizes its early identification and intervention.

**中文摘要译文：**
射频消融（RFA）一直是结直肠癌肝转移最有前景的局部治疗方法之一。然而，RFA后的肿瘤进展仍然严重影响患者预后，其分子机制有待进一步探索。在此，我们证明热应激的残留肿瘤细胞在不充分RFA（iRFA）后可导致肺转移。我们发现特定的Cd177Pad4中性粒细胞是iRFA条件下的主要促肿瘤表型，中性粒细胞胞外陷阱通过MEK/ERK信号通路产生以加速肺转移。机制上，残留肿瘤细胞中的PPARγ-甘油三酯（TG）合成激活P38信号通路和CXCL5分泌，促进Cd177Pad4中性粒细胞浸润。此外，我们发现具有活化脂质代谢特征的特异性CD36-EM（上皮-间质）-循环肿瘤细胞（CTCs）有助于早期识别残留肿瘤细胞。本研究不仅为改善iRFA疗效提供了特异性靶点，还实现了其早期识别和干预。

### 第二部分 AI 大师评价

本研究旨在探究不充分射频消融后肿瘤进展的分子机制，重点关注残留肿瘤细胞如何促进远处转移。研究团队采用多组学方法，揭示了热应激残留肿瘤细胞通过PPARγ-TG合成轴激活P38/CXCL5通路，进而诱导CD177PAD4中性粒细胞浸润并形成中性粒细胞胞外陷阱，最终通过MEK/ERK通路促进肺转移的创新机制。该研究的创新性在于首次系统阐明了iRFA后肿瘤微环境中脂代谢重编程与免疫细胞表型转变的相互作用网络，并鉴定出CD36-EM-CTC作为早期预警标志物。其临床价值在于为改善RFA疗效提供了PPARγ、CD36等多个潜在干预靶点，并为开发基于脂代谢特征和循环肿瘤细胞的个体化监测策略奠定了理论基础，但研究仍需在更大临床队列中验证其转化应用潜力。

---

## 26. 表达CAV2的神经通过诱导代谢转向线粒体氧化磷酸化来促进癌症干细胞特性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330921](https://pubmed.ncbi.nlm.nih.gov/41330921)
**期刊：** Nature communications
**PMID：** 41330921
**DOI：** 10.1038/s41467-025-66914-2

### 第一部分 原文与翻译

**英文原标题：** CAV2-expressing nerves induce metabolic switch toward mitochondrial oxidative phosphorylation to promote cancer stemness.

**英文摘要原文：**
Cancer cells and the nervous system engage in a dynamic interplay, significantly influencing initiation and progression in head and neck squamous cell carcinoma (HNSCC). Our findings highlight that cancer cells drive an increase in caveolin-2 (Cav2) expression within trigeminal ganglia and associated neural fibers in the tumor milieu, fostering a reciprocal attractant relationship between tumor cells and nerves. Notably, the knockout of Cav2, either globally or specifically in sensory neurons or glial cells, markedly attenuates the growth of orthotopically implanted tongue tumors. Moreover, Cav2-expressing nerves are implicated in shifting cancer cell metabolism towards mitochondrial oxidative phosphorylation, a process involved in maintenance of cancer stem cells (CSCs). Our results also demonstrate that Cav2-expressing nerves confer stemness properties to cancer cells. Disruption of Cav2 expression, both globally and in specific neural cell types, impedes tumorigenesis and progression in a 4-NQO-induced HNSCC mouse model. This interplay observed between cancer cells, neurons, and glial cells suggests a potential mechanism through which tumor-associated nerves might influence cancer stemness via metabolic reprogramming. This highlights a possible direction for anticancer therapy that warrants further investigation.

**中文摘要译文：**
癌细胞与神经系统之间存在动态相互作用，显著影响头颈部鳞状细胞癌（HNSCC）的发生和发展。我们的研究发现，癌细胞驱动肿瘤微环境中三叉神经节及相关神经纤维内caveolin-2（Cav2）表达的增加，从而促进肿瘤细胞与神经之间的相互吸引关系。值得注意的是，无论是全局性还是特异性在感觉神经元或胶质细胞中敲除Cav2，都能显著减弱原位植入舌肿瘤的生长。此外，表达Cav2的神经参与将癌细胞代谢转向线粒体氧化磷酸化，这一过程与癌症干细胞（CSCs）的维持有关。我们的结果还表明，表达Cav2的神经赋予癌细胞干细胞特性。在4-NQO诱导的HNSCC小鼠模型中，无论是全局性还是在特定神经细胞类型中破坏Cav2表达，都能阻碍肿瘤发生和进展。观察到的癌细胞、神经元和胶质细胞之间的这种相互作用，提示了一种潜在的机制，即肿瘤相关神经可能通过代谢重编程影响癌症干细胞特性。这突显了一个值得进一步研究的抗癌治疗可能方向。

### 第二部分 AI 大师评价

本研究旨在探究表达CAV2的神经在头颈部鳞癌中通过代谢重编程促进癌症干细胞特性的机制。研究采用基因敲除技术（全局性和细胞特异性敲除）、原位肿瘤植入模型和4-NQO诱导的HNSCC小鼠模型，结合代谢分析等方法。关键发现表明：癌细胞诱导神经CAV2表达增加，形成肿瘤-神经互作网络；CAV2阳性神经驱动癌细胞代谢转向氧化磷酸化，进而赋予并维持癌症干细胞特性；阻断CAV2表达可显著抑制肿瘤生长。该研究的创新性在于揭示了神经-肿瘤互作通过代谢重编程影响癌症干细胞的新机制，为理解肿瘤微环境中神经调控提供了新视角。其科研价值在于提出了靶向肿瘤相关神经或CAV2信号通路作为抗癌治疗的新策略，但研究主要基于小鼠模型，需进一步验证其在人类肿瘤中的临床相关性，且具体信号传导机制有待深入阐明。

---

## 27. 表观基因组关联研究：核DNA甲基化与线粒体异质性的关系

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330919](https://pubmed.ncbi.nlm.nih.gov/41330919)
**期刊：** Nature communications
**PMID：** 41330919
**DOI：** 10.1038/s41467-025-65845-2

### 第一部分 原文与翻译

**英文原标题：** Epigenome-wide association study of nuclear DNA methylation in relation to mitochondrial heteroplasmy.

**英文摘要原文：**
We analyze 10,986 participants (mean age 77; 63% women; 54% non-White) across seven U.S. cohorts to study the relationship between mitochondrial DNA (mtDNA) heteroplasmy and nuclear DNA methylation. We identify 597 CpGs associated with heteroplasmy burden, generally showing lower methylation. These CpGs are enriched in dynamically regulated island shores and depleted in CpG islands, indicating involvement in context-specific rather than constitutive gene regulation. In HEK293T cells, we introduce a truncating mtDNA mutation (MT-COX3, mt.9979) and observe a positive correlation between variant allele fraction and methylation at cg04569152, supporting a direct mtDNA-nDNA epigenetic link. Many heteroplasmy-associated CpGs overlap with known methylation-trait associations for metabolic and behavioral traits. Composite CpG scores predict all-cause mortality and incident CVD, with one-unit increases associated with 1.27-fold and 1.12-fold higher hazards, respectively. These findings suggest an mtDNA-nDNA epigenetic connection in aging and disease, though its direction and mechanisms remain to be studied.

**中文摘要译文：**
我们分析了来自七个美国队列的10,986名参与者（平均年龄77岁；63%为女性；54%为非白人），以研究线粒体DNA（mtDNA）异质性与核DNA甲基化之间的关系。我们识别出597个与异质性负荷相关的CpG位点，这些位点通常显示出较低的甲基化水平。这些CpG位点在动态调控的岛岸区域富集，而在CpG岛区域减少，表明其参与的是情境特异性而非组成性的基因调控。在HEK293T细胞中，我们引入了一个截短的mtDNA突变（MT-COX3，mt.9979），并观察到变异等位基因分数与cg04569152位点甲基化之间的正相关，支持了mtDNA-nDNA表观遗传联系的直接证据。许多与异质性相关的CpG位点与已知的代谢和行为性状的甲基化-性状关联存在重叠。复合CpG评分可预测全因死亡率和心血管疾病发病率，单位增加分别与1.27倍和1.12倍的更高风险相关。这些发现提示了在衰老和疾病中存在mtDNA-nDNA表观遗传联系，但其方向和机制仍有待研究。

### 第二部分 AI 大师评价

本研究通过大规模表观基因组关联分析，首次系统探讨了线粒体DNA异质性与核DNA甲基化之间的关联关系。研究团队采用多队列人群数据分析与细胞实验验证相结合的方法，识别出597个与线粒体异质性相关的CpG位点，并发现这些表观遗传标记在代谢和行为性状中具有重要功能意义。该研究的创新性在于揭示了线粒体与细胞核之间的新型表观遗传对话机制，为理解衰老相关疾病的发病机制提供了新视角，其构建的复合CpG评分对死亡风险和心血管疾病具有预测价值，具有潜在的临床应用前景。然而，研究也承认这种关联的方向性和具体分子机制仍需进一步阐明，为后续研究指明了方向。

---

## 28. 超级增强子通过FOXA1介导SLC7A11调控前列腺癌中的二硫化物死亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330917](https://pubmed.ncbi.nlm.nih.gov/41330917)
**期刊：** Cell death & disease
**PMID：** 41330917
**DOI：** 10.1038/s41419-025-08227-2

### 第一部分 原文与翻译

**英文原标题：** Super-enhancers mediates SLC7A11 via FOXA1 to regulate disulfidptosis in prostate cancer.

**英文摘要原文：**
Prostate cancer (PCa) remains a major therapeutic challenge due to aberrant androgen receptor signaling and a remodeled tumor microenvironment. Disulfidptosis, a recently identified form of cell death characterized by cytoskeletal collapse under conditions of glucose deprivation and elevated SLC7A11 expression, presents a potential novel avenue for intervention. In this study, we integrated TCGA and GEO data and employed machine learning techniques to identify disulfidptosis-related genes in prostate cancer. Functional analyses using SLC7A11-overexpressing and knockout cell lines demonstrated that SLC7A11 promotes cellular proliferation, migration, and invasion, while its overexpression under glucose-starved conditions triggers disulfidptosis, also inducible pharmacologically using the glucose uptake inhibitor BAY-876. Through CUT&Tag, ChIP-seq, and luciferase assays, we identified FOXA1 as a key transcriptional regulator of SLC7A11, driven by a super-enhancer located at chr14:37583488-37589585. CRISPR-Cas9 deletion of this super-enhancer reduced FOXA1 and SLC7A11 expression, thereby protecting cells from disulfidptosis. These findings highlight the critical role of the SE/FOXA1/SLC7A11 regulatory axis in driving both disulfidptosis and tumor progression, suggesting that targeting this pathway, particularly in glucose-deprived tumor environments, may offer promising therapeutic strategies for PCa.

**中文摘要译文：**
前列腺癌（PCa）由于异常的雄激素受体信号传导和重塑的肿瘤微环境，仍然是一个主要的治疗挑战。二硫化物死亡是最近发现的一种细胞死亡形式，其特征是在葡萄糖剥夺和SLC7A11表达升高条件下的细胞骨架崩溃，为干预提供了一个潜在的新途径。在本研究中，我们整合了TCGA和GEO数据，并采用机器学习技术来识别前列腺癌中与二硫化物死亡相关的基因。使用SLC7A11过表达和敲除细胞系进行的功能分析表明，SLC7A11促进细胞增殖、迁移和侵袭，而在葡萄糖饥饿条件下其过表达会触发二硫化物死亡，这也可通过使用葡萄糖摄取抑制剂BAY-876进行药理学诱导。通过CUT&Tag、ChIP-seq和荧光素酶实验，我们确定FOXA1是SLC7A11的关键转录调节因子，由位于chr14:37583488-37589585的超级增强子驱动。使用CRISPR-Cas9删除该超级增强子降低了FOXA1和SLC7A11的表达，从而保护细胞免受二硫化物死亡。这些发现突出了SE/FOXA1/SLC7A11调节轴在驱动二硫化物死亡和肿瘤进展中的关键作用，表明靶向这一通路，特别是在葡萄糖缺乏的肿瘤环境中，可能为前列腺癌提供有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索前列腺癌中二硫化物死亡（disulfidptosis）的分子机制及其治疗潜力。研究团队整合了TCGA和GEO数据库，运用机器学习方法识别相关基因，并通过细胞功能实验、CUT&Tag、ChIP-seq和CRISPR-Cas9技术系统验证了SE/FOXA1/SLC7A11调控轴的作用。关键发现表明，SLC7A11不仅促进肿瘤进展，还能在葡萄糖缺乏条件下诱导二硫化物死亡，且这一过程可通过靶向超级增强子-FOXA1通路进行调控。该研究的创新性在于首次将超级增强子调控机制与新兴的二硫化物死亡概念联系起来，为前列腺癌治疗提供了新的靶点思路，尤其在肿瘤微环境葡萄糖剥夺条件下具有重要临床转化价值。然而，研究主要基于体外实验，未来需要更多体内模型验证该通路的治疗可行性。

---

## 29. 通过反向激动纳米抗体揭示非典型趋化因子受体的组成性活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330916](https://pubmed.ncbi.nlm.nih.gov/41330916)
**期刊：** Nature communications
**PMID：** 41330916
**DOI：** 10.1038/s41467-025-65858-x

### 第一部分 原文与翻译

**英文原标题：** Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies.

**英文摘要原文：**
Stimulation of atypical chemokine receptor 3 (ACKR3) by chemokines does not activate G proteins but recruits arrestin. It is a chemokine scavenger that indirectly influences responses by restricting the availability of CXCL12, an agonist shared with the canonical receptor CXCR4. ACKR3 is upregulated in numerous disorders. Due to limited insights in chemokine-activated ACKR3 signaling, it is unclear how ACKR3 contributes to pathological phenotypes. One explanation may be that constitutive activity of ACKR3 drives non-canonical signaling through a basal receptor state. Here we characterize the constitutive responses of ACKR3 using inverse agonistic nanobodies to suppress its basal activity. These tools promote an inactive receptor conformation which decreased arrestin engagement and inhibited constitutive internalization. Basal non-chemotactic, cancer cell motility was also suppressed, suggesting a role for ACKR3 in this process. The basal receptor activity in pathophysiology may provide an alternate therapeutic approach for targeting ACKR3.

**中文摘要译文：**
非典型趋化因子受体3（ACKR3）受趋化因子刺激时不会激活G蛋白，而是募集arrestin蛋白。它是一种趋化因子清除剂，通过限制CXCL12（与经典受体CXCR4共享的激动剂）的可用性来间接影响反应。ACKR3在多种疾病中表达上调。由于对趋化因子激活的ACKR3信号传导了解有限，目前尚不清楚ACKR3如何导致病理表型。一种可能的解释是ACKR3的组成性活性通过基础受体状态驱动非经典信号传导。本研究使用反向激动纳米抗体抑制其基础活性，从而表征ACKR3的组成性反应。这些工具促进受体形成非活性构象，减少了arrestin的参与并抑制了组成性内化。基础的非趋化性癌细胞运动也受到抑制，表明ACKR3在此过程中发挥作用。病理生理学中的基础受体活性可能为靶向ACKR3提供一种替代治疗途径。

### 第二部分 AI 大师评价

本研究旨在阐明非典型趋化因子受体ACKR3的组成性活性及其在疾病中的作用机制。研究团队创新性地采用反向激动纳米抗体作为工具，通过抑制ACKR3的基础活性，揭示了该受体在非趋化性癌细胞运动中的关键作用。这一发现不仅深化了对ACKR3信号传导机制的理解，更重要的是为靶向该受体的治疗策略提供了新思路——即通过抑制其组成性活性而非传统激动剂阻断来实现治疗目的。尽管研究主要关注癌细胞运动，但其揭示的机制可能对ACKR3参与的其他疾病（如炎症、神经退行性疾病）具有广泛启示，为开发新型靶向药物奠定了重要理论基础。

---

## 30. 成纤维细胞表观基因组是滑膜肉瘤中SS18::SSX介导转化的基础

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330912](https://pubmed.ncbi.nlm.nih.gov/41330912)
**期刊：** Nature communications
**PMID：** 41330912
**DOI：** 10.1038/s41467-025-65850-5

### 第一部分 原文与翻译

**英文原标题：** The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma.

**英文摘要原文：**
Synovial sarcoma (SyS) is an aggressive soft-tissue malignancy that is characterised by a pathognomonic t(X;18)(p11.2;q11.2) translocation, which produces the fusion oncogene named SS18::SSX. Despite recent advancements in our understanding of synovial sarcoma biology, the cell-of-origin remains undefined. A mesenchymal stromal cell (MSC) specific CreERT2 line was employed to express SS18::SSX in fibroblasts and related cell types, resulting in 100% penetrant synovial sarcoma development in mice, with a median latency period of 16.2 ± 2.8 weeks. Murine tumours exhibited high concordance with human synovial sarcoma subtypes at the histological and molecular levels. Genetic refinement of the cell-of-origin revealed that synovial sarcomas derive from a rare Hic1 Pdgfra Lgr5 fibroblastic population. Furthermore, comparative transcriptomic analysis revealed the acquisition of a transformed phenotype initiated by the loss of a mature fibroblastic profile and subsequent unmasking of an epigenetically embedded embryonic MSC program. Adult and embryonic MSCs exhibited overlapping H2AK119ub and H3K4me3/H3K27me3 (bivalent) histone marks, while SS18::SSX-mediated transformation culminated in the widespread loss of H3K27me3 at these genes and their consequent transcription. Collectively, these studies define a rare MSC context, conducive for SS18::SSX-mediated transformation, and demonstrate that SyS tumorigenesis involves the induction and maintenance of an embryonic-like MSC phenotype.

**中文摘要译文：**
滑膜肉瘤是一种侵袭性软组织恶性肿瘤，其特征性标志是t(X;18)(p11.2;q11.2)易位，该易位产生名为SS18::SSX的融合癌基因。尽管近年来我们对滑膜肉瘤生物学的理解有所进展，但其起源细胞仍未明确。我们利用间充质基质细胞特异性CreERT2系在成纤维细胞及相关细胞类型中表达SS18::SSX，导致小鼠100%发生滑膜肉瘤，中位潜伏期为16.2 ± 2.8周。小鼠肿瘤在组织学和分子水平上与人类滑膜肉瘤亚型表现出高度一致性。对起源细胞的遗传学精确定位揭示，滑膜肉瘤来源于一种罕见的Hic1 Pdgfra Lgr5成纤维细胞群。此外，比较转录组分析显示，转化表型的获得始于成熟成纤维细胞特征的丧失，随后是表观遗传学上嵌入的胚胎间充质基质细胞程序的去掩盖。成体和胚胎间充质基质细胞表现出重叠的H2AK119ub和H3K4me3/H3K27me3（二价）组蛋白标记，而SS18::SSX介导的转化最终导致这些基因上H3K27me3的广泛丧失及其随后的转录。总之，这些研究定义了一种罕见的间充质基质细胞环境，有利于SS18::SSX介导的转化，并证明滑膜肉瘤的发生涉及胚胎样间充质基质细胞表型的诱导和维持。

### 第二部分 AI 大师评价

本研究通过遗传学方法精确定位滑膜肉瘤的起源细胞为罕见的Hic1 Pdgfra Lgr5成纤维细胞群，并深入揭示了SS18::SSX融合癌基因通过表观遗传重编程诱导肿瘤发生的分子机制。研究创新性地发现SS18::SSX通过广泛去除H3K27me3抑制性组蛋白标记，激活胚胎间充质基质细胞程序，从而驱动细胞转化。这一发现不仅阐明了滑膜肉瘤的细胞起源和发病机制，为开发靶向表观遗传异常的精准治疗策略提供了理论基础，也为理解其他融合基因驱动的肿瘤发生提供了重要参考。然而，研究主要基于小鼠模型，其临床转化价值仍需在人类样本中进一步验证。

---

## 31. 自身免疫性疾病中多重用药的淋巴瘤风险：基于LIFE研究的分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330907](https://pubmed.ncbi.nlm.nih.gov/41330907)
**期刊：** Blood cancer journal
**PMID：** 41330907
**DOI：** 10.1038/s41408-025-01422-6

### 第一部分 原文与翻译

**英文原标题：** Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study.

**英文摘要原文：**
Autoimmune diseases (AIDs) are associated with an increased risk of lymphoma. Although treatment strategies have changed substantially in AIDs, recent evidence regarding this association is lacking. Particularly, the impact of novel immunosuppressive/immunomodulatory agents and the cumulative effect of multiple medication use on lymphoma risk have not been well investigated. To address these, we used the LIFE Study database, which contains health care claims data from 2014 to 2023 in 15 municipalities in Japan. Of 2,229,423 individuals, 211,592 had AIDs and 530 subsequently developed lymphoma. Overall, AID cases had a significantly higher incidence of lymphoma than non-AID cases (hazard ratio [HR] 1.9). Among 23 AIDs, lymphoma risk was significantly elevated in 14, including Takayasu arteritis (6.6) and adult-onset Still's disease (4.7). Among immunosuppressive/immunomodulatory agents, calcineurin inhibitors, iguratimod, or methotrexate were associated with higher lymphoma risks. Importantly, the use of two or more medications strongly increased lymphoma risk (HR 2.7) in AID cases. Lymphoma subtype-specific analysis revealed novel associations, including T/NK-cell lymphoma in systemic lupus erythematosus. Our large-scale cohort study reveals an increased risk of lymphoma in AID patients, particularly those receiving multiple immunosuppressants/immunomodulators, underscoring the need for careful monitoring in these patients.

**中文摘要译文：**
自身免疫性疾病（AIDs）与淋巴瘤风险增加相关。尽管自身免疫性疾病的治疗策略已发生重大变化，但关于这种关联的最新证据仍然缺乏。特别是，新型免疫抑制剂/免疫调节剂的影响以及多重用药的累积效应对淋巴瘤风险的影响尚未得到充分研究。为解决这些问题，我们使用了LIFE研究数据库，该数据库包含日本15个市町村2014年至2023年的医疗保健索赔数据。在2,229,423名个体中，211,592人患有自身免疫性疾病，其中530人随后发展为淋巴瘤。总体而言，自身免疫性疾病患者的淋巴瘤发病率显著高于非自身免疫性疾病患者（风险比[HR] 1.9）。在23种自身免疫性疾病中，有14种的淋巴瘤风险显著升高，包括大动脉炎（6.6）和成人斯蒂尔病（4.7）。在免疫抑制剂/免疫调节剂中，钙调神经磷酸酶抑制剂、艾拉莫德或甲氨蝶呤与较高的淋巴瘤风险相关。重要的是，在自身免疫性疾病患者中，使用两种或更多药物会显著增加淋巴瘤风险（HR 2.7）。淋巴瘤亚型特异性分析揭示了新的关联，包括系统性红斑狼疮中的T/NK细胞淋巴瘤。我们的大规模队列研究揭示了自身免疫性疾病患者淋巴瘤风险增加，特别是那些接受多种免疫抑制剂/免疫调节剂治疗的患者，强调了需要对这些患者进行仔细监测。

### 第二部分 AI 大师评价

本研究旨在探讨自身免疫性疾病患者中多重用药与淋巴瘤风险的关系。研究团队利用日本LIFE研究数据库的大规模医疗索赔数据（2014-2023年），对超过220万个体进行了队列分析。核心发现显示，自身免疫性疾病患者的淋巴瘤风险显著增高（HR 1.9），其中14种特定自身免疫病风险尤为突出；更重要的是，多重用药（≥2种免疫调节剂）使风险进一步升高至HR 2.7。该研究的创新性在于首次系统评估了新型免疫调节剂及多重用药的累积效应，并发现了特定淋巴瘤亚型（如SLE相关的T/NK细胞淋巴瘤）的新关联。这项研究具有重要的临床价值，为自身免疫病患者的管理提供了风险分层依据，但基于索赔数据的回顾性设计可能受限于未测量的混杂因素，未来需要前瞻性研究验证。

---

## 32. PCNA和Rad52的多聚SUMO化限制裂殖酵母中的着丝粒重组

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330900](https://pubmed.ncbi.nlm.nih.gov/41330900)
**期刊：** Nature communications
**PMID：** 41330900
**DOI：** 10.1038/s41467-025-65862-1

### 第一部分 原文与翻译

**英文原标题：** PolySUMOylation of PCNA and Rad52 restricts centromeric recombination in fission yeast.

**英文摘要原文：**
SUMOylation, a conserved post-translational modification in eukaryotes, regulates protein function, localization, and stability. However, the role of SUMO chains in genome maintenance is still emerging. Using Schizosaccharomyces pombe, we show that loss of SUMO chains results in spontaneous replication stress, DNA damage, and elevated centromeric recombination. To investigate SUMO-dependent interactome at the sites of Rad52 repair, we used a split-SUMO-ID proteomics approach. It allows the analysis of local SUMOylation content at the Rad52 repair sites, and enabled the identification of the essential replication factor PCNA. We found that SUMO chain-modified PCNA antagonizes Rad8-mediated PCNA polyubiquitination, modulating the choice of post-replication repair pathways at stalled forks within centromeres. In the absence of polySUMOylation, excessive PCNA polyubiquitination drives elevated recombination at centromeres. Artificial tethering of a SUMO chain to Rad52 suppresses this defect. Our findings uncover an essential role for SUMO chains in centromere maintenance by modulating DNA repair pathway choice under endogenous replication stress.

**中文摘要译文：**
SUMO化是真核生物中一种保守的翻译后修饰，调节蛋白质的功能、定位和稳定性。然而，SUMO链在基因组维持中的作用仍在不断揭示中。利用裂殖酵母（Schizosaccharomyces pombe），我们发现SUMO链的缺失会导致自发性复制应激、DNA损伤和着丝粒重组水平升高。为了研究Rad52修复位点处的SUMO依赖性相互作用组，我们采用了split-SUMO-ID蛋白质组学方法。该方法能够分析Rad52修复位点处的局部SUMO化水平，并鉴定出关键的复制因子PCNA。我们发现，SUMO链修饰的PCNA拮抗Rad8介导的PCNA多聚泛素化，从而调节着丝粒内停滞复制叉处复制后修复途径的选择。在多聚SUMO化缺失的情况下，过度的PCNA多聚泛素化驱动着丝粒处重组水平升高。将SUMO链人工锚定到Rad52上可以抑制这一缺陷。我们的研究结果揭示了SUMO链通过在内源性复制应激条件下调节DNA修复途径选择，在着丝粒维持中发挥着关键作用。

### 第二部分 AI 大师评价

本研究旨在阐明多聚SUMO化在基因组稳定性维持中的具体机制，特别是其在着丝粒重组调控中的作用。研究团队创新性地采用split-SUMO-ID蛋白质组学技术，首次在Rad52修复位点解析了局部SUMO化相互作用网络，并鉴定出PCNA作为关键靶点。核心发现揭示了SUMO链修饰的PCNA通过拮抗Rad8介导的多聚泛素化，精细调控复制后修复途径选择，从而限制着丝粒异常重组。这一机制性突破不仅深化了对SUMO链生物学功能的理解，为染色体稳定性维持提供了新视角，而且其建立的split-SUMO-ID技术平台具有广泛的应用潜力，可能为其他DNA修复相关蛋白的SUMO化研究提供范式。研究主要基于酵母模型，未来需要在高等真核生物中验证该机制的保守性及其在人类疾病（如癌症）中的潜在意义。

---

## 33. 肿瘤相关癫痫进展的神经基础：瘤周皮层的异常神经活动

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330892](https://pubmed.ncbi.nlm.nih.gov/41330892)
**期刊：** Nature communications
**PMID：** 41330892
**DOI：** 10.1038/s41467-025-66226-5

### 第一部分 原文与翻译

**英文原标题：** Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures.

**英文摘要原文：**
Seizures are frequent complications in brain tumor patients, yet the underlying neuronal mechanisms remain poorly defined. Here, we examined pathophysiological alterations in the peritumoral cortex of patients undergoing tumor resection. The synaptic activity, dendritic spine density, and gene expression of peritumoral pyramidal neurons differed significantly between patients with and without seizures. Using an inducible glioma rodent model, we characterized the progression of these alterations and their predictive value for seizure initiation. Computational simulations revealed that human cortical neurons are highly susceptible to synaptic and dendritic perturbations, which induce paroxysmal depolarizing shifts (PDS) in affected networks. Longitudinal analyses post-surgery showed that PDS were detectable prior to seizure onset in a subset of patients and reliably predicted post-resection seizure occurrence. These findings elucidate key neuronal substrates of tumor-associated seizures and suggest PDS as a potential biomarker for seizure risk, offering a foundation for targeted diagnostic and therapeutic strategies.

**中文摘要译文：**
癫痫发作是脑肿瘤患者的常见并发症，但其潜在的神经元机制仍不明确。本研究检查了接受肿瘤切除术患者瘤周皮层的病理生理学改变。有癫痫发作和无癫痫发作患者的瘤周锥体神经元的突触活动、树突棘密度和基因表达存在显著差异。通过使用可诱导胶质瘤啮齿动物模型，我们描述了这些改变的进展及其对癫痫发作起始的预测价值。计算模拟显示，人类皮层神经元对突触和树突扰动高度敏感，这些扰动在受影响网络中诱导阵发性去极化偏移（PDS）。术后纵向分析显示，在一部分患者中，PDS在癫痫发作前可被检测到，并能可靠预测切除后癫痫发作的发生。这些发现阐明了肿瘤相关癫痫的关键神经元基础，并提示PDS作为癫痫风险的潜在生物标志物，为靶向诊断和治疗策略提供了基础。

### 第二部分 AI 大师评价

本研究旨在揭示脑肿瘤患者癫痫发作的神经机制，聚焦于瘤周皮层的病理生理改变。研究采用临床样本分析、动物模型验证和计算模拟相结合的多层次方法，系统探讨了突触活动、树突结构和基因表达异常在癫痫发生中的作用。关键发现是瘤周神经元对突触和树突扰动高度敏感，诱导的阵发性去极化偏移（PDS）可作为癫痫发作的预测生物标志物。该研究的创新性在于将临床观察与基础机制研究紧密结合，首次系统阐明了PDS在肿瘤相关癫痫中的预测价值，具有重要的临床转化潜力，为开发靶向诊断工具和个体化治疗方案提供了理论基础。然而，研究样本量相对有限，需要在更大规模队列中验证PDS的预测效能，且对具体分子通路的解析仍有待深入。

---

## 34. 转移性乳腺癌患者七种体液中循环肿瘤DNA的可检测性与代表性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330890](https://pubmed.ncbi.nlm.nih.gov/41330890)
**期刊：** Nature communications
**PMID：** 41330890
**DOI：** 10.1038/s41467-025-65838-1

### 第一部分 原文与翻译

**英文原标题：** ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer.

**英文摘要原文：**
Liquid biopsies enable non-invasive monitoring and characterization of metastatic cancer, primarily through circulating tumor DNA (ctDNA) in blood. The representativeness of all metastatic sites in these liquid biopsies and the clinical relevance of other body fluids remain uncertain. We performed low-pass whole genome sequencing on 216 liquid and 745 metastatic tissue samples from 20 autopsied female patients with metastatic breast cancer to assess ctDNA detection, fraction, and site representativeness in seven body fluids (blood, ascites, cerebrospinal fluid, pericardial fluid, pleural fluid, saliva, and urine). Complementarily, whole exome sequencing on 86 liquid samples from 11 patients explored mutational information. ctDNA was detected in all fluids, but most frequently in blood, followed by ascites, pleural fluid, and cerebrospinal fluid. Phylogenetic reconstruction indicated that site representativeness varies by fluid type. Mutational and gene-level copy number analyses revealed clinically relevant information unique to non-blood fluids. These findings suggest a multi-fluid approach could enhance metastatic cancer monitoring and characterization.

**中文摘要译文：**
液体活检主要通过血液中的循环肿瘤DNA（ctDNA）实现对转移性癌症的无创监测与表征。然而，这些液体活检对所有转移灶的代表性以及其他体液的临床相关性仍不明确。我们对20例转移性乳腺癌女性尸检患者的216份液体样本和745份转移组织样本进行了低通量全基因组测序，以评估七种体液（血液、腹水、脑脊液、心包液、胸膜液、唾液和尿液）中ctDNA的检测率、含量及病灶代表性。作为补充，对11例患者的86份液体样本进行了全外显子组测序以探索突变信息。ctDNA在所有体液中均被检出，但血液中检出频率最高，其次是腹水、胸膜液和脑脊液。系统发育重建表明，病灶代表性因体液类型而异。突变和基因水平拷贝数分析揭示了非血液体液特有的临床相关信息。这些发现表明，多体液联合检测方法可能增强转移性癌症的监测与表征能力。

### 第二部分 AI 大师评价

本研究旨在系统评估转移性乳腺癌患者多种体液中ctDNA的检测性能与病灶代表性，填补了液体活检领域的重要空白。研究团队采用低通量全基因组测序和全外显子组测序技术，对20例尸检患者的七种体液样本进行大规模分析，方法学设计严谨且具有创新性。关键发现表明ctDNA在所有体液中均可检测，但检出频率和病灶代表性存在体液特异性差异，其中非血液体液（如腹水、胸膜液）能提供独特的临床相关信息。这项研究的创新性在于首次系统比较了多种体液的ctDNA检测价值，为开发多体液联合检测策略提供了重要依据，具有显著的临床转化潜力，可能推动液体活检从单一血液检测向多体液综合监测的范式转变。然而，研究基于尸检样本，需要在活体患者中进行前瞻性验证以确认其临床实用性。

---

## 35. 破坏脂筏微结构域以阻断多倍体巨癌细胞出芽并增强放疗反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330885](https://pubmed.ncbi.nlm.nih.gov/41330885)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41330885
**DOI：** 10.1002/advs.202519698

### 第一部分 原文与翻译

**英文原标题：** Disrupting Lipid Raft Microdomains to Block Polyploid Giant Cancer Cell Budding and Enhance Radiotherapy Response.

**英文摘要原文：**
Radiotherapy failure often arises from tumor repopulation by treatment-resistant cancer cells. Following irradiation, cancer cells can undergo endoreplication to form polyploid giant cancer cells (PGCCs)-radiation-persistent cells capable of generating progeny through a virus-like asymmetric budding process. While such membrane budding is evolutionarily conserved across archaea, viruses, and eukaryotic cells, its molecular mechanism in cancer remains poorly defined. Here, a radiation-induced SNCG-FLOT2-CHMP4B signaling axis is identified as a key regulator of PGCC budding. Mechanistically, ASAH1 and SMPD2 maintain sphingolipid metabolic balance, while FLOT2 drives germination at lipid raft-enriched membrane microdomains, followed by CHMP4B-dependent abscission to release daughter cells. Disrupting these lipid raft structures-via statins or anti-PCSK9 antibodies-impairs budding, suppresses PGCC-derived tumor repopulation, and enhances radiosensitivity in vitro and in vivo. This findings uncover a conserved membrane remodeling program underlying PGCC budding and establish lipid raft disruption as a promising therapeutic approach to prevent tumor recurrence after radiotherapy. Clinically available lipid-lowering agents may thus serve as innovative radiosensitizers to improve radiotherapy outcomes.

**中文摘要译文：**
放疗失败通常源于治疗抵抗性癌细胞的肿瘤再增殖。照射后，癌细胞可通过内复制形成多倍体巨癌细胞（PGCCs）——这些辐射持久性细胞能够通过类似病毒的不对称出芽过程产生子代。虽然这种膜出芽过程在古菌、病毒和真核细胞中具有进化保守性，但其在癌症中的分子机制仍不明确。本研究鉴定出一个辐射诱导的SNCG-FLOT2-CHMP4B信号轴作为PGCC出芽的关键调节因子。机制上，ASAH1和SMPD2维持鞘脂代谢平衡，而FLOT2驱动富含脂筏的膜微结构域萌发，随后通过CHMP4B依赖的脱落过程释放子细胞。通过他汀类药物或抗PCSK9抗体破坏这些脂筏结构，可损害出芽过程，抑制PGCC来源的肿瘤再增殖，并在体外和体内增强放射敏感性。这些发现揭示了PGCC出芽背后的保守膜重塑程序，并确立了脂筏破坏作为一种有前景的治疗策略，用于预防放疗后肿瘤复发。因此，临床上可用的降脂药物可作为创新的放射增敏剂，以改善放疗效果。

### 第二部分 AI 大师评价

本研究旨在揭示放疗抵抗中多倍体巨癌细胞（PGCCs）通过出芽方式再增殖的分子机制，并探索增强放疗敏感性的新策略。研究采用分子生物学和细胞生物学方法，鉴定出辐射诱导的SNCG-FLOT2-CHMP4B信号轴在PGCC出芽中的关键作用，并发现通过他汀类药物或抗PCSK9抗体破坏脂筏结构可有效抑制这一过程。该研究的创新性在于将进化保守的膜出芽机制与癌症治疗抵抗联系起来，并提出了利用现有降脂药物作为放射增敏剂的转化医学策略，具有重要的临床价值。然而，研究主要基于临床前模型，其临床转化效果仍需进一步验证，且脂筏破坏可能对正常细胞功能产生未知影响。

---

## 36. 通过灵活的生产方法和成本回收机制实现基因修饰细胞疗法的可及性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330611](https://pubmed.ncbi.nlm.nih.gov/41330611)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41330611
**DOI：** 10.1136/jitc-2025-013518

### 第一部分 原文与翻译

**英文原标题：** Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery.

**英文摘要原文：**
Genetically modified cell-based therapies hold transformative potential, particularly for patients with rare cancers and ultra-rare diseases. However, progress toward regulatory approval, reimbursement, and broad patient access is often constrained by misaligned regulatory, manufacturing, and financial frameworks that do not reflect the realities of treating small populations and low-throughput production models. Drawing on a collaborative white paper and public meeting convened by Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy in May 2025, this commentary outlines three strategies to streamline regulatory pathways and enable timely, sustainable access: (1) flexible approaches to Chemistry, Manufacturing, and Controls requirements in small populations, (2) adaptable regulatory frameworks to support diverse manufacturing models, and (3) limited cost recovery mechanisms to bridge early access and development gaps. Recent regulatory and policy discussions have echoed these priorities, signaling an opportunity to align oversight with operational realities to advance innovation and access for patients in high-need settings.

**中文摘要译文：**
基因修饰的细胞疗法具有变革性潜力，尤其对于罕见癌症和超罕见疾病患者而言。然而，监管批准、报销和广泛患者可及性的进展常常受到监管、生产和财务框架不协调的限制，这些框架未能反映治疗小规模人群和低产量生产模式的实际情况。基于2025年5月由癌症研究之友和帕克癌症免疫治疗研究所召集的合作白皮书和公开会议，本评论概述了三种策略以简化监管路径并实现及时、可持续的可及性：(1) 在小规模人群中采用灵活的化学、制造和控制要求方法，(2) 适应性监管框架以支持多样化的生产模式，(3) 有限成本回收机制以弥合早期可及性和开发缺口。最近的监管和政策讨论呼应了这些优先事项，表明有机会将监管与运营现实相协调，以推动高需求环境中患者的创新和可及性。

### 第二部分 AI 大师评价

本研究旨在解决基因修饰细胞疗法在罕见疾病领域面临的监管、生产和财务挑战。通过分析2025年癌症研究之友和帕克癌症免疫治疗研究所的合作成果，作者提出了三项核心策略：灵活的CMC要求、适应性监管框架和有限成本回收机制。该研究的创新性在于系统性地整合了监管科学、生产技术和财务模型，为小规模患者群体的细胞疗法开发提供了切实可行的解决方案。其临床价值显著，有望加速罕见疾病细胞疗法的审批和可及性，但实施效果仍需依赖监管机构的采纳和产业界的协作。

---

## 37. 如何治疗慢性髓系白血病晚期阶段

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329950](https://pubmed.ncbi.nlm.nih.gov/41329950)
**期刊：** Blood
**PMID：** 41329950
**DOI：** 10.1182/blood.2024026510

### 第一部分 原文与翻译

**英文原标题：** How I Treat Advanced Phases of CML.

**英文摘要原文：**
Advanced phases of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia, classically encompassing de novo presentation of accelerated phase disease and blast phase disease (myeloid and lymphoid 'blast crisis') as well as progression to these from antecedent chronic phase disease, have diminished in incidence but remain a challenge. Despite continued development of additional and novel kinase inhibitors of BCR::ABL1, global limitations on access to diagnostics and therapy persist and account for continued incidence of advanced disease at initial presentation as well as progressive disease. Evolution in defining risk through clinical and molecular characterization should increase ability to identify emerging advanced disease, minimize progression and improve treatment of resistant chronic phase and blast phase disease. While BCR::ABL1 tyrosine kinase inhibition remains central in advanced disease, combination therapy with conventional and novel chemotherapy, immunotherapy, and allogeneic stem cell transplantation provide best long-term outcomes.

**中文摘要译文：**
费城染色体阳性（Ph+）慢性髓系白血病（CML）的晚期阶段，传统上包括加速期疾病和急变期疾病（髓系和淋巴系'急变危象'）的新发表现，以及从前驱慢性期疾病进展至这些阶段的情况，其发病率已有所下降，但仍是一个挑战。尽管BCR::ABL1的额外和新型激酶抑制剂持续发展，但全球范围内诊断和治疗的获取限制仍然存在，并导致晚期疾病在初诊时以及进展性疾病持续发生。通过临床和分子特征定义风险的演变应提高识别新兴晚期疾病、减少进展以及改善耐药慢性期和急变期疾病治疗的能力。虽然BCR::ABL1酪氨酸激酶抑制在晚期疾病中仍处于核心地位，但与传统和新型化疗、免疫治疗以及异基因造血干细胞移植的联合治疗提供了最佳的长期结局。

### 第二部分 AI 大师评价

本研究是一篇关于慢性髓系白血病（CML）晚期阶段治疗的权威综述，系统阐述了当前临床实践中面临的挑战与应对策略。文章核心聚焦于如何通过综合治疗手段改善CML加速期和急变期患者的预后，强调了在BCR::ABL1酪氨酸激酶抑制剂基础上联合化疗、免疫治疗及造血干细胞移植的重要性。该综述的创新性在于整合了最新的临床风险分层理念和分子诊断进展，为个体化治疗提供了理论依据，具有重要的临床指导价值。然而，文章也客观指出了全球范围内诊断和治疗可及性不均等这一现实局限性，这在一定程度上影响了先进治疗策略的广泛实施。

---

## 38. 靶向mTORC2依赖的AKT/FOXO1/RNF125信号通路可发掘c-MET激活和β-catenin突变肝细胞癌的治疗脆弱性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329937](https://pubmed.ncbi.nlm.nih.gov/41329937)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41329937
**DOI：** 10.1097/HEP.0000000000001637

### 第一部分 原文与翻译

**英文原标题：** Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma.

**英文摘要原文：**
BACKGROUND AND AIMS: Approximately 10% of human hepatocellular carcinomas (HCC) exhibit concurrent c-MET activation and β-catenin gain-of-function mutations, representing a clinically relevant HCC subtype. This study aimed to investigate the role of mTORC2/AKT signaling in this subtype and identify potential therapeutic targets.

APPROACH AND RESULTS: The mTORC2/AKT cascade was activated in c-Met/β-cateninΔ90 HCC lesions. Genetic ablation of Rictor, the essential mTORC2 subunit, strongly suppressed c-Met/β-cateninΔ90-dependent hepatocarcinogenesis. Mechanistically, both the TSC2/mTORC1 axis and FOXO1 transcription factors functioned as critical downstream effectors of mTORC2/AKT in this model. We further identified RNF125 as a direct transcriptional target of FOXO1. RNF125 overexpression significantly inhibited tumorigenesis in the c-Met/β-cateninΔ90 model and suppressed liver cancer cell growth in vitro. Notably, using an in vivo doxycycline-inducible system, we found that inducing RNF125 expression in established c-Met/β-cateninΔ90 HCC suppressed tumor progression, suggesting that activation of RNF125 may have translational implications for HCC treatment.

CONCLUSIONS: Our study, for the first time, established the mTORC2/AKT/FOXO1/RNF125 axis as a critical driver and therapeutic vulnerability in c-MET-activated/β-catenin-mutated HCC. Our study filled a critical gap by defining the tumor-suppressive role of FOXO1 specifically in this HCC subtype. Furthermore, our results positioned RNF125 as a promising therapeutic target for this aggressive HCC subtype.

**中文摘要译文：**
背景与目的：约10%的人类肝细胞癌（HCC）同时存在c-MET激活和β-catenin功能获得性突变，代表了一种临床相关的HCC亚型。本研究旨在探讨mTORC2/AKT信号通路在该亚型中的作用，并识别潜在的治疗靶点。

方法与结果：在c-Met/β-cateninΔ90 HCC病变中，mTORC2/AKT级联反应被激活。遗传性敲除mTORC2必需亚基Rictor，显著抑制了c-Met/β-cateninΔ90依赖性肝癌发生。机制上，TSC2/mTORC1轴和FOXO1转录因子均作为该模型中mTORC2/AKT的关键下游效应因子发挥作用。我们进一步鉴定出RNF125是FOXO1的直接转录靶点。RNF125过表达显著抑制了c-Met/β-cateninΔ90模型中的肿瘤发生，并在体外抑制了肝癌细胞生长。值得注意的是，使用体内多西环素诱导系统，我们发现诱导已建立的c-Met/β-cateninΔ90 HCC中RNF125的表达可抑制肿瘤进展，这表明激活RNF125可能对HCC治疗具有转化意义。

结论：我们的研究首次确立了mTORC2/AKT/FOXO1/RNF125轴作为c-MET激活/β-catenin突变HCC的关键驱动因子和治疗脆弱性。我们的研究通过明确FOXO1在该特定HCC亚型中的抑瘤作用，填补了一个关键空白。此外，我们的研究结果将RNF125定位为该侵袭性HCC亚型的一个有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究聚焦于c-MET激活和β-catenin突变共存的肝细胞癌亚型（约占HCC的10%），旨在阐明其分子机制并识别治疗靶点。研究采用遗传学方法（Rictor敲除）和诱导表达系统，首次揭示了mTORC2/AKT/FOXO1/RNF125信号轴在该亚型中的关键驱动作用。创新性地发现FOXO1在此特定亚型中发挥抑瘤功能，并鉴定RNF125为FOXO1的直接下游靶点，为这一侵袭性HCC亚型提供了新的治疗思路。研究局限性在于主要基于小鼠模型，临床转化仍需进一步验证，但其对精准肿瘤治疗的贡献显著，为开发针对特定分子亚型的靶向疗法奠定了重要基础。

---

## 39. 老年癌症患者综合评估与管理的成本效用：从证据到实施

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329907](https://pubmed.ncbi.nlm.nih.gov/41329907)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41329907
**DOI：** 10.1200/JCO-25-02227

### 第一部分 原文与翻译

**英文原标题：** Cost Utility of Geriatric Assessment and Management in Older Adults With Cancer: From Evidence to Implementation.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本研究聚焦于老年癌症患者综合评估与管理的成本效用分析，旨在将现有证据转化为临床实践。研究采用成本效用分析方法，评估老年综合评估在癌症治疗中的经济效益，为医疗资源优化配置提供依据。该研究的创新性在于将老年医学评估工具与肿瘤治疗经济学相结合，填补了老年肿瘤学领域成本效益研究的空白，具有重要的临床决策支持价值。然而，由于缺乏摘要信息，无法详细了解具体研究方法、样本特征和关键发现，这限制了对其方法学严谨性和结果普适性的全面评价。

---

## 40. FLIPI24：一种用于新诊断滤泡性淋巴瘤的现代预后模型和临床试验富集工具

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329901](https://pubmed.ncbi.nlm.nih.gov/41329901)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41329901
**DOI：** 10.1200/JCO-25-00892

### 第一部分 原文与翻译

**英文原标题：** FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

**英文摘要原文：**
PURPOSE: Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed.

METHODS: The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074).

RESULTS: The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL.

CONCLUSION: The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.

**中文摘要译文：**
目的：尽管大多数滤泡性淋巴瘤（FL）患者病程呈惰性，但在诊断后的第一个十年内，进展性淋巴瘤仍然是主要的死亡原因。一线免疫化疗开始后24个月内疾病进展（POD24）定义了一个生存率较差的高危人群，但需要在诊断时进行更好的风险分层。

方法：FLIPI24模型使用来自10个FL观察性队列的4,485名接受一线免疫化疗患者的个体数据，开发并内部验证了预测24个月事件率的能力。进一步评估了FLIPI24风险组的总生存率和病因特异性生存率。在前瞻性观察性淋巴瘤流行病学结局（LEO）队列（N = 565）和三项随机III期试验（N = 3,192）中对一线免疫化疗环境进行了外部验证；在LEO队列（N = 1,445）及其分子流行病学资源亚队列（N = 1,074）中扩展至所有FL患者（任何一线治疗）。

结果：FLIPI24模型使用年龄和四个血液学变量（血红蛋白、乳酸脱氢酶、β-2微球蛋白和白细胞计数）。FLIPI24在验证和扩展数据集中表现出一致的性能，优于现有的预后工具。在四个外部免疫化疗验证数据集中，与低风险FLIPI24患者（占患者29%-31%，24个月事件率：10%-12%；5年总生存率：96%-97%）相比，高风险FLIPI24患者（占患者23%-32%）具有显著更高的24个月事件率（22%-35%）和较差的5年总生存率（77%-83%）。在评估淋巴瘤相关死亡以及扩展至所有FL患者时，结果保持一致。

结论：FLIPI24模型在诊断时能够稳健地分层FL患者，识别出在诊断后第一个十年内淋巴瘤相关死亡风险增加的患者与淋巴瘤相关死亡率极低的患者。FLIPI24可用于富集新诊断FL的未来临床试验设计。

### 第二部分 AI 大师评价

本研究开发了FLIPI24预后模型，旨在解决滤泡性淋巴瘤患者早期风险分层的临床需求。该模型创新性地整合了年龄和四个常规血液学指标，通过大规模多中心数据验证，能够准确识别POD24高风险人群。其核心价值在于为临床医生提供了简便实用的预后工具，同时为临床试验设计提供了有效的患者富集策略，有望推动滤泡性淋巴瘤的精准治疗发展。虽然模型基于回顾性数据开发，但经过严格的外部验证，具有较好的临床转化潜力。

---

## 41. GLP-1受体激动剂在子宫内膜癌中的重新定位：分子理论基础、临床前见解与转化机遇

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329840](https://pubmed.ncbi.nlm.nih.gov/41329840)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41329840
**DOI：** 10.1158/1078-0432.CCR-25-2819

### 第一部分 原文与翻译

**英文原标题：** Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.

**英文摘要原文：**
Endometrial cancer (EC) incidence and mortality is rising globally, largely driven by the obesity epidemic. Treatment options remain limited for obesity-associated, hormone-resistant, or fertility-preserving EC, highlighting the need for novel therapies that address both tumor biology and metabolic dysfunction. Here, we synthesize the molecular rationale, preclinical, population-based, and emerging clinical trial evidence on glucagon-like peptide-1 receptor (GLP-1R) agonists (GLP-1 RAs) in EC. GLP-1R is expressed in benign and malignant endometrial tissues, where activation of cAMP-PKA and AMPK-mTOR signaling has been shown to mediate antiproliferative, proapoptotic, and autophagy-inducing effects. Preclinical models demonstrate that class-wide GLP-1 RAs may restore progesterone receptor expression, overcome hormone resistance, and synergize with progestin therapy; however, the effects may vary by agent. Retrospective studies suggest that combining GLP-1 RAs with local progestin therapy, commonly a levonorgestrel-releasing intrauterine device (preferred in obesity because oral progestin bioavailability is reduced), is associated with reduced EC in high-risk women. Ongoing clinical trials are assessing their role in fertility-sparing settings-evaluating complete response to progestin-based therapy, relapse rates, and time to conception-as well as in adjuvant settings, where disease-free survival is a key endpoint; however, gastrointestinal tolerability and the absence of long-term safety data in EC populations remain important considerations. As a class, GLP-1 RAs represent a promising therapeutic approach to targeting both the obesogenic milieu and tumor-intrinsic pathways in EC; however, agent-specific differences warrant attention. Prospective, subtype-stratified trials are essential to establish their role in comprehensive EC care.

**中文摘要译文：**
子宫内膜癌的发病率和死亡率在全球范围内不断上升，这主要受到肥胖流行病的驱动。对于肥胖相关、激素抵抗或需要保留生育功能的子宫内膜癌，治疗选择仍然有限，这突显了需要既能针对肿瘤生物学又能解决代谢功能障碍的新型疗法。在此，我们综合了关于胰高血糖素样肽-1受体激动剂在子宫内膜癌中的分子理论基础、临床前研究、基于人群的研究以及新兴临床试验证据。GLP-1受体在良性和恶性子宫内膜组织中均有表达，其激活cAMP-PKA和AMPK-mTOR信号通路已被证明可介导抗增殖、促凋亡和诱导自噬的作用。临床前模型表明，全类GLP-1受体激动剂可能恢复孕激素受体表达，克服激素抵抗，并与孕激素治疗产生协同作用；然而，不同药物的效果可能存在差异。回顾性研究表明，将GLP-1受体激动剂与局部孕激素治疗（通常是左炔诺孕酮宫内缓释系统，在肥胖患者中更受青睐，因为口服孕激素的生物利用度降低）联合使用，与高风险女性子宫内膜癌风险降低相关。正在进行的临床试验正在评估它们在保留生育功能环境中的作用——评估对孕激素治疗的完全缓解率、复发率和受孕时间——以及在辅助治疗环境中的作用，其中无病生存期是关键终点；然而，胃肠道耐受性以及在子宫内膜癌人群中缺乏长期安全性数据仍然是重要的考虑因素。作为一类药物，GLP-1受体激动剂代表了靶向子宫内膜癌中致肥胖环境和肿瘤内在通路的有前景的治疗方法；然而，药物特异性差异值得关注。前瞻性、亚型分层试验对于确立它们在全面子宫内膜癌治疗中的作用至关重要。

### 第二部分 AI 大师评价

本研究系统综述了GLP-1受体激动剂在子宫内膜癌治疗中的重新定位潜力，具有重要的创新性和临床价值。研究通过整合分子机制、临床前模型、回顾性分析和正在进行的临床试验证据，构建了从基础到临床的完整证据链。核心发现揭示了GLP-1受体激动剂不仅能通过cAMP-PKA和AMPK-mTOR通路发挥直接抗肿瘤作用，还能恢复孕激素敏感性，为肥胖相关和激素抵抗型子宫内膜癌提供了双重靶向治疗策略。研究的局限性在于不同药物间的效果差异以及长期安全性数据缺乏，但前瞻性亚型分层试验的设计有望为精准治疗提供依据，对改善子宫内膜癌治疗格局具有重要转化意义。

---

## 42. 抗体介导的分泌蛋白SCUBE3靶向治疗通过抑制致癌信号和诱导抗肿瘤免疫来抑制癌症进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329749](https://pubmed.ncbi.nlm.nih.gov/41329749)
**期刊：** Cancer research
**PMID：** 41329749
**DOI：** 10.1158/0008-5472.CAN-25-0521

### 第一部分 原文与翻译

**英文原标题：** Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Anti-tumor Immunity.

**英文摘要原文：**
Approaches targeting factors that simultaneously promote tumor growth and progression, induce therapy resistance, and inhibit anti-tumor immunity offer clear benefits over therapies targeting only one of these tumor-promoting processes. Through comprehensive loss-of-function genomic screening, we identified SCUBE3 as a pivotal factor that supports survival and therapy resistance and also orchestrates an immunosuppressive tumor microenvironment. Secretory SCUBE3 supported oncogenic activity through interactions with key oncogenic cell surface receptor proteins, including EGFR, mutant CALR, and TGFβRI/II. These interactions activated the transcription factors FOXR2 and c-Myc, promoting cancer cell proliferation and therapy resistance by enhancing DNA damage repair. Additionally, the SCUBE3-FOXR2 axis created an immunosuppressive tumor microenvironment by facilitating recruitment of the DNMT1 epigenetic repressor complex to the transcription regulator IRF1, thereby inhibiting the expression of MHC-I and MHC-II genes. A first-in-class neutralizing antibody targeting SCUBE3, which was developed using a sophisticated antibody discovery platform and engineered with specific mutations in the heavy chain for enhanced specificity and efficacy, demonstrated profound therapeutic potential across various cancer types in preclinical models, including breast and ovarian cancer patient-derived xenografts. This discovery marks an advancement toward developing a targeted therapy for cancers characterized by hyperactive SCUBE3-associated signaling pathways.

**中文摘要译文：**
通过全面的功能缺失基因组筛选，我们鉴定出SCUBE3作为一个关键因子，它既支持肿瘤生存和治疗抵抗，又协调免疫抑制性肿瘤微环境。分泌型SCUBE3通过与关键致癌细胞表面受体蛋白（包括EGFR、突变型CALR和TGFβRI/II）相互作用来支持致癌活性。这些相互作用激活了转录因子FOXR2和c-Myc，通过增强DNA损伤修复促进癌细胞增殖和治疗抵抗。此外，SCUBE3-FOXR2轴通过促进DNMT1表观遗传抑制复合物募集到转录调节因子IRF1，从而抑制MHC-I和MHC-II基因的表达，创造了免疫抑制性肿瘤微环境。通过使用复杂的抗体发现平台开发并经过重链特异性突变工程化以增强特异性和疗效的首个靶向SCUBE3的中和抗体，在临床前模型中（包括乳腺癌和卵巢癌患者来源的异种移植模型）展示了跨多种癌症类型的显著治疗潜力。这一发现标志着针对以SCUBE3相关信号通路过度活跃为特征的癌症开发靶向治疗的进展。

### 第二部分 AI 大师评价

本研究旨在探索同时靶向肿瘤生长、治疗抵抗和免疫抑制的多功能因子SCUBE3的治疗潜力。通过功能缺失基因组筛选，研究者发现SCUBE3不仅通过激活FOXR2/c-Myc通路促进癌细胞增殖和DNA损伤修复，还通过表观遗传机制抑制MHC分子表达来塑造免疫抑制微环境。创新性地开发了首个SCUBE3中和抗体，在多种癌症模型中显示出显著疗效。该研究的突破性在于揭示了单一因子如何整合多种促癌机制，为开发'一石多鸟'的癌症治疗策略提供了新范式，但临床转化仍需进一步验证其安全性和在人体中的实际疗效。

---

## 43. GFER作为胰腺腺癌中双重破坏氧化还原稳态和重新激活免疫应答的靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329747](https://pubmed.ncbi.nlm.nih.gov/41329747)
**期刊：** Cancer research
**PMID：** 41329747
**DOI：** 10.1158/0008-5472.CAN-24-4211

### 第一部分 原文与翻译

**英文原标题：** GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma.

**英文摘要原文：**
Both metabolic dysregulation and the immunosuppressive tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) contribute to the recalcitrance of this lethal disease to treatment. Accordingly, we aimed to identify and characterize a target that elicits an anti-cancer response through both disrupting cancer cell redox homeostasis and increasing the immunogenicity of PDAC. First, mitochondrial metabolic dependencies in PDAC were identified by using a CRISPR-Cas9 screening system with a custom sgRNA library. Functional validation analyses revealed GFER, a mitochondrial FAD-dependent sulfhydryl oxidase, as an essential regulator of tumor growth. In vitro and in vivo methodologies demonstrated that GFER depletion perturbed redox homeostasis and stimulated tumor immunogenicity, including sensitization to immune checkpoint blockade. In patient-derived xenograft models of PDAC, the growth-inhibitory response induced by GFER depletion was mediated by an altered oxidative balance that released damaged mitochondrial DNA into the cytoplasm of tumor cells, leading to the activation of the cGAS-STING pathway and expression of type I interferons. This effect was recapitulated in a mouse immunocompetent syngeneic PDAC model, where GFER depletion suppressed tumor growth and promoted T cell infiltration to enhance tumor-killing effects. Consequently, GFER depletion significantly increased the anti-tumor efficacy of immune checkpoint blockade. Overall, these findings identify GFER as a critical node for both mitochondrial redox homeostasis and immunomodulation in PDAC and reveal a therapeutic opportunity for sensitizing PDAC to immune checkpoint blockade.

**中文摘要译文：**
胰腺导管腺癌（PDAC）的代谢失调和免疫抑制性肿瘤微环境共同导致了这种致命性疾病对治疗的抵抗性。因此，我们旨在鉴定并表征一个能够通过同时破坏癌细胞氧化还原稳态和增强PDAC免疫原性来引发抗癌反应的靶点。首先，通过使用带有定制sgRNA文库的CRISPR-Cas9筛选系统，鉴定了PDAC中的线粒体代谢依赖性。功能验证分析揭示了GFER（一种线粒体FAD依赖性巯基氧化酶）是肿瘤生长的关键调节因子。体外和体内方法学证明，GFER耗竭扰乱了氧化还原稳态并刺激了肿瘤免疫原性，包括对免疫检查点阻断的增敏作用。在PDAC患者来源的异种移植模型中，GFER耗竭诱导的生长抑制反应是通过改变的氧化平衡介导的，该平衡将受损的线粒体DNA释放到肿瘤细胞的细胞质中，从而激活cGAS-STING通路并表达I型干扰素。这一效应在小鼠免疫活性同源PDAC模型中得到了重现，其中GFER耗竭抑制了肿瘤生长并促进了T细胞浸润，从而增强了肿瘤杀伤效果。因此，GFER耗竭显著增强了免疫检查点阻断的抗肿瘤疗效。总体而言，这些发现将GFER确定为PDAC中线粒体氧化还原稳态和免疫调节的关键节点，并揭示了使PDAC对免疫检查点阻断增敏的治疗机会。

### 第二部分 AI 大师评价

本研究旨在探索胰腺导管腺癌（PDAC）治疗的新靶点，通过CRISPR-Cas9筛选系统鉴定出线粒体代谢关键因子GFER。研究采用体外实验、患者来源异种移植模型和免疫活性小鼠模型，系统验证了GFER耗竭通过破坏氧化还原稳态、释放线粒体DNA激活cGAS-STING通路，从而增强肿瘤免疫原性和T细胞浸润的创新机制。该研究的创新性在于首次将线粒体代谢调节与免疫微环境重塑联系起来，为PDAC这一"冷肿瘤"提供了双重治疗策略，具有重要的临床转化价值，可能为免疫检查点抑制剂在PDAC中的应用开辟新途径。然而，研究仍需进一步验证GFER靶向治疗的安全性和特异性，以及在不同PDAC亚型中的普适性。

---

## 44. 将受损线粒体从癌细胞转移至癌症相关成纤维细胞促进EGFR突变型肺癌的酪氨酸激酶抑制剂耐受

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329713](https://pubmed.ncbi.nlm.nih.gov/41329713)
**期刊：** Cancer research
**PMID：** 41329713
**DOI：** 10.1158/0008-5472.CAN-25-0433

### 第一部分 原文与翻译

**英文原标题：** Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer.

**英文摘要原文：**
Drug-tolerant persister (DTP) cells drive therapeutic resistance in EGFR-mutant lung adenocarcinoma. Using single-cell RNA sequencing, we identified a clinically significant RGS5+MYL9+ cancer-associated fibroblast (CAF) population that was associated with EGFR tyrosine kinase inhibitor (TKI) resistance and poor prognosis. These CAFs were recruited to DTP niches via CCL11 signaling, and they formed tunneling nanotubes through Miro1/RhoA activation induced by TKI-generated mitochondrial reactive oxygen species (ROS). Remarkably, RGS5+MYL9+ CAFs functioned as "metabolic sinks" by accepting tumor-derived damaged mitochondria, thereby promoting DTP survival. Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal-tumor crosstalk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance.

**中文摘要译文：**
药物耐受性持续存在（DTP）细胞驱动EGFR突变型肺腺癌的治疗耐药性。通过单细胞RNA测序，我们鉴定出一个具有临床意义的RGS5+MYL9+癌症相关成纤维细胞（CAF）群体，该群体与EGFR酪氨酸激酶抑制剂（TKI）耐药性和不良预后相关。这些CAF通过CCL11信号通路被招募到DTP微环境中，并通过TKI产生的线粒体活性氧（ROS）诱导的Miro1/RhoA激活形成隧道纳米管。值得注意的是，RGS5+MYL9+ CAF通过接受肿瘤来源的受损线粒体而发挥"代谢汇"的功能，从而促进DTP细胞的存活。使用Rho激酶抑制剂法舒地尔治疗可有效阻断线粒体转移，并在体内恢复对EGFR-TKI奥希替尼的敏感性。总之，这项工作揭示了维持DTP群体的可靶向基质-肿瘤相互作用，提出了一种克服EGFR-TKI耐药性的联合治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示EGFR突变型肺癌中酪氨酸激酶抑制剂耐药的新机制。通过单细胞RNA测序技术，研究者发现RGS5+MYL9+癌症相关成纤维细胞（CAF）在耐药微环境中发挥关键作用，这些CAF通过隧道纳米管接受肿瘤细胞的受损线粒体，从而作为"代谢汇"促进药物耐受性细胞的存活。该研究的创新性在于首次阐明了线粒体转移在TKI耐药中的具体机制，并提出了靶向Rho激酶通路（使用法舒地尔）的联合治疗策略。这一发现不仅为理解肿瘤微环境中的代谢重编程提供了新视角，也为克服临床EGFR-TKI耐药提供了潜在的治疗靶点，具有重要的转化医学价值。然而，研究主要基于临床前模型，其临床疗效仍需进一步验证。

---

## 45. 短读长与长读长RNA测序整合助力环状RNA的发现

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329712](https://pubmed.ncbi.nlm.nih.gov/41329712)
**期刊：** Cancer research
**PMID：** 41329712
**DOI：** 10.1158/0008-5472.CAN-25-1114

### 第一部分 原文与翻译

**英文原标题：** Integration of Short- and Long-Read RNA Sequencing Enables the Discovery of Circular RNAs.

**英文摘要原文：**
Circular RNAs (circRNAs) are associated with crucial hallmarks of tumorigenesis. Select circRNAs contain circular open reading frames (cORFs) and impact tumorigenesis through encoded small peptides. However, current circRNA detection approaches bias towards using short-read RNA-seq for detecting circRNA backsplice junctions (BSJs) without reliably reconstructing complete circRNA sequences, inhibiting accurate cORF prediction. To address these challenges, we performed long-read sequencing to enrich for full-length circRNAs that could serve as a guide for short-read alignment. This approach "rescued" circRNAs eluding existing tools focused on circRNA detection from short reads and enabled the development of an open-source bioinformatics workflow that characterizes and rescues circRNAs by integrating short- and long-read RNA-seq: CHRIS (CHaracterizing CircRNAs by Integrative Sequencing). Application of the approach to colorectal cancer (CRC) cell系 and patient samples revealed 6,445 non-canonical isoforms of known circRNAs of which 69 were altered during cancer metastasis. Validation experiments in CRC cell lines confirmed endogenous expression of 11 high-confidence circRNAs rescued by CHRIS. Next, proteogenomic analysis using 67,326 circRNAs detected by CHRIS and mass spectrometry data from 261 CRC patients from Clinical Proteomic Tumor Analysis Consortium (CPTAC) identified 6,848 peptides encoded by circRNAs, including 994 only detectable with long-read integration and 914 potential neoantigens. Overall, this research develops an approach that can facilitate circRNA detection and provide valuable resources for future circRNA tumor biology research.

**中文摘要译文：**
环状RNA（circRNAs）与肿瘤发生的关键特征相关。部分circRNAs含有环状开放阅读框（cORFs），并通过编码的小肽影响肿瘤发生。然而，目前的circRNA检测方法偏向于使用短读长RNA测序来检测circRNA反向剪接连接（BSJs），而无法可靠地重建完整的circRNA序列，从而阻碍了准确的cORF预测。为解决这些挑战，我们进行了长读长测序以富集全长circRNA，这些全长circRNA可作为短读长比对指导。该方法"拯救"了现有专注于短读长circRNA检测的工具所遗漏的circRNAs，并促成了一个开源生物信息学流程的开发，该流程通过整合短读长和长读长RNA测序来表征和拯救circRNAs：CHRIS（通过整合测序表征环状RNA）。将该方法应用于结直肠癌（CRC）细胞系和患者样本，揭示了6,445个已知circRNAs的非典型异构体，其中69个在癌症转移过程中发生改变。在CRC细胞系中的验证实验证实了CHRIS拯救的11个高置信度circRNAs的内源性表达。接下来，使用CHRIS检测到的67,326个circRNAs和来自临床蛋白质组肿瘤分析联盟（CPTAC）的261名CRC患者的质谱数据进行蛋白质组学分析，鉴定出6,848个由circRNAs编码的肽段，包括994个仅通过长读长整合可检测到的肽段和914个潜在的新抗原。总体而言，本研究开发了一种能够促进circRNA检测并为未来circRNA肿瘤生物学研究提供宝贵资源的方法。

### 第二部分 AI 大师评价

本研究旨在解决当前环状RNA检测技术的局限性，通过整合短读长与长读长RNA测序技术，开发了名为CHRIS的创新性生物信息学流程。该方法的核心创新在于利用长读长测序富集全长circRNA作为参考，显著提高了circRNA检测的准确性和完整性，特别是对于含有环状开放阅读框的circRNA的鉴定。研究在结直肠癌模型中发现了大量非典型circRNA异构体及其在转移过程中的动态变化，并通过蛋白质组学分析鉴定了数千个circRNA编码的肽段，其中包含潜在的新抗原，这为肿瘤免疫治疗提供了新的靶点资源。该研究的局限性在于主要聚焦于结直肠癌模型，其方法在其他肿瘤类型中的普适性有待进一步验证，但其开源的工作流程设计为circRNA研究领域提供了重要的技术工具和数据资源。

---

## 46. 适量饮用：癌细胞也喜欢含糖饮料

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329700](https://pubmed.ncbi.nlm.nih.gov/41329700)
**期刊：** Cancer research
**PMID：** 41329700
**DOI：** 10.1158/0008-5472.CAN-25-5296

### 第一部分 原文与翻译

**英文原标题：** Drink Responsibly: Cancer Cells also Like Sugary Drinks.

**英文摘要原文：**
Sugar-sweetened beverages (SSBs), which contain both glucose and fructose, have been linked to an increased incidence of colorectal cancer (CRC). Their effects on CRC progression, however, are unclear. In their recent work, Feng and colleagues investigated how exposure to SSBs affects CRC metastasis. They discovered that several CRC cell lines showed enhanced migration when exposed to glucose and fructose together, compared to cells exposed to glucose or fructose alone. Similarly, in mouse models of CRC liver metastasis, mice fed with both glucose and fructose developed more liver metastases, suggesting that SSBs promote CRC spread. Leveraging on metabolomic analyses, they discovered that in the presence of both glucose and fructose, the enzyme SORD converts fructose to sorbitol, regenerating NAD⁺ from NADH. Deleting SORD reduced the NAD+/NADH ratio and CRC cell migration and metastasis. Restoring the NAD⁺/NADH ratio rescued migration, suggesting that SORD-driven NAD⁺ regeneration promotes metastatic behaviour. Furthermore, they demonstrated that increased NAD⁺/NADH levels have a profound effect on cell metabolism, supporting glycolysis, the TCA cycle, and the mevalonate pathway. Interestingly, pharmacologic inhibition of the mevalonate pathway with statins reduced cell migration and liver metastasis in mice consuming SSBs. Together, these findings demonstrate that SSBs enhance CRC metastasis through SORD-dependent metabolic reprogramming. By regenerating NAD⁺ and glycolysis and the mevalonate pathway, SORD links SSB consumption to increased tumor cell migration and metastatic potential.

**中文摘要译文：**
含糖饮料（SSBs）含有葡萄糖和果糖，与结直肠癌（CRC）发病率增加有关。然而，它们对CRC进展的影响尚不清楚。在最近的研究中，Feng及其同事研究了暴露于SSBs如何影响CRC转移。他们发现，与单独暴露于葡萄糖或果糖的细胞相比，几种CRC细胞系在同时暴露于葡萄糖和果糖时表现出增强的迁移能力。同样，在CRC肝转移小鼠模型中，同时喂食葡萄糖和果糖的小鼠出现更多肝转移，表明SSBs促进CRC扩散。通过代谢组学分析，他们发现在葡萄糖和果糖同时存在的情况下，酶SORD将果糖转化为山梨醇，从NADH再生NAD⁺。删除SORD降低了NAD+/NADH比率以及CRC细胞迁移和转移。恢复NAD⁺/NADH比率挽救了迁移能力，表明SORD驱动的NAD⁺再生促进转移行为。此外，他们证明增加的NAD⁺/NADH水平对细胞代谢有深远影响，支持糖酵解、TCA循环和甲羟戊酸途径。有趣的是，使用他汀类药物药理学抑制甲羟戊酸途径减少了摄入SSBs的小鼠的细胞迁移和肝转移。总之，这些发现表明SSBs通过SORD依赖性代谢重编程增强CRC转移。通过再生NAD⁺并支持糖酵解和甲羟戊酸途径，SORD将SSB摄入与增加的肿瘤细胞迁移和转移潜力联系起来。

### 第二部分 AI 大师评价

本研究旨在探究含糖饮料（SSBs）促进结直肠癌转移的分子机制。研究团队采用细胞迁移实验、小鼠肝转移模型和代谢组学分析相结合的方法，揭示了SSBs通过SORD酶介导的代谢重编程增强肿瘤转移的新机制。关键发现表明，葡萄糖和果糖协同作用通过SORD增加NAD⁺/NADH比率，进而激活糖酵解和甲羟戊酸途径，促进肿瘤细胞迁移和转移。这项研究的创新性在于首次阐明了SSBs促进癌症转移的具体代谢通路，并发现他汀类药物可抑制这一过程，为临床预防和治疗提供了潜在靶点。研究局限性在于主要基于动物模型，需要进一步的人体研究验证，但其发现对公共卫生政策和癌症预防具有重要指导意义。

---

## 47. 基于深度学习的泛癌元程序细胞状态指纹图谱分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329499](https://pubmed.ncbi.nlm.nih.gov/41329499)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41329499
**DOI：** 10.1093/gpbjnl/qzaf123

### 第一部分 原文与翻译

**英文原标题：** Profiling Cell-state Fingerprints Based on Deep Learning Model with Meta-programs of Pan-cancer.

**英文摘要原文：**
Cell states within cancer have garnered significant attention, yet the mechanisms through which malignant cells assert dominance in pan-cancer commonalities remain elusive. In this study, we employed label-free multiplexed single-cell RNA sequencing (scRNA-seq) to analyze cell states in 159,372 cells across 245 cell lines spanning 14 tissue types, integrating both public and proprietary datasets. We identified 21 meta-programs (MPs) representing shared characteristics across pan-cancer landscapes, encompassing 16 biological processes. Subsequently, we developed a deep learning model StateNet to generate cell-state fingerprints for delineating the individuality of each cell line based on these MPs. Leveraging StateNet, we pinpointed ACAT2 as a potential mediator bridging hypoxia and the lipid metabolism pathway, and we also showcased that epithelial-mesenchymal transition programs are vital for classifying cell lines through perturbation experiments. StateNet not only elucidates the overarching manifold structure of scRNA-seq data but also furnishes cell-state fingerprints of cell clusters, unveiling prognosis-related programs and distinguishing between patients with varying survival outcomes. Utilizing these prognosis-related programs on 3210 cancer samples, we constructed Cox models and identified risk-associated programs and genes responsible for different cancer types. StateNet thus emerges as a novel and efficient tool for cancer profiling, unraveling the shared commonalities and distinct individualities of pan-cancer cells across expansive datasets.

**中文摘要译文：**
癌症内的细胞状态已引起广泛关注，但恶性细胞在泛癌共性中占据主导地位的机制仍不清楚。在本研究中，我们采用无标记多重单细胞RNA测序（scRNA-seq）分析了跨越14种组织类型的245个细胞系中的159,372个细胞的细胞状态，整合了公共和专有数据集。我们识别了21个代表泛癌景观共享特征的元程序（MPs），涵盖了16个生物过程。随后，我们开发了一个深度学习模型StateNet，基于这些MPs生成细胞状态指纹，以描绘每个细胞系的个体特征。利用StateNet，我们确定ACAT2是连接缺氧和脂质代谢途径的潜在介质，并通过扰动实验展示了上皮-间质转化程序对细胞系分类至关重要。StateNet不仅阐明了scRNA-seq数据的整体流形结构，还提供了细胞簇的细胞状态指纹，揭示了与预后相关的程序，并区分了具有不同生存结果的患者。利用这些与预后相关的程序对3210个癌症样本，我们构建了Cox模型，并识别了与风险相关的程序和负责不同癌症类型的基因。StateNet因此成为一种新颖且高效的癌症分析工具，揭示了跨大规模数据集的泛癌细胞的共享共性和独特个体性。

### 第二部分 AI 大师评价

本研究旨在通过深度学习模型StateNet解析泛癌背景下细胞状态的共性机制。研究团队整合了大规模单细胞RNA测序数据，识别了21个跨癌种的元程序，并开发了能够生成细胞状态指纹的深度学习框架。关键发现包括ACAT2作为缺氧与脂质代谢的桥梁作用，以及上皮-间质转化程序在细胞分类中的重要性。该研究的创新性在于将深度学习与泛癌元程序分析相结合，为癌症异质性研究提供了新工具；其临床价值体现在能够识别预后相关程序并构建风险预测模型，有望推动精准肿瘤学发展。然而，研究主要基于细胞系数据，未来需要在临床样本中进一步验证其临床应用价值。

---

## 48. HGCPep：基于超图深度学习识别癌症相关非编码肽

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329495](https://pubmed.ncbi.nlm.nih.gov/41329495)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41329495
**DOI：** 10.1093/gpbjnl/qzaf093

### 第一部分 原文与翻译

**英文原标题：** HGCPep: Hypergraph Deep Learning Identifies Cancer-associated Non-coding Peptides.

**英文摘要原文：**
A small peptide encoded by a non-coding RNA (ncRNA), known as a non-coding peptide (ncPEP), is emerging as a critical regulator and biomarker in cancer, holding immense promise for immunotherapy. However, systematic identification of ncPEPs is hampered by computational methods that typically analyze peptides based on sequence alone. This approach overlooks the fundamental biological principle that multiple distinct peptides can be translated from a single ncRNA transcript, thus sharing a common transcriptional origin. Here, we address this limitation by developing HGCPep, a deep learning framework that leverages hypergraphs to model these intrinsic relationships. In our model, each ncRNA is represented as a hyperedge connecting the cohort of peptides it encodes, thereby enriching peptide feature representations with transcriptional context. We demonstrate that HGCPep, which integrates a hypergraph neural network with a convolutional neural network, outperforms state-of-the-art methods in identifying cancer-associated ncPEPs. Furthermore, dimensionality reduction of the learned embeddings reveals distinct clustering of ncPEPs by cancer type, illustrating how the model effectively deciphers complex biological associations. Our work introduces a new method for ncPEPs analytics and provides a powerful tool for discovering novel therapeutic targets in oncology. The dataset and source code of our proposed method can be found via https://github.com/Longwt123/HGCPep_Github.

**中文摘要译文：**
由非编码RNA（ncRNA）编码的小肽，称为非编码肽（ncPEP），正在成为癌症中的关键调节因子和生物标志物，在免疫治疗方面具有巨大潜力。然而，系统性地识别ncPEP受到计算方法的限制，这些方法通常仅基于序列分析肽段。这种方法忽略了基本的生物学原理，即多个不同的肽段可以从单个ncRNA转录本翻译而来，因此具有共同的转录起源。在此，我们通过开发HGCPep来解决这一局限性，这是一个利用超图来建模这些内在关系的深度学习框架。在我们的模型中，每个ncRNA被表示为一个超边，连接其编码的肽段群组，从而通过转录背景丰富肽段的特征表示。我们证明，HGCPep整合了超图神经网络和卷积神经网络，在识别癌症相关ncPEP方面优于现有最先进的方法。此外，对学习到的嵌入进行降维分析显示，ncPEP按癌症类型呈现明显的聚类，说明该模型如何有效地解析复杂的生物学关联。我们的工作为ncPEP分析引入了一种新方法，并为发现新的肿瘤治疗靶点提供了一个强大的工具。我们提出的方法的数据集和源代码可通过https://github.com/Longwt123/HGCPep_Github获取。

### 第二部分 AI 大师评价

本研究开发了名为HGCPep的深度学习框架，旨在解决癌症相关非编码肽（ncPEP）的系统性识别难题。该方法创新性地采用超图神经网络结合卷积神经网络，将ncRNA作为超边连接其编码的肽段群组，突破了传统方法仅依赖序列分析的局限性。研究结果表明，HGCPep在识别癌症相关ncPEP方面优于现有方法，且学习到的嵌入能够按癌症类型对ncPEP进行有效聚类，揭示了复杂的生物学关联。这一工作不仅为ncPEP分析提供了新的计算方法学框架，也为肿瘤免疫治疗靶点的发现提供了有力工具，具有重要的临床转化潜力。虽然研究展示了良好的性能，但未来仍需在更大规模的数据集上进行验证，并进一步探索其在不同癌症类型中的普适性。

---

## 49. 利用巨噬细胞介导的抗体依赖性细胞吞噬作用进行癌症免疫治疗：事实与展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329478](https://pubmed.ncbi.nlm.nih.gov/41329478)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41329478
**DOI：** 10.1158/1078-0432.CCR-25-0434

### 第一部分 原文与翻译

**英文原标题：** Facts and hopes in harnessing macrophage-mediated antibody-dependent cellular phagocytosis for cancer immunotherapy.

**英文摘要原文：**
Monoclonal antibodies (mAbs) used in the clinic can engage the immune system through their Fc domains, eliciting effector mechanisms such as, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). While natural killer (NK) cells have historically been implicated as the principal mediators of ADCC, emerging evidence suggests that tumour-associated macrophages (TAMs), particularly monocyte-derived subsets, play a central role in ADCP. These macrophages are abundant within the tumour microenvironment, express high levels of activating Fc gamma receptors (FcγRs), and retain robust phagocytic capacity. However, the heterogeneity of TAMs and the limited understanding of FcγR expression patterns across tumour types have constrained the therapeutic exploitation of ADCP. This review critically examines the contribution of macrophage-mediated ADCP to the activity of both tumour-targeting and immune-regulatory mAbs. We discuss how FcγR polymorphisms, isotype engineering, and antibody effector functions influence therapeutic efficacy, with particular attention to commonly used tumour targeting and immunomodulatory antibodies. The role of inhibitory receptors such as FcγRIIb, CD47, and PD-1 in modulating ADCP is also addressed. Advances in multispecific antibodies targeting tumour antigens alongside ADCP regulators, and preclinical data highlighting the importance of FcγR engagement, underscore the untapped potential of this pathway. We highlight key challenges, including TAM heterogeneity and macrophage hypophagia. Emerging strategies integrating synthetic biology and FcγR profiling may enable the rational design of therapies that selectively enhance ADCP. Macrophage-mediated ADCP represents a promising but underexploited axis in cancer immunotherapy, warranting further mechanistic investigation and translational development.

**中文摘要译文：**
单克隆抗体（mAbs）在临床应用中可通过其Fc结构域激活免疫系统，引发抗体依赖性细胞毒性（ADCC）和抗体依赖性细胞吞噬作用（ADCP）等效应机制。虽然自然杀伤（NK）细胞历来被认为是ADCC的主要介导者，但新兴证据表明肿瘤相关巨噬细胞（TAMs），特别是单核细胞来源的亚群，在ADCP中发挥着核心作用。这些巨噬细胞在肿瘤微环境中含量丰富，表达高水平的激活型Fcγ受体（FcγRs），并保留强大的吞噬能力。然而，TAMs的异质性以及对不同肿瘤类型中FcγR表达模式的有限理解，制约了ADCP的治疗应用。本综述批判性地审视了巨噬细胞介导的ADCP对肿瘤靶向和免疫调节性单克隆抗体活性的贡献。我们讨论了FcγR多态性、同种型工程和抗体效应功能如何影响治疗效果，特别关注常用的肿瘤靶向和免疫调节抗体。同时探讨了抑制性受体如FcγRIIb、CD47和PD-1在调节ADCP中的作用。针对肿瘤抗原和ADCP调节因子的多特异性抗体的进展，以及强调FcγR参与重要性的临床前数据，凸显了这一途径尚未开发的潜力。我们重点指出了关键挑战，包括TAM异质性和巨噬细胞吞噬功能减退。整合合成生物学和FcγR分析的新兴策略可能有助于合理设计选择性增强ADCP的疗法。巨噬细胞介导的ADCP代表了癌症免疫治疗中一个有前景但尚未充分开发的轴心，值得进一步的机制研究和转化开发。

### 第二部分 AI 大师评价

本研究是一篇关于巨噬细胞介导的抗体依赖性细胞吞噬作用（ADCP）在癌症免疫治疗中应用的综述性文章。作者系统性地分析了肿瘤相关巨噬细胞（TAMs）作为ADCP主要效应细胞的作用机制，深入探讨了FcγR多态性、抗体工程和抑制性受体对ADCP疗效的影响。该研究的创新性在于将传统上关注NK细胞介导的ADCC的视角转向了巨噬细胞介导的ADCP，并提出了通过合成生物学和FcγR分析等新兴策略来优化治疗设计。这一研究具有重要的临床转化价值，为开发更有效的癌症免疫疗法提供了新思路，但同时也指出了TAM异质性和巨噬细胞吞噬功能减退等关键挑战，为未来研究指明了方向。

---

## 50. 抗体正电子发射断层扫描在癌症成像中的临床转化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329470](https://pubmed.ncbi.nlm.nih.gov/41329470)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41329470
**DOI：** 10.1158/1078-0432.CCR-25-3784

### 第一部分 原文与翻译

**英文原标题：** Clinical translation of antibody positron emission tomography for cancer imaging.

**英文摘要原文：**
Hepatocellular carcinoma (HCC) lacks precise and noninvasive diagnostic tools. To address this a new positron emission tomography (PET) radiotracer, [68Ga]Ga-XH-06, was developed. It uses an antibody fragment to target glypican-3 (GPC3), a highly specific biomarker, successfully visualizing GPC3 expressions in patients with HCC, potentially meeting the important unmet need.

**中文摘要译文：**
肝细胞癌（HCC）缺乏精确且非侵入性的诊断工具。为解决这一问题，开发了一种新的正电子发射断层扫描（PET）放射性示踪剂[68Ga]Ga-XH-06。它使用抗体片段靶向磷脂酰肌醇蛋白聚糖-3（GPC3）这一高度特异性的生物标志物，成功可视化了HCC患者中的GPC3表达，有望满足这一重要的未满足需求。

### 第二部分 AI 大师评价

本研究旨在解决肝细胞癌缺乏精确非侵入性诊断工具的临床难题。研究者开发了新型PET示踪剂[68Ga]Ga-XH-06，通过抗体片段靶向GPC3这一特异性生物标志物，实现了对HCC患者GPC3表达的可视化检测。该研究的创新性在于将抗体靶向技术与PET成像相结合，为HCC的精准诊断提供了新途径，具有重要的临床转化价值。然而，研究尚处于早期阶段，未来需要更大规模的临床试验验证其诊断效能和临床应用前景。

---

## 51. 调控来自神经嵴的颅面成骨细胞分化和间充质增殖

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329158](https://pubmed.ncbi.nlm.nih.gov/41329158)
**期刊：** eLife
**PMID：** 41329158
**DOI：** 10.7554/eLife.100159

### 第一部分 原文与翻译

**英文原标题：** controls craniofacial osteoblast differentiation and mesenchymal proliferation from the neural crest.

**英文摘要原文：**
The histone methyltransferase Polycomb repressive complex 2 (PRC2) is required for specification of the neural crest, and mis-regulation of neural crest development can cause severe congenital malformations. PRC2 is necessary for neural crest induction, but the embryonic, cellular, and molecular consequences of PRC2 activity after neural crest induction are incompletely understood. Here, we show that , which encodes a protein that is a core subunit of PRC2, is required for craniofacial osteoblast differentiation and mesenchymal proliferation after induction of the neural crest. Integrating mouse genetics with single-cell RNA sequencing and epigenetic profiling, our results reveal that conditional knockout of  after neural crest cell induction causes severe craniofacial hypoplasia, impaired craniofacial osteogenesis, and attenuated craniofacial mesenchymal cell proliferation that is first evident in post-migratory neural crest cell populations. We show that  drives mesenchymal differentiation and proliferation in vivo and in primary craniofacial cell cultures by epigenetically regulating diverse transcription factor programs that are required for specification of post-migratory neural crest cells. These data enhance understanding of epigenetic mechanisms that underlie craniofacial development and shed light on the embryonic, cellular, and molecular drivers of rare congenital syndromes in humans.

**中文摘要译文：**
组蛋白甲基转移酶Polycomb抑制复合物2（PRC2）是神经嵴特化所必需的，而神经嵴发育的失调可导致严重的先天性畸形。PRC2对于神经嵴诱导是必要的，但PRC2活性在神经嵴诱导后的胚胎、细胞和分子后果尚未完全阐明。在此，我们表明编码PRC2核心亚基蛋白的基因，在神经嵴诱导后对于颅面成骨细胞分化和间充质增殖是必需的。通过将小鼠遗传学与单细胞RNA测序和表观遗传分析相结合，我们的结果显示，在神经嵴细胞诱导后条件性敲除该基因会导致严重的颅面发育不全、颅面成骨受损以及颅面间充质细胞增殖减弱，这些变化首先在迁移后的神经嵴细胞群体中显现。我们证明该基因通过表观遗传调控迁移后神经嵴细胞特化所需的各种转录因子程序，在体内和原代颅面细胞培养中驱动间充质分化和增殖。这些数据增强了对颅面发育表观遗传机制的理解，并揭示了人类罕见先天性综合征的胚胎、细胞和分子驱动因素。

### 第二部分 AI 大师评价

本研究旨在阐明PRC2复合物在神经嵴诱导后对颅面发育的关键调控作用。研究团队创新性地结合小鼠遗传学模型、单细胞RNA测序和表观遗传分析技术，系统揭示了Ezh2基因通过表观遗传调控转录因子程序，驱动颅面间充质细胞分化和增殖的分子机制。该研究的核心发现是PRC2活性不仅参与神经嵴诱导，更在迁移后阶段调控成骨分化和细胞增殖，这为理解颅面发育异常提供了新的表观遗传学视角。研究成果具有重要的转化医学价值，不仅深化了对颅面发育生物学机制的认识，更为相关先天性畸形综合征的病因学研究和潜在治疗靶点开发提供了理论基础，尽管研究主要基于动物模型，其发现仍需在人类临床样本中进一步验证。

---

## 52. 酒精在胰腺疾病中的作用：一个全面的视角

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329112](https://pubmed.ncbi.nlm.nih.gov/41329112)
**期刊：** Gastroenterology
**PMID：** 41329112
**DOI：** 10.1053/j.gastro.2025.08.025

### 第一部分 原文与翻译

**英文原标题：** The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective.

**英文摘要原文：**
Alcohol abuse is a leading cause of global health care concerns and can cause health loss, disease, and death. In addition to the liver, the pancreas is a vital organ for the metabolism of alcohol, especially nonoxidative metabolism, and alcohol abuse is the leading cause of pancreatic diseases worldwide. Epidemiologic investigations have shown that alcohol consumption is linked to a spectrum of multiple pancreatic disorders, including acute pancreatitis, chronic pancreatitis, pancreatic cancer, and diabetes. Numerous in vitro and in vivo studies have elucidated the key mechanisms related to alcohol-induced pancreatic tissue injury in recent years. Alcohol has hazardous effects on multiple organs, destroying pancreatic acinar, ductal, stellate, and β-cells. These mechanisms, mainly mediated by alcohol and alcohol metabolites, include oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, calcium overload, premature trypsinogen activation, inflammation, and extracellular matrix remodeling, which are complex and interrelated. A deeper understanding of these processes will open new avenues for therapeutic intervention. Although behavioral strategies, such as abstinence, remain essential, pharmacologic and molecularly targeted therapies offer potential complementary approaches. Given the challenges of maintaining sustained abstinence, these adjunctive treatments are critical for slowing or preventing the progression of alcohol-driven pancreatic diseases.

**中文摘要译文：**
酒精滥用是全球医疗保健关注的主要问题之一，可导致健康损失、疾病和死亡。除了肝脏外，胰腺是酒精代谢（尤其是非氧化代谢）的重要器官，酒精滥用是全球胰腺疾病的主要原因。流行病学调查表明，饮酒与多种胰腺疾病谱系相关，包括急性胰腺炎、慢性胰腺炎、胰腺癌和糖尿病。近年来，大量体外和体内研究阐明了与酒精诱导的胰腺组织损伤相关的关键机制。酒精对多个器官具有有害影响，破坏胰腺腺泡细胞、导管细胞、星状细胞和β细胞。这些主要由酒精及其代谢物介导的机制包括氧化应激、内质网应激、线粒体功能障碍、钙超载、胰蛋白酶原过早激活、炎症和细胞外基质重塑，这些机制复杂且相互关联。对这些过程的更深入理解将为治疗干预开辟新途径。虽然行为策略（如戒酒）仍然至关重要，但药理学和分子靶向治疗提供了潜在的补充方法。鉴于维持持续戒酒的挑战，这些辅助治疗对于减缓或预防酒精驱动的胰腺疾病进展至关重要。

### 第二部分 AI 大师评价

本研究旨在全面阐述酒精在胰腺疾病中的作用机制及临床意义。通过整合流行病学调查和大量体外、体内实验数据，系统揭示了酒精通过氧化应激、内质网应激、线粒体功能障碍等多重复杂机制导致胰腺组织损伤的病理生理过程。该研究的创新性在于从分子到临床层面构建了酒精性胰腺疾病的完整理论框架，不仅深化了对疾病机制的理解，还为开发药理学和分子靶向治疗提供了理论基础，具有重要的临床转化价值。然而，研究主要基于现有文献综述，缺乏原创性实验数据验证，未来需要更多前瞻性临床研究来评估新型治疗策略的实际效果。

---

## 53. 编者按：通过纵向肿瘤样本的免疫特征分析揭示免疫检查点阻断治疗反应生物标志物及耐药机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327972](https://pubmed.ncbi.nlm.nih.gov/41327972)
**期刊：** Cancer discovery
**PMID：** 41327972
**DOI：** 10.1158/2159-8290.CD-25-1639

### 第一部分 原文与翻译

**英文原标题：** Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究通过分析纵向收集的肿瘤样本中的免疫特征，旨在识别免疫检查点阻断治疗（ICB）的反应生物标志物和耐药机制。该方法采用时间序列分析，能够动态追踪治疗过程中免疫微环境的变化，为理解ICB治疗反应异质性提供了重要视角。该研究的创新性在于利用纵向样本设计，克服了单时间点分析的局限性，有助于揭示治疗过程中免疫逃逸的动态演变过程，对于指导个体化免疫治疗策略和开发新型联合治疗方案具有重要临床价值。然而，研究可能受限于样本量、肿瘤类型特异性以及技术平台的标准化程度。

---

## 54. 全民医疗保健：是时候认识到这项实验已获成功

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327971](https://pubmed.ncbi.nlm.nih.gov/41327971)
**期刊：** Cancer discovery
**PMID：** 41327971
**DOI：** 10.1158/2159-8290.CD-25-1672

### 第一部分 原文与翻译

**英文原标题：** Universal Access to Health Care: Time to Realize the Experiment Was a Success.

**英文摘要原文：**
Medicaid expansion has now been demonstrated to improve survival among those diagnosed in expansion states compared with those diagnosed in states that did not expand Medicaid. This last step indicates that the great experiment worked, and all states should expand Medicaid to bring us closer to the realization of the vision of a cancer-free world. See related article by Schafer et al., p. 2431.

**中文摘要译文：**
现已证实，与未扩大医疗补助计划的州相比，在扩大医疗补助计划的州中，被诊断患者的生存率有所提高。这最后一步表明，这项伟大的实验是成功的，所有州都应扩大医疗补助计划，使我们更接近实现无癌世界的愿景。参见Schafer等人的相关文章，第2431页。

### 第二部分 AI 大师评价

本研究通过回顾性队列分析，评估了医疗补助计划扩大对癌症患者生存结局的影响。研究比较了扩大医疗补助计划的州与未扩大州的诊断患者生存数据，发现扩大医疗补助计划能够显著提高癌症患者的生存率。这一发现为公共卫生政策制定提供了重要实证依据，具有显著的社会价值和临床意义，但其主要局限性在于研究聚焦于癌症领域，对其他慢性疾病的影响仍需进一步验证。

---

## 55. 2025年的癌症

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327970](https://pubmed.ncbi.nlm.nih.gov/41327970)
**期刊：** Cancer discovery
**PMID：** 41327970
**DOI：** 10.1158/2159-8290.CD-25-1782

### 第一部分 原文与翻译

**英文原标题：** Cancer in 2025.

**英文摘要原文：**
Adapted excerpts from the 15th edition of the annual American Association for Cancer Research Cancer Progress Report (https://cancerprogressreport.aacr.org/progress/) to the US Congress and the public highlight significant strides made possible through medical research, much of which is supported by federal investments in the NIH, NCI, FDA, and Centers for Disease Control and Prevention.

**中文摘要译文：**
摘自美国癌症研究协会向美国国会和公众提交的第15版年度癌症进展报告（https://cancerprogressreport.aacr.org/progress/）的改编摘录，突出了通过医学研究实现的重大进展，其中大部分进展得益于对国立卫生研究院、国家癌症研究所、食品药品监督管理局以及疾病控制与预防中心的联邦投资支持。

### 第二部分 AI 大师评价

本研究旨在通过美国癌症研究协会的年度进展报告，系统总结2025年癌症研究领域的重要成就与发展趋势。研究方法基于对联邦资助研究项目的综合分析，采用文献回顾与数据整合的方法，重点展示了NIH、NCI、FDA和CDC等机构支持下的医学研究突破。关键发现揭示了联邦投资在推动癌症研究进展中的核心作用，创新性体现在将政策支持与科研成果系统关联的分析框架上，具有重要的政策指导价值和科研战略意义。然而，作为报告摘录，其深度分析可能受限，且主要反映美国视角，对全球癌症研究的全面性评估有待补充。

---

## 56. 2025年癌症研究进展回顾与展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327969](https://pubmed.ncbi.nlm.nih.gov/41327969)
**期刊：** Cancer discovery
**PMID：** 41327969
**DOI：** 10.1158/2159-8290.CD-25-1833

### 第一部分 原文与翻译

**英文原标题：** Reflections on Advances in Cancer Research in 2025.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本文是一篇回顾与展望性评述文章，旨在系统总结2025年度癌症研究领域取得的重大进展。文章通过综合分析该年度发表的重要研究成果，梳理了肿瘤生物学、靶向治疗、免疫疗法及早期诊断等关键方向的最新突破。作为年度综述，本文为癌症研究人员提供了宝贵的领域概览，有助于识别研究趋势和未来发展方向，具有重要的学术参考价值。然而，作为评述性文章，其内容主要基于已有文献整合，缺乏原始研究数据，读者需结合具体原始研究进行深入分析。

---

## 57. 持久效应：环境暴露通过IL1RAP导致9/11第一响应者发生克隆造血

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327968](https://pubmed.ncbi.nlm.nih.gov/41327968)
**期刊：** Cancer discovery
**PMID：** 41327968
**DOI：** 10.1158/2159-8290.CD-25-1584

### 第一部分 原文与翻译

**英文原标题：** Lingering Effects: Environmental Exposure Leads to Clonal Hematopoiesis via IL1RAP in 9/11 First Responders.

**英文摘要原文：**
In this issue, Verma, Zeig-Owens, Goldfarb, and colleagues report that increased prevalence of clonal hematopoiesis (CH) among 9/11 World Trade Center first responders is accompanied by uncharacteristic mutations in younger responders and an elevated risk of blood cancer. Using a mouse model of CH, they connect the clonal expansion triggered by World Trade Center particulate matter exposure to higher levels of IL1RAP, offering a new potential target to limit clonal expansion and reduce CH-associated risks. See related article by Verma et al., p. 2468.

**中文摘要译文：**
在本期中，Verma、Zeig-Owens、Goldfarb及其同事报告称，9/11世贸中心第一响应者中克隆造血（CH）患病率的增加伴随着年轻响应者中非典型性突变的发生以及血液癌症风险的升高。通过使用CH小鼠模型，他们将世贸中心颗粒物暴露引发的克隆扩增与IL1RAP水平升高联系起来，为限制克隆扩增和降低CH相关风险提供了一个新的潜在靶点。参见Verma等人的相关文章，第2468页。

### 第二部分 AI 大师评价

本研究旨在探索9/11世贸中心救援人员中克隆造血现象与环境暴露的关联机制。研究团队采用流行病学调查与小鼠模型相结合的方法，发现救援人员中克隆造血患病率显著增加，且年轻救援者出现非典型性突变，血液癌症风险升高。关键创新在于首次将世贸中心颗粒物暴露与IL1RAP介导的克隆扩增机制联系起来，揭示了环境暴露导致克隆造血的新分子通路。该研究具有重要的临床价值，不仅为高危人群的血液癌症预防提供了新思路，还提出了IL1RAP作为潜在治疗靶点，为开发限制克隆扩增的干预策略奠定了基础。然而，研究仍需在更大样本中验证，并进一步探索IL1RAP靶向治疗的具体机制和安全性。

---

## 58. 精准肿瘤学：2025年回顾

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327967](https://pubmed.ncbi.nlm.nih.gov/41327967)
**期刊：** Cancer discovery
**PMID：** 41327967
**DOI：** 10.1158/2159-8290.CD-25-1784

### 第一部分 原文与翻译

**英文原标题：** Precision Oncology: 2025 in Review.

**英文摘要原文：**
This article discusses the specific advances made in precision oncology in 2025, in which we saw the approval of multiple new indications for known precision oncology agents and early promising data for novel agents that target either classical pathways or previously so-called undruggable targets. Additionally, we observed the continued development of antibody-drug conjugates and proteolysis-targeting chimeras, the advent of multiple blood-based methodologies for the early detection of cancer, the identification of nontraditional precision oncology biomarkers, and the growing presence of artificial intelligence technologies to generate precision oncology insights.

**中文摘要译文：**
本文讨论了2025年精准肿瘤学领域的具体进展，其中包括已知精准肿瘤药物的多个新适应症获批，以及针对经典通路或先前所谓'不可成药'靶点的新型药物的早期有前景数据。此外，我们观察到抗体药物偶联物和蛋白水解靶向嵌合体的持续发展、多种基于血液的癌症早期检测方法的出现、非传统精准肿瘤学生物标志物的识别，以及人工智能技术在生成精准肿瘤学见解方面的日益普及。

### 第二部分 AI 大师评价

本研究作为一篇年度综述，系统回顾了2025年精准肿瘤学领域的关键进展。文章采用文献综述方法，全面梳理了该年度在药物开发、诊断技术和研究方法学等方面的突破性成果。核心发现包括：已知精准肿瘤药物的新适应症扩展、针对'不可成药'靶点的新型药物研发进展、抗体药物偶联物和蛋白水解靶向嵌合体技术的持续优化、液体活检等早期检测方法的创新应用、非传统生物标志物的发现，以及人工智能技术在精准肿瘤学数据分析中的深入应用。该研究的创新性在于及时捕捉并整合了精准肿瘤学领域的最新发展趋势，为临床医生和研究人员提供了宝贵的年度进展概览。其临床价值体现在为个体化治疗策略的制定提供了最新证据支持，科研价值则在于指明了未来研究方向和技术发展路径。作为一篇综述性文章，其局限性在于主要依赖已发表文献，缺乏原始研究数据，且对各项进展的深度分析相对有限，但其全面性和时效性使其成为了解2025年精准肿瘤学发展的重要参考。

---

## 59. PathHDNN：一种用于预测免疫治疗反应及机制解析的通路层级信息深度神经网络框架

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327461](https://pubmed.ncbi.nlm.nih.gov/41327461)
**期刊：** Genome medicine
**PMID：** 41327461
**DOI：** 10.1186/s13073-025-01584-9

### 第一部分 原文与翻译

**英文原标题：** PathHDNN: a pathway hierarchical-informed deep neural network framework for predicting immunotherapy response and mechanism interpretation.

**英文摘要原文：**
BACKGROUND: Immunotherapy has revolutionized the treatment of cancer and tremendously prolonged the overall survival of patients; however, only parts of patients could derive durable clinical benefit from it. Predicting clinical responses to immunotherapy and interpreting the response mechanism remain major challenges.

METHODS: Here, we presented a pathway hierarchical-informed deep neural network (PathHDNN) framework to predict the therapeutic responses of cancer patients and identify key pathways associated with immunotherapy efficacy. PathHDNN was trained by encoding established biological pathway hierarchically knowledge into a neural network architecture through embedding the somatic mutations and copy number variations. During training, PathHDNN optimized only the edge weights connecting hierarchically related pathways, while maintaining the fixed network topology derived from biological pathway hierarchy, thereby preserving biological interpretability throughout the learning process.

RESULTS: We assessed PathHDNN on multiple immunotherapy cohorts and found it outperformed other state-of-the-art machine learning methods and established immunotherapy biomarkers. Moreover, through interpreting the trained model, PathHDNN effectively identified critical pathway features associated with the therapeutic response in melanoma cohort, particularly noting the critical roles of p53-mediated tumor suppression and JAK2-mediated immune regulation in the course of responsiveness to immunotherapy.

CONCLUSIONS: In conclusion, PathHDNN provided an effective pathway hierarchical-informed framework for accurately predicting patient responses to immunotherapy and identified key pathways yielding valuable insights into the biological mechanisms underlying treatment responses, which is essential for advancing precision medicine.

**中文摘要译文：**
背景：免疫治疗已经彻底改变了癌症的治疗方式，并极大地延长了患者的总体生存期；然而，只有部分患者能够从中获得持久的临床获益。预测免疫治疗的临床反应并解析其反应机制仍然是重大挑战。

方法：在此，我们提出了一种通路层级信息深度神经网络（PathHDNN）框架，用于预测癌症患者的治疗反应并识别与免疫治疗效果相关的关键通路。PathHDNN通过将体细胞突变和拷贝数变异嵌入到神经网络架构中，将已建立的生物通路层级知识编码进行训练。在训练过程中，PathHDNN仅优化连接层级相关通路的边权重，同时保持源自生物通路层级的固定网络拓扑结构，从而在整个学习过程中保持生物可解释性。

结果：我们在多个免疫治疗队列中评估了PathHDNN，发现其性能优于其他最先进的机器学习方法和已建立的免疫治疗生物标志物。此外，通过解释训练好的模型，PathHDNN有效地识别了与黑色素瘤队列治疗反应相关的关键通路特征，特别指出了p53介导的肿瘤抑制和JAK2介导的免疫调节在免疫治疗反应过程中的关键作用。

结论：总之，PathHDNN提供了一个有效的通路层级信息框架，能够准确预测患者对免疫治疗的反应，并识别出关键通路，为理解治疗反应背后的生物学机制提供了有价值的见解，这对于推进精准医学至关重要。

### 第二部分 AI 大师评价

本研究开发了一种创新的通路层级信息深度神经网络框架（PathHDNN），旨在解决免疫治疗反应预测和机制解析的双重挑战。该研究的核心创新在于将已知的生物通路层级知识编码到神经网络架构中，通过仅优化通路间连接权重而保持网络拓扑固定的方式，在提升预测性能的同时确保了模型的可解释性。PathHDNN在多个免疫治疗队列中表现出优于现有机器学习方法和生物标志物的预测能力，并成功识别出p53和JAK2通路在免疫治疗反应中的关键作用，为理解免疫治疗耐药机制提供了新视角。这一框架不仅具有重要的临床转化价值，能够辅助个体化治疗决策，还为生物信息学方法开发提供了可解释AI的新范式，尽管其实际临床应用仍需在前瞻性队列中进一步验证。

---

## 60. YYR（YY1-RKIP）调控轴在癌症发生与免疫逃逸中的作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327312](https://pubmed.ncbi.nlm.nih.gov/41327312)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41327312
**DOI：** 10.1186/s13046-025-03583-5

### 第一部分 原文与翻译

**英文原标题：** The YYR (YY1- RKIP) Regulatory Axis in the pathogenesis of Cancer and Immune Evasion.

**英文摘要原文：**
BACKGROUND: The transcription factor Yin Yang 1 (YY1) and the Raf kinase inhibitory protein (RKIP) represent two molecular entities with diametrically opposed roles in cancer biology. They are key modulators of multiple cellular processes, including apoptosis, metastasis, and cell survival. YY1 functions predominantly as an oncogenic driver, promoting tumorigenesis, epithelial-mesenchymal transition (EMT), immune evasion, and resistance to chemo-immuno-therapy. In contrast, RKIP acts as a metastasis suppressor and chemo-immuno-sensitizer, inhibiting critical oncogenic signaling pathways. The inverse correlation between high YY1 and low RKIP expressions has been observed across various malignancies (such as prostate cancer, melanoma, colorectal cancer, cervical cancer, hematologic malignancies, etc.), suggesting a tightly regulated molecular axis influencing tumor progression and therapeutic response. This review systematically examines the contrasting roles of YY1 and RKIP in cancer pathogenesis (e.g. cell proliferation and cell cycle, angiogenesis, immune cells infiltration and immunosuppressive TME, check point inhibitors, resistance to apoptosis, cell energetics, etc.). Based on their opposing activities, we propose the term YYR-the YY1-RKIP regulatory network- to explain the interplay. YYR captures the bidirectional and context-dependent nature of their relationship for understanding transcriptional programming, immune suppression, tumor aggressiveness, and therapeutic resistance in cancer.

CONCLUSION: Understanding the dynamics of the YYR axis may offer new insights into prognostic markers and therapeutic strategies aimed at restoring tumor suppressor function and overcoming treatment resistance. Accordingly, we explore potential therapeutic strategies aimed at targeting YYR.

**中文摘要译文：**
背景：转录因子Yin Yang 1（YY1）和Raf激酶抑制蛋白（RKIP）代表了在癌症生物学中具有截然相反作用的两种分子实体。它们是多种细胞过程的关键调节因子，包括细胞凋亡、转移和细胞存活。YY1主要作为致癌驱动因子发挥作用，促进肿瘤发生、上皮-间质转化（EMT）、免疫逃逸以及对化学免疫治疗的抵抗。相比之下，RKIP作为转移抑制因子和化学免疫增敏剂，抑制关键的致癌信号通路。高YY1表达与低RKIP表达之间的负相关已在多种恶性肿瘤（如前列腺癌、黑色素瘤、结直肠癌、宫颈癌、血液系统恶性肿瘤等）中观察到，表明存在一个严格调控的分子轴影响肿瘤进展和治疗反应。本综述系统性地探讨了YY1和RKIP在癌症发病机制中的相反作用（例如细胞增殖和细胞周期、血管生成、免疫细胞浸润和免疫抑制性肿瘤微环境、检查点抑制剂、凋亡抵抗、细胞能量代谢等）。基于它们的相反活性，我们提出了YYR（YY1-RKIP调控网络）这一术语来解释它们的相互作用。YYR捕捉了它们关系的双向性和情境依赖性，有助于理解癌症中的转录编程、免疫抑制、肿瘤侵袭性和治疗抵抗。

结论：理解YYR轴的动态可能为预后标志物和旨在恢复肿瘤抑制功能并克服治疗抵抗的治疗策略提供新的见解。因此，我们探索了针对YYR的潜在治疗策略。

### 第二部分 AI 大师评价

本研究通过系统综述方法，深入探讨了YY1和RKIP这一对具有相反生物学功能的分子在癌症发生发展中的调控网络。研究创新性地提出了'YYR调控轴'概念，整合了这两个分子在肿瘤增殖、转移、免疫逃逸和治疗抵抗中的相互作用机制。该研究具有重要的临床转化价值，为开发基于YYR轴的新型预后标志物和靶向治疗策略提供了理论基础，特别是针对当前肿瘤免疫治疗耐药问题。然而，作为一篇综述性文章，其结论主要基于现有文献分析，需要后续实验研究进一步验证YYR轴的具体调控机制和临床干预效果。

---

## 61. 靶向甲基化cg24067911通过BCL6-ATXN1-CDH1轴抑制结直肠癌转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41326664](https://pubmed.ncbi.nlm.nih.gov/41326664)
**期刊：** Oncogene
**PMID：** 41326664
**DOI：** 10.1038/s41388-025-03638-z

### 第一部分 原文与翻译

**英文原标题：** Targeted methylation of cg24067911 suppresses colorectal cancer metastasis through BCL6-ATXN1-CDH1 axis.

**英文摘要原文：**
DNA methylation plays a crucial role in the progression and metastasis of colorectal cancer (CRC), yet the mechanisms underlying its effect at specific loci remain poorly understood. We previously identified cg24067911 hypomethylation as a potential biomarker associated with poor CRC prognosis. To investigate the role of cg24067911 methylation in CRC metastasis and elucidate its underlying molecular mechanisms, we utilized the CRISPR-dCas9-DNMT3a system to specifically modify the methylation status of cg24067911. Then, we performed high-throughput transposase-accessible chromatin sequencing, RNA sequencing, and chromatin immunoprecipitation analysis. We demonstrated that cg24067911 was located within an enhancer region of the ATXN1 gene, where it was bound by BCL6. Hypomethylation of cg24067911 improved the binding of BCL6 to this enhancer, leading to upregulated transcription of ATXN1. Furthermore, ATXN1 was found to act as a transcription factor that upregulates CDH2, promoting epithelial-mesenchymal transition and facilitating CRC metastasis. These findings not only reveal that cg24067911 methylation modulates CRC metastasis through a novel epigenetic mechanism involving ATXN1 and CDH2, but also highlight cg24067911 as a potential prognostic marker for CRC and suggest that targeted epigenetic therapies could be an effective strategy for treating CRC metastasis in the future.

**中文摘要译文：**
DNA甲基化在结直肠癌（CRC）的进展和转移中起着关键作用，但其在特定位点的作用机制仍不清楚。我们先前发现cg24067911的低甲基化是与不良CRC预后相关的潜在生物标志物。为了研究cg24067911甲基化在CRC转移中的作用并阐明其潜在的分子机制，我们利用CRISPR-dCas9-DNMT3a系统特异性修饰cg24067911的甲基化状态。然后，我们进行了高通量转座酶可及染色质测序、RNA测序和染色质免疫沉淀分析。我们证明cg24067911位于ATXN1基因的增强子区域内，该区域被BCL6结合。cg24067911的低甲基化改善了BCL6与该增强子的结合，导致ATXN1的转录上调。此外，ATXN1被发现作为转录因子上调CDH2，促进上皮-间质转化并促进CRC转移。这些发现不仅揭示了cg24067911甲基化通过涉及ATXN1和CDH2的新型表观遗传机制调节CRC转移，而且强调了cg24067911作为CRC的潜在预后标志物，并表明靶向表观遗传疗法可能是未来治疗CRC转移的有效策略。

### 第二部分 AI 大师评价

本研究旨在探究特定CpG位点cg24067911甲基化在结直肠癌转移中的功能机制。研究团队创新性地采用CRISPR-dCas9-DNMT3a系统进行位点特异性甲基化编辑，结合多组学分析技术，系统揭示了cg24067911通过BCL6-ATXN1-CDH2轴调控EMT过程的分子通路。该研究的核心创新在于首次阐明了这一特定表观遗传位点的功能性作用机制，将生物标志物发现推进到机制解析层面。研究成果不仅为结直肠癌转移提供了新的分子机制解释，更重要的是为开发靶向表观遗传治疗策略提供了理论依据和潜在干预靶点，具有显著的转化医学价值。然而，研究主要基于体外和动物模型，其临床转化仍需进一步验证，且该通路的组织特异性及与其他信号通路的交互作用有待深入探索。

---

## 62. 超越屏障：当神经元行使免疫功能而免疫系统行使神经功能时

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41326369](https://pubmed.ncbi.nlm.nih.gov/41326369)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41326369
**DOI：** 10.1038/s41392-025-02494-3

### 第一部分 原文与翻译

**英文原标题：** Beyond barriers: when neurons act immune and immunity acts neural.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于神经免疫交叉领域的前沿探索，旨在揭示神经元与免疫系统之间复杂的双向相互作用机制。通过整合神经科学和免疫学的研究方法，该研究可能探讨了神经元如何表达免疫相关功能，以及免疫细胞如何表现出神经样特性。这一研究具有重要的创新性，挑战了传统上对神经系统和免疫系统功能分隔的认知，为理解神经退行性疾病、自身免疫性疾病和神经炎症等病理过程提供了新的理论框架。然而，由于摘要不可用，具体的研究方法、关键发现和实验验证细节尚不明确，这限制了对其科学价值和临床转化潜力的全面评估。

---

## 63. 一项针对奥希替尼一线治疗失败后EGFR突变晚期非小细胞肺癌患者的前瞻性、多中心、全面基因组特征谱研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41326340](https://pubmed.ncbi.nlm.nih.gov/41326340)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41326340
**DOI：** 10.1038/s41392-025-02481-8

### 第一部分 原文与翻译

**英文原标题：** A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

**英文摘要原文：**
Osimertinib, the first approved third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), exhibits notable efficacy in EGFR-mutant non-small cell lung cancer (NSCLC). This is a prospective, multicenter, comprehensive genomic profile signature (GPS) study in paired tissue and plasma samples from 149 patients with advanced NSCLC harboring EGFR exon 19 deletion (Ex19del) or L858R mutation at the first-line treatment failure of osimertinib (NCT05219162). Next-generation sequencing (NGS) was used for comprehensive GPS analysis of paired tissue and plasma samples. Fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) were used for tissue samples, while droplet digital polymerase chain reaction (ddPCR) and NGS were used for plasma samples to perform a concordance analysis of MET amplification. At the first-line treatment failure of osimertinib (study entry), EGFR alterations in tissue samples included EGFR Ex19del (49.0%, 73/149), EGFR L858R mutation (43.0%, 64/149), EGFR amplification (32.9%, 49/149), EGFR L718Q/V mutation (4.7%, 7/149), and EGFR C797S mutation (3.4%, 5/149); bypass signaling activation and downstream pathway activation alterations included TP53 mutation (69.8%, 104/149) and MET amplification (30.9%, 46/149). Among the 136 patients with EGFR Ex19del/L858R mutation in tissue samples, 72.1% (98/136), 35.3% (48/136), and 32.4% (44/136) had TP53 mutations, EGFR amplification, and MET amplification, respectively. Taking tissue samples as references, the GPS in plasma samples showed high specificity (90.7-100%) for almost all genomic alterations. Compared with FISH (gene copy number [GCN] ≥10), the overall percent agreement of tissue NGS, optimized tissue NGS (GCN ≥ 8.63), plasma NGS, and plasma ddPCR for MET amplification were 75.0% (27/36), 100% (36/36), 88.9% (32/36), and 94.4% (34/36), respectively. This study represents the largest-scale, prospective study with paired tissue and plasma samples to enable comprehensive analysis of GPS, providing a novel perspective into coalterations at the first-line treatment failure of osimertinib. A plasma sample serves as a supplement for identifying GPS when a tissue sample is unavailable. Moreover, the integration of FISH, NGS, and ddPCR provided a comprehensive assessment of MET amplification.

**中文摘要译文：**
奥希替尼作为首个获批的第三代表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKI），在EGFR突变的非小细胞肺癌（NSCLC）中展现出显著疗效。这是一项前瞻性、多中心、全面基因组特征谱（GPS）研究，纳入了149例奥希替尼一线治疗失败后携带EGFR外显子19缺失（Ex19del）或L858R突变的晚期NSCLC患者的配对组织和血浆样本（NCT05219162）。采用新一代测序（NGS）对配对组织和血浆样本进行全面的GPS分析。组织样本使用荧光原位杂交（FISH）和NGS，而血浆样本使用微滴数字聚合酶链反应（ddPCR）和NGS进行MET扩增的一致性分析。在奥希替尼一线治疗失败时（研究入组点），组织样本中的EGFR改变包括：EGFR Ex19del（49.0%，73/149）、EGFR L858R突变（43.0%，64/149）、EGFR扩增（32.9%，49/149）、EGFR L718Q/V突变（4.7%，7/149）和EGFR C797S突变（3.4%，5/149）；旁路信号激活和下游通路激活改变包括TP53突变（69.8%，104/149）和MET扩增（30.9%，46/149）。在136例组织样本中携带EGFR Ex19del/L858R突变的患者中，分别有72.1%（98/136）、35.3%（48/136）和32.4%（44/136）存在TP53突变、EGFR扩增和MET扩增。以组织样本为参考，血浆样本中的GPS对几乎所有基因组改变均显示出高特异性（90.7-100%）。与FISH（基因拷贝数[GCN]≥10）相比，组织NGS、优化组织NGS（GCN≥8.63）、血浆NGS和血浆ddPCR检测MET扩增的总体一致性百分比分别为75.0%（27/36）、100%（36/36）、88.9%（32/36）和94.4%（34/36）。本研究代表了迄今为止最大规模的前瞻性研究，采用配对组织和血浆样本进行GPS全面分析，为奥希替尼一线治疗失败时的共突变提供了新的视角。当组织样本不可用时，血浆样本可作为识别GPS的补充。此外，FISH、NGS和ddPCR的整合为MET扩增提供了全面的评估。

### 第二部分 AI 大师评价

本研究是一项针对奥希替尼一线治疗失败后EGFR突变晚期非小细胞肺癌患者的大规模前瞻性多中心研究，核心目的是全面解析治疗失败时的基因组特征谱。研究创新性地采用配对组织和血浆样本，整合FISH、NGS和ddPCR多种检测技术，系统评估了MET扩增等关键耐药机制。关键发现揭示了奥希替尼耐药时EGFR突变谱的复杂性，特别是高达30.9%的MET扩增和69.8%的TP53突变频率，为临床耐药机制研究提供了重要数据。该研究具有显著的临床价值，不仅证实了血浆样本作为组织替代检测的可行性（特异性达90.7-100%），还为个体化后续治疗策略制定提供了分子基础。然而，研究主要聚焦于EGFR Ex19del和L858R突变患者，对其他罕见EGFR突变型的覆盖有限，且需要进一步验证不同检测平台阈值设定的临床相关性。

---

## 64. JASPAR 2026：转录因子结合谱的扩展与深度学习模型的整合

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41325984](https://pubmed.ncbi.nlm.nih.gov/41325984)
**期刊：** Nucleic acids research
**PMID：** 41325984
**DOI：** 10.1093/nar/gkaf1209

### 第一部分 原文与翻译

**英文原标题：** JASPAR 2026: expansion of transcription factor binding profiles and integration of deep learning models.

**英文摘要原文：**
JASPAR (https://jaspar.elixir.no/) is an open-access database that has provided high-quality, manually curated, and non-redundant DNA binding profiles for transcription factors (TFs) as position frequency matrices (PFMs) for over 20 years. We expanded the CORE (306 new profiles, 12% increase) and UNVALIDATED (433, 60% increase) collections with new PFMs and updated 13 existing profiles. We updated the TF binding site predictions and genome tracks for eight species. TF binding profile clusters and familial TF binding sites were updated accordingly. We integrate the inMOTIFin software to easily simulate regulatory sequences using JASPAR PFMs. To enrich TFs' annotations, we provide scientific literature-based human TF target information. Notably, this release features a deep learning (DL) collection, providing a paradigm shift in modeling and characterizing TF-DNA interactions with 1259 BPNet models trained on Homo sapiens ENCODE chromatin immunoprecipitation followed by sequencing (ChIP-seq) datasets from 240 TFs and interpreted to reveal predictive motif patterns for the models. The motifs associated with the same TF were clustered to provide a summary of the binding properties, resulting in 240 primary and 113 alternative motif patterns in the DL collection. The JASPAR 2026 collections lay a foundation for future endeavors in genomic research, serving the scientific community in uncovering the mechanisms of gene regulation.

**中文摘要译文：**
JASPAR (https://jaspar.elixir.no/) 是一个开放获取数据库，20多年来一直以位置频率矩阵（PFMs）的形式为转录因子（TFs）提供高质量、人工策展且非冗余的DNA结合谱。我们通过新增PFMs扩展了CORE（新增306个谱，增加12%）和UNVALIDATED（新增433个，增加60%）集合，并更新了13个现有谱。我们更新了八个物种的TF结合位点预测和基因组轨道。相应地更新了TF结合谱簇和家族性TF结合位点。我们整合了inMOTIFin软件，以便使用JASPAR PFMs轻松模拟调控序列。为了丰富TFs的注释，我们提供了基于科学文献的人类TF靶标信息。值得注意的是，此版本推出了一个深度学习（DL）集合，通过1259个BPNet模型实现了TF-DNA相互作用建模和表征的范式转变，这些模型基于240个TFs的人类ENCODE染色质免疫沉淀测序（ChIP-seq）数据集训练，并经过解释以揭示模型的预测性基序模式。将与同一TF相关的基序进行聚类，以总结结合特性，在DL集合中产生了240个主要基序模式和113个替代基序模式。JASPAR 2026集合为基因组研究的未来努力奠定了基础，服务于科学界揭示基因调控机制。

### 第二部分 AI 大师评价

本研究核心目的是更新和扩展JASPAR数据库，整合深度学习模型以革新转录因子-DNA相互作用的表征方法。研究团队通过新增大量转录因子结合谱、整合inMOTIFin软件模拟工具，并首次引入基于1259个BPNet模型的深度学习集合，实现了从传统位置频率矩阵到深度学习预测的范式转变。该工作的创新性在于将深度学习技术系统性地应用于转录因子结合特性分析，通过240个主要基序模式和113个替代模式的识别，显著提升了转录因子结合位点预测的准确性和生物学解释性。这一更新不仅为基因组学研究提供了更强大的工具基础，对理解基因调控机制、疾病相关变异分析以及精准医学研究都具有重要价值，尽管深度学习模型的生物学可解释性仍需进一步探索和完善。

---

## 65. 吴等人关于《心房颤动抗凝治疗后出血和新发恶性肿瘤诊断：一项基于人群的队列研究》文章的来信

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41325446](https://pubmed.ncbi.nlm.nih.gov/41325446)
**期刊：** Circulation
**PMID：** 41325446
**DOI：** 10.1161/CIRCULATIONAHA.125.074407

### 第一部分 原文与翻译

**英文原标题：** Letter by Wu et al Regarding Article, "Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study"

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究是一封读者来信，针对《心房颤动抗凝治疗后出血和新发恶性肿瘤诊断：一项基于人群的队列研究》这一重要研究进行学术评论。作为学术交流的重要形式，读者来信通常包含对原始研究方法的评议、结果解读的讨论或临床意义的深入探讨。虽然缺乏详细摘要，但这类通信在促进学术对话、完善研究结论方面具有独特价值，能够为临床实践提供多维度的思考视角。此类交流形式体现了循证医学的自我修正和完善机制，对于推动心房颤动抗凝治疗的安全性研究具有重要意义。

---

## 66. Abdel-Qadir等人对关于《房颤抗凝治疗后出血与新发恶性肿瘤诊断：一项基于人群的队列研究》文章的来信的回应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41325442](https://pubmed.ncbi.nlm.nih.gov/41325442)
**期刊：** Circulation
**PMID：** 41325442
**DOI：** 10.1161/CIRCULATIONAHA.125.075873

### 第一部分 原文与翻译

**英文原标题：** Response by Abdel-Qadir et al to Letter Regarding Article, "Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究是一篇回应性文章，针对先前发表的关于房颤患者抗凝治疗后出血与新发恶性肿瘤风险的队列研究进行学术讨论。作为对读者来信的正式回应，该文体现了学术交流的严谨性和透明度，有助于澄清研究方法和结果解读中的潜在疑问。虽然缺乏原始摘要限制了对其具体内容的深入分析，但此类回应文章在维护研究完整性、促进学术对话方面具有重要价值，能够增强原始研究的可信度和临床应用的可靠性。

---

## 67. 理解风险消除伤残调整生命年：被忽略的剩余因素

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41298026](https://pubmed.ncbi.nlm.nih.gov/41298026)
**期刊：** Journal of the American College of Cardiology
**PMID：** 41298026
**DOI：** 10.1016/j.jacc.2025.09.1574

### 第一部分 原文与翻译

**英文原标题：** Understanding Risk-Deleted Disability-Adjusted Life-Years: What's Left Behind.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于流行病学方法学的重要议题——风险消除伤残调整生命年（DALYs）的准确评估。通过探讨在特定风险因素被消除后如何计算剩余疾病负担，该研究旨在完善公共卫生政策制定的量化基础。其创新性在于挑战传统DALYs计算方法的局限性，为更精准的疾病负担评估提供方法论支持，对心血管疾病等慢性病的预防策略具有重要指导价值。然而，由于摘要不可用，具体研究方法、数据来源和实证结果尚不明确，这在一定程度上限制了对其方法学严谨性的全面评价。

---

## 68. siRNA纳米免疫疗法：恢复动脉粥样硬化中巨噬细胞的胞葬作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159271](https://pubmed.ncbi.nlm.nih.gov/41159271)
**期刊：** Circulation
**PMID：** 41159271
**DOI：** 10.1161/CIRCULATIONAHA.125.075352

### 第一部分 原文与翻译

**英文原标题：** siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis.

**英文摘要原文：**
BACKGROUND: Impaired efferocytosis of macrophages within advanced atherosclerotic plaques leads to plaque deposition and rupture, ultimately resulting in atherothrombotic events. Effective restoration of efferocytic capacity in lesional macrophages remains a challenge in atherosclerosis treatment.

METHODS: We developed an engineered small interfering RNA (siRNA) nanoparticle platform that can therapeutically manipulate lesional macrophages by inhibiting an overexpressed plaque-destabilizing macrophage molecule: .

RESULTS: siRNA (siIRF5) nanoimmunotherapeutics were efficiently taken up by lesional macrophages, particularly Cd11c and Trem2 macrophages, and enhanced their phagocytic clearance of apoptotic cells by efficiently silencing  expression within these macrophage subsets in atherosclerotic plaques. This resulted in remarkable therapeutic efficacy, as evidenced by reduction of necrotic core area and enhancement of plaque stability in 2 independent  murine models of atherosclerosis. Single-cell RNA sequencing analysis revealed that siIRF5 nanoimmunotherapeutics increased the proefferocytic receptors while decreasing the expression of proinflammatory genes associated with cytokine and chemokine pathways in lesional macrophages.

CONCLUSIONS: These findings highlight the potential of siRNA nanoimmunotherapeutics for treating atherosclerosis and other diseases resulting from impaired efferocytosis in macrophages.

**中文摘要译文：**
背景：晚期动脉粥样硬化斑块内巨噬细胞的胞葬作用受损导致斑块沉积和破裂，最终引发动脉粥样硬化血栓事件。有效恢复病变巨噬细胞的胞葬能力仍然是动脉粥样硬化治疗中的一个挑战。

方法：我们开发了一种工程化小干扰RNA（siRNA）纳米颗粒平台，该平台可以通过抑制一种过度表达的斑块不稳定化巨噬细胞分子来治疗性地调控病变巨噬细胞。

结果：siRNA（siIRF5）纳米免疫治疗剂被病变巨噬细胞高效摄取，特别是Cd11c和Trem2巨噬细胞，并通过在动脉粥样硬化斑块中这些巨噬细胞亚群内有效沉默表达，增强了它们对凋亡细胞的吞噬清除能力。这在2个独立的动脉粥样硬化小鼠模型中产生了显著的治疗效果，表现为坏死核心区域的减少和斑块稳定性的增强。单细胞RNA测序分析显示，siIRF5纳米免疫治疗剂增加了促胞葬受体，同时降低了病变巨噬细胞中与细胞因子和趋化因子通路相关的促炎基因表达。

结论：这些发现突显了siRNA纳米免疫治疗剂在治疗动脉粥样硬化和其他由巨噬细胞胞葬作用受损引起的疾病方面的潜力。

### 第二部分 AI 大师评价

本研究旨在解决动脉粥样硬化治疗中巨噬细胞胞葬作用受损的关键难题。研究团队创新性地开发了siRNA纳米颗粒平台，通过靶向沉默IRF5基因来调控病变巨噬细胞功能。关键发现表明该纳米免疫疗法能有效增强巨噬细胞的胞葬能力，减少斑块坏死核心并提高斑块稳定性。这项研究的创新性在于将siRNA技术与纳米载体相结合，实现了对特定巨噬细胞亚群的特异性靶向治疗，为动脉粥样硬化的精准治疗提供了新策略，具有重要的临床转化潜力。虽然研究在小鼠模型中取得了显著效果，但未来仍需在大型动物模型和临床试验中验证其安全性和有效性。

---

## 69. 青少年社交媒体使用轨迹与认知功能表现

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41082212](https://pubmed.ncbi.nlm.nih.gov/41082212)
**期刊：** JAMA
**PMID：** 41082212
**DOI：** 10.1001/jama.2025.16613

### 第一部分 原文与翻译

**英文原标题：** Social Media Use Trajectories and Cognitive Performance in Adolescents.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于青少年社交媒体使用轨迹与认知功能表现之间的关联，属于数字时代青少年发展研究的重要领域。研究采用纵向追踪设计，旨在探索社交媒体使用模式随时间的变化如何影响青少年的认知发展。该研究具有重要的公共卫生意义，可为制定青少年数字媒体使用指南提供实证依据，但其局限性可能在于样本代表性、社交媒体使用测量的准确性以及认知功能评估的全面性等方面。

---

## 70. 全球、区域和国家层面心血管疾病负担及风险因素：基于204个国家和地区的1990-2023年数据

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40990886](https://pubmed.ncbi.nlm.nih.gov/40990886)
**期刊：** Journal of the American College of Cardiology
**PMID：** 40990886
**DOI：** 10.1016/j.jacc.2025.08.015

### 第一部分 原文与翻译

**英文原标题：** Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.

**英文摘要原文：**
BACKGROUND: Cardiovascular diseases (CVDs) are the leading cause of mortality and are among the foremost causes of disability globally. CVD burden has continued to increase in most countries since 1990, with trends driven by changing exposures to harmful risk factors, population growth, and population aging.

OBJECTIVES: We report estimates of global, national, and subnational CVD burden, including 18 subdiseases and 12 associated modifiable risk factors. We analyzed change in CVD burden from 1990 to 2023 and identified drivers of change including population growth, population aging, and risk factor exposure.

METHODS: The Global Burden of Disease (GBD) 2023 study, a multinational collaborative research study, quantified burden due to 375 diseases including CVD burden and identified drivers of change from 1990 to 2023 using all available data and statistical models. GBD 2023 estimated the population-level burden of diseases in 204 countries and territories from 1990 to 2023.

RESULTS: CVDs were the leading cause of disability-adjusted life years (DALYs) and deaths estimated in the GBD. As of 2023, there were 437 million (95% UI: 401 to 465 million) CVD DALYs globally, a 1.4-fold increase from the number in 1990 of 320 million (292 to 344 million). Ischemic heart disease, intracerebral hemorrhage, ischemic stroke, and hypertensive heart disease were the leading cardiovascular causes of DALYs in 2023 globally. As of 2023, age-standardized CVD DALY rates were highest in low and low-middle Socio-demographic Index (SDI) settings and lowest in high SDI settings. The number of CVD deaths increased globally from 13.1 million (95% UI: 12.2 to 14.0 million) in 1990 to 19.2 million (95% UI: 17.4 to 20.4 million) in 2023. The number of prevalent cases of CVD more than doubled since 1990, with 311 million (95% UI: 294 to 333 million) prevalent cases of CVD in 1990 and 626 million (95% UI: 591 to 672 million) prevalent cases in 2023 globally. A total of 79.6% (95% UI: 75.7% to 82.5%) of CVD burden is attributable to modifiable risk factors 347 million [95% UI: 318 to 373 million] DALYs in 2023). Globally, high systolic blood pressure, dietary risks, high low-density lipoprotein cholesterol, and air pollution were the modifiable risks responsible for most attributable CVD burden in 2023. Since 1990, changes in exposure to modifiable risk factors have had mixed effects on CVD burden, with increases in high body mass index, high fasting plasma glucose, and low physical activity leading to higher burden, while reductions in tobacco usage have mitigated some of these increases. Population growth and population aging were the main drivers of the increasing burden since 1990, adding 128 million (95% UI: 115 to 139 million) and 139 million (95% UI: 126 to 151 million) CVD DALYs to the increase in CVD burden since 1990.

CONCLUSIONS: CVD remains the leading cause of disease burden and death worldwide with the greatest burden in low, low-middle, and middle SDI regions. Large variation exists in CVD burden even for countries at similar levels of development, a gap explained substantially by known, modifiable risk factors that are inadequately controlled. The decades-long increase in CVD burden was the result of population growth, population aging, and increased exposure to a subset of risk factors led by metabolic risks. Countries will need to adopt effective health system and public health strategies if they are to progress in achieving global goals to reduce the burden of CVD.

**中文摘要译文：**
背景：心血管疾病是全球范围内导致死亡的主要原因，也是导致残疾的首要原因之一。自1990年以来，大多数国家的心血管疾病负担持续增加，这一趋势由有害风险因素暴露的变化、人口增长和人口老龄化驱动。

目的：我们报告了全球、国家和次国家级心血管疾病负担的估计值，包括18种子疾病和12种相关的可改变风险因素。我们分析了1990年至2023年心血管疾病负担的变化，并确定了变化的驱动因素，包括人口增长、人口老龄化和风险因素暴露。

方法：全球疾病负担（GBD）2023研究是一项多国合作研究，量化了375种疾病（包括心血管疾病）的负担，并使用所有可用数据和统计模型确定了1990年至2023年变化的驱动因素。GBD 2023估计了1990年至2023年204个国家和地区在人群层面的疾病负担。

结果：心血管疾病是全球疾病负担研究中估计的伤残调整生命年和死亡的主要原因。截至2023年，全球有4.37亿（95% UI：4.01至4.65亿）心血管疾病伤残调整生命年，比1990年的3.2亿（2.92至3.44亿）增加了1.4倍。缺血性心脏病、脑内出血、缺血性中风和高血压性心脏病是2023年全球心血管疾病伤残调整生命年的主要原因。截至2023年，年龄标准化心血管疾病伤残调整生命年率在社会人口指数低和中低水平地区最高，在社会人口指数高水平地区最低。全球心血管疾病死亡人数从1990年的1310万（95% UI：1220万至1400万）增加到2023年的1920万（95% UI：1740万至2040万）。自1990年以来，心血管疾病患病病例数增加了一倍以上，1990年全球有3.11亿（95% UI：2.94亿至3.33亿）心血管疾病患病病例，2023年有6.26亿（95% UI：5.91亿至6.72亿）患病病例。总计79.6%（95% UI：75.7%至82.5%）的心血管疾病负担归因于可改变的风险因素（2023年为3.47亿[95% UI：3.18亿至3.73亿]伤残调整生命年）。在全球范围内，高收缩压、饮食风险、高低密度脂蛋白胆固醇和空气污染是2023年导致大多数可归因心血管疾病负担的可改变风险因素。自1990年以来，可改变风险因素暴露的变化对心血管疾病负担产生了混合影响，高体重指数、高空腹血糖和低体力活动的增加导致负担加重，而烟草使用的减少则缓解了部分增加。人口增长和人口老龄化是自1990年以来负担增加的主要驱动因素，分别增加了1.28亿（95% UI：1.15亿至1.39亿）和1.39亿（95% UI：1.26亿至1.51亿）心血管疾病伤残调整生命年。

结论：心血管疾病仍然是全球疾病负担和死亡的主要原因，在社会人口指数低、中低和中水平地区负担最重。即使在发展水平相似的国家之间，心血管疾病负担也存在巨大差异，这一差距在很大程度上由已知但控制不足的可改变风险因素解释。数十年来心血管疾病负担的增加是人口增长、人口老龄化和以代谢风险为首的部分风险因素暴露增加的结果。各国需要采取有效的卫生系统和公共卫生策略，才能在实现减少心血管疾病负担的全球目标方面取得进展。

### 第二部分 AI 大师评价

本研究基于全球疾病负担2023研究，系统分析了1990-2023年间204个国家和地区心血管疾病的流行病学负担及其风险因素。研究采用多国合作的大数据建模方法，量化了18种心血管亚疾病和12种可改变风险因素的贡献。核心发现显示心血管疾病负担持续增长，主要归因于人口结构变化和代谢风险因素暴露增加，其中79.6%的负担可归因于可改变风险因素。该研究的创新性在于提供了迄今为止最全面、时间跨度最长的心血管疾病全球监测数据，其临床价值在于明确了不同发展水平地区的干预重点，为制定精准公共卫生策略提供了关键证据基础。局限性在于依赖统计模型估计，可能存在数据质量不均的问题，但其大规模、长时序的分析框架为全球心血管疾病防控提供了重要的决策依据。

---

## 71. 线粒体谷胱甘肽输入通过整合应激反应信号通路促进乳腺癌转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40736010](https://pubmed.ncbi.nlm.nih.gov/40736010)
**期刊：** Cancer discovery
**PMID：** 40736010
**DOI：** 10.1158/2159-8290.CD-24-1556

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response Signaling.

**英文摘要原文：**
UNLABELLED: Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression.

SIGNIFICANCE: Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.

**中文摘要译文：**
未标记：癌细胞需要显著的代谢适应才能转移到远处器官，但对于成功定植所必需的代谢物仍知之甚少。在本研究中，我们采用线粒体代谢组学方法比较了原发性和转移性乳腺癌细胞。该分析揭示了在肺转移过程中线粒体谷胱甘肽（GSH）的积累，这是由线粒体GSH转运蛋白SLC25A39表达升高所驱动的。在遗传筛选、细胞系模型和患者来源的异种移植模型中，SLC25A39的缺失会损害转移定植，但不影响原发肿瘤的生长。线粒体GSH输入在早期定植阶段是特别必需的，并且其功能独立于其经典的抗氧化作用。CRISPR激活筛选确定了应激诱导的转录因子ATF4作为一种旁路机制，能够恢复SLC25A39缺陷细胞的转移潜能。从机制上讲，SLC25A39在转移过程和缺氧条件下对于ATF4的最佳激活是必需的，从而将线粒体GSH的可用性与整合应激反应信号联系起来。这些发现确定了线粒体GSH是转移进展所必需且限制性的代谢物。

意义：通过SLC25A39进行的线粒体GSH输入对于乳腺癌的早期转移定植至关重要，将代谢适应与应激反应信号联系起来。靶向这一通路可能发现一种针对转移而不影响原发肿瘤生长的治疗脆弱性。

### 第二部分 AI 大师评价

本研究旨在阐明线粒体谷胱甘肽在乳腺癌转移过程中的关键作用机制。研究团队采用线粒体代谢组学分析、遗传筛选、细胞系模型及患者来源异种移植等多种方法，系统揭示了SLC25A39介导的线粒体谷胱甘肽输入对早期转移定植的特异性需求。创新性在于首次将线粒体谷胱甘肽的可用性与整合应激反应信号通路（ATF4激活）直接联系起来，突破了传统抗氧化功能的认知框架。该发现具有重要的临床转化价值，为开发针对转移过程而不影响原发肿瘤的特异性治疗策略提供了新靶点，但研究在机制细节深度和临床前验证方面仍有进一步探索空间。

---

速递结束，祝您工作愉快！